CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS
20250326731 ยท 2025-10-23
Inventors
Cpc classification
C07D307/935
CHEMISTRY; METALLURGY
C07D401/06
CHEMISTRY; METALLURGY
C07D405/04
CHEMISTRY; METALLURGY
C07D307/88
CHEMISTRY; METALLURGY
C07D307/33
CHEMISTRY; METALLURGY
C07D307/94
CHEMISTRY; METALLURGY
B01J31/2239
PERFORMING OPERATIONS; TRANSPORTING
B01J31/181
PERFORMING OPERATIONS; TRANSPORTING
C07D401/10
CHEMISTRY; METALLURGY
C07D401/04
CHEMISTRY; METALLURGY
International classification
C07D307/935
CHEMISTRY; METALLURGY
C07D307/33
CHEMISTRY; METALLURGY
C07D405/04
CHEMISTRY; METALLURGY
C07D307/94
CHEMISTRY; METALLURGY
C07D307/88
CHEMISTRY; METALLURGY
Abstract
Disclosed herein is the catalyst-controlled site-selective activation of - and -methylene CH bonds of free carboxylic acids which heretofore was unknown and has remained a tremendous challenge. Described herein in the enablement of such chemical reactivity with ubiquitous dicarboxylic acids which possess inert, methylene-rich backbones and dual functional groups which opened up pathways for the construction of complex molecular scaffolds for organic synthesis. Herein we show that with a pair of palladium catalysts, it is possible to perform highly site-selective monolactonization reactions with a wide range of dicarboxylic acids, generating topologically diverse and synthetically useful - and -lactones via site-selective - or -methylene CH activation. The remaining carboxyl group serves as a versatile linchpin for further synthetic applications as demonstrated by the total synthesis of two natural products, myrotheciumone A and pedi cellosine, from abundant dicarboxylic acids.
Claims
1. A method of - or -lactonization via -CH activation, comprising i) treating a dicarboxylic acid substrate with a quinoline-pyridone or pyridine-pyridone ligand in the presence of a Pd source; and ii) addition of p-xyloquinone (BQ3), an Ag salt, and K.sub.2HPO.sub.4 in a reaction vessel.
2. The method of claim 1, wherein the quinoline-pyridone or pyridine-pyridone ligand is selected from the group consisting of: ##STR00234##
3. The method of any one of claims 1-2, wherein the Pd source is Pd(OAc).sub.2.
4. The method of any one of claims 1-3, wherein the Ag salt is Ag.sub.2CO.sub.3.
5. The method of any one of claims 1-4, wherein the quinoline-pyridone ligand is L1.
6. The method of any one of claims 1-4, wherein the pyridine-pyridone ligand is L18.
7. The method of any one of claims 1-4, wherein the pyridine-pyridone ligand is L17.
8. The method of any one of claims 1-4, wherein the pyridine-pyridone ligand is L13.
9. The method of any one of claims 1-4, wherein the pyridine-pyridone ligand is L14.
10. The method of any one of claims 1-4, wherein the pyridine-pyridone ligand is L11.
11. The method of any one of claims 1-4, wherein the quinoline-pyridone ligand is L10.
12. The method of any one of claims 1-4, wherein the quinoline-pyridone ligand is L16.
13. The method of any one of claims 1-4, wherein the pyridine-pyridone ligand is L12.
14. The method of any one of claims 1-4, wherein the pyridine-pyridone ligand is L15.
15. The method of -CH lactonization via -CH activation of claim 1, wherein the dicarboxylic acid substrate is 1.0 eq. adipic acid, the quinoline-pyridone ligand is 12 mol % L1, the Pd source is 10 mol % Pd(OAc).sub.2, the Ag salt is 2.0 eq. Ag.sub.2CO.sub.3, with 2.0 eq. BQ3, 1.0 eq. K.sub.2HPO.sub.4 in HFIP at 100 C. for 36 h and the reaction vessel is an 8-10 mL vial.
16. The method of -lactonization via CH activation of claim 1, wherein the dicarboxylic acid substrate is 1.0 eq. pimelic acid, the quinoline-pyridone ligand is 12 mol % L1, the Pd source is 10 mol % Pd(OAc).sub.2, the Ag salt is 2.0 eq. Ag.sub.2CO.sub.3, with 2.0 eq. BQ3, 1.0 eq. K.sub.2HPO.sub.4 in HFIP at 100 C. for 36 h and the reaction vessel is an 8-10 mL vial.
17. The method of either one of claim 15 or 16, wherein the 1.0 eq. K.sub.2HPO.sub.4 is replaced with 0.75 eq. K.sub.2HPO.sub.4.
18. The method of either one of claim 15 or 16, wherein the 1.0 eq. K.sub.2HPO.sub.4 is replaced with a mixture of 0.35 eq. K.sub.2HPO.sub.4 and 0.4 eq. CsOAc.
19. The method of either one of claim 15 or 16, wherein the 2.0 eq. Ag.sub.2CO.sub.3 is replaced with 4.0 eq. MnO.sub.2 and the 1.0 eq. K.sub.2HPO.sub.4 is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1.0:1.5:1.0, 0.75 eq. total).
20. A method of -lactonization via -CH activation comprising i) treating a dicarboxylic acid substrate with a quinoline-pyridone or pyridine-pyridone ligand in the presence of a Pd source; and ii) addition of BQ3, Ag.sub.2CO.sub.3 and K.sub.2HPO.sub.4 in a reaction vessel.
21. The method of claim 20, wherein the quinoline-pyridone or pyridine-pyridone ligand is selected from the group consisting of: ##STR00235## ##STR00236##
22. The method of claim 21, wherein the quinoline-pyridone ligand is L2.
23. The method of claim 21, wherein the quinoline-pyridone ligand is L9.
24. The method of claim 21, wherein the quinoline-pyridone ligand is L8.
25. The method of claim 21, wherein the quinoline-pyridone ligand is L7.
26. The method of claim 21, wherein the pyridine-pyridone ligand is L5.
27. The method of claim 21, wherein the pyridine-pyridone ligand is L4.
28. The method of claim 21, wherein the quinoline-pyridone ligand is L6.
29. The method of claim 21, wherein the quinoline-pyridone ligand is L1.
30. A method of -lactonization via -CH activation comprising i) treating a dicarboxylic acid substrate with L2 in the presence of a Pd source; and ii) addition of an oxidant and K.sub.2HPO.sub.4.
31. The method of claim 30, wherein the oxidant is 2.0 eq. Na.sub.2S.sub.2O.sub.8.
32. The method of claim 30, wherein the oxidant is 2.0 eq. K.sub.2S.sub.2O.sub.8.
33. The method of claim 30, wherein the oxidant is 2.0 eq. BzOO.sup.tBu.
34. The method of claim 30, wherein the oxidant is 2.0 eq. AcOO.sup.tBu.
35. The method of claim 30, wherein the oxidant is 2.0 eq. Ce(SO.sub.4).sub.2.
36. The method of claim 30, wherein the oxidant is 2.0 eq. CMHP.
37. The method of claim 30, wherein the oxidant is 2.0 eq. .sup.tBuOO.sup.tBu.
38. The method of claim 30, wherein the oxidant is 2.0 eq. 1-iodo-3,5-bis(trifluoromethyl)benzene.
39. The method of claim 30, wherein the oxidant is 2.0 eq. methyl 4-iodobenzoate.
40. The method of claim 30, wherein the oxidant is 2.0 eq. 1,2,3,4,5-pentafluoro-6-iodobenzene.
41. The method of claim 30, wherein the oxidant is 2.0 eq. TBHP in H.sub.2O.
42. The method of claim 30, wherein the oxidant is 2.0 eq. H.sub.2O.sub.2 in H.sub.2O.
43. The method of claim 30, wherein the oxidant is selected from the group consisting of: ##STR00237##
44. The method of claim 43, wherein the oxidant is BQ8.
45. The method of claim 43, wherein the oxidant is BQ5.
46. The method of claim 43, wherein the oxidant is BQ4.
47. The method of claim 43, wherein the oxidant is BQ6.
48. The method of claim 43, wherein the oxidant is BQ1.
49. The method of claim 43, wherein the oxidant is BQ12.
50. The method of claim 43, wherein the oxidant is BQ2.
51. The method of claim 43, wherein the oxidant is BQ9.
52. The method of claim 43, wherein the oxidant is BQ7.
53. The method of claim 43, wherein the oxidant is BQ11.
54. The method of claim 43, wherein the oxidant is BQ13.
55. The method of claim 30, wherein the oxidant is AgOAc.
56. The method of claim 30, wherein the oxidant is Ag2O.
57. The method of claim 30, wherein the oxidant is AgF.
58. The method of claim 30, wherein the oxidant is Ag.sub.2CO.sub.3.
59. The method of claim 30, wherein the oxidant is AgNO.sub.3.
60. The method of claim 30, wherein the oxidant is Ag.sub.3PO.sub.4.
61. The method of claim 30, wherein the oxidant is CuSO.sub.4.Math.5H.sub.2O.
62. The method of claim 30, wherein the oxidant is CuF.sub.2.
63. The method of claim 30, wherein the oxidant is CuO.
64. The method of claim 30, wherein the oxidant is Cu.sub.3(PO.sub.4).sub.2.
65. The method of claim 30, wherein the oxidant is CuBr.sub.2.
66. The method of claim 30, wherein the oxidant is CuCO.sub.3.
67. The method of claim 30, wherein the oxidant is a mixture of BQ3 and an Ag salt.
68. The method of claim 67, wherein the Ag salt is Ag.sub.2CO.sub.3.
69. The method of claim 67, wherein the Ag salt is Ag.sub.3PO.sub.4.
70. The method of claim 67, wherein the Ag salt is AgF.
71. The method of claim 67, wherein the Ag salt is Ag.sub.2O.
72. The method of claim 67, wherein the Ag salt is AgOAc.
73. The method of any one of claims 20-72, wherein the Pd source is Pd(OAc).sub.2.
74. The method of any one of claims 20-72, wherein the Pd source is Pd(TFA).sub.2.
75. The method of any one of claims 20-72, wherein the Pd source is Pd(MeCN).sub.4(BF.sub.4).sub.2.
76. The method of any one of claims 20-72, wherein the Pd source is Pd(MeCN).sub.4(OTf).sub.2.
77. The method of any one of claims 20-72, wherein the Pd source is PdCl.sub.2.
78. The method of any one of claims 20-72, wherein the Pd source is PdCl.sub.2(PhCN).sub.2.
79. The method of any one of claims 20-72, wherein the Pd source is Pd.sub.2(dba).sub.3.
80. The method of any one of claims 20-72, wherein the Pd source is PdCl.sub.2(MeCN).sub.2.
81. The method of any one of claims 20-80, wherein the dicarboxylic acid substrate is pimelic acid
82. The method of any one of claims 20-80, wherein the dicarboxylic acid substrate is 2,2,6,6-tetramethylpimelic acid.
83. The method of claim 20, wherein the dicarboxylic acid substrate is 1.0 eq. pimelic acid, the quinoline-pyridone ligand is 12 mol % L2, the Pd source is 10 mol % Pd(OAc).sub.2, the oxidant is 2.0 eq. BQ3 and 2.0 eq. of an Ag salt, and 1.0 eq. K.sub.2HPO.sub.4, the reaction vessel is a vial between 8-10 mL, the reaction temperature is between 80-100 C., and the reaction time is between 12-72 h.
84. The method of claim 83, wherein the Ag salt is Ag.sub.2CO.sub.3.
85. The method of claim 83, wherein the Ag salt is Ag.sub.3PO.sub.4.
86. The method of claim 83, wherein the Ag salt is AgF.
87. The method of claim 83, wherein the Ag salt is Ag.sub.2O.
88. The method of claim 83, wherein the Ag salt is AgOAc.
89. The method of claim 84, wherein the Ag.sub.2CO.sub.3 is replaced by K.sub.2S.sub.2O.sub.8.
90. The method of claim 84, wherein the Ag.sub.2CO.sub.3 is replaced with 0.5 eq. Ag.sub.2CO.sub.3 in addition to replacing the 2.0 eq. BQ3 with 0.5 eq. BQ3.
91. The method of claim 84, wherein the 2.0 eq. Ag.sub.2CO.sub.3 is replaced with 1.0 eq. Ag.sub.2CO.sub.3 in addition to replacing the 2.0 eq. BQ3 with 1.0 eq. BQ3.
92. The method of any one of claims 20-91, wherein the reaction temperature is 100 C.
93. The method of any one of claims 20-91, wherein the reaction temperature is 80 C.
94. The method of any one of claims 20-91, wherein the reaction temperature is 120 C.
95. The method of any one of claims 20-94, wherein the reaction time is 12 h.
96. The method of any one of claims 20-94, wherein the reaction time is 24 h.
97. The method of any one of claims 20-94, wherein the reaction time is 36 h.
98. The method of any one of claims 20-94, wherein the reaction time is 72 h.
99. The method of any one of claims 20-98, wherein the reaction vessel is a 10 mL vial.
100. The method of any one of claims 20-98, wherein the reaction vessel is an 8 mL vial, the reaction temperature is 100 C., and the reaction time is 36 h.
101. The method of claim 83, wherein the 1.0 eq. of K.sub.2HPO.sub.4 is replaced with 0.75 eq. K.sub.2HPO.sub.4 and the reaction vessel is an 8 mL vial, the reaction temperature is 100 C., and the reaction time is 36 h.
102. The method of claim 83, wherein the 1.0 eq. of K.sub.2HPO.sub.4 is replaced with 0.35 eq K.sub.2HPO.sub.4 and 0.4 eq. CsOAc, the reaction vessel is an 8 mL vial, the reaction temperature is 100 C., and the reaction time is 36 h.
103. The method of claim 83, wherein the 1.0 eq. of K.sub.2HPO.sub.4 is replaced with 0.35 eq K.sub.2HPO.sub.4 and 0.4 eq. CsOAc, L2 is replaced with L10, and the reaction vessel is an 8 mL vial, the reaction temperature is 100 C., and the reaction time is 36 h.
104. The method of claim 83, wherein the 1.0 eq. of K.sub.2HPO.sub.4 is replaced with 0.35 eq K.sub.2HPO.sub.4 and 0.4 eq. CsOAc, L2 is replaced with L10, the reaction vessel is an 8 mL vial, the reaction temperature is 100 C., and the reaction time is 48 h.
105. The method of claim 83, wherein the 2.0 eq. of an Ag salt is replaced with 2.0 eq. of MnO.sub.2.
106. The method of claim 83, wherein the 2.0 eq. of an Ag salt is replaced with 6.0 eq. of MnO.sub.2.
107. The method of claim 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:1.5:1, total 0.75 eq.).
108. The method of claim 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:1.5:1, total 1.0 eq.).
109. The method of claim 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:2:1, total 0.75 eq.).
110. The method of claim 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:2:1, total 1.0 eq.).
111. The method of claim 83, wherein the reaction time is 48 h.
112. The method of claim 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:1.5:1, total 0.75 eq.) and L2 is replaced with L10.
113. The method of claim 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:1.5:1, total 0.75 eq.), L2 is replaced with L10, and the reaction time is 48 h.
114. The method of claim 83, wherein, the oxidant is 2.0 eq. BQ3 and 2.0 eq. of Ag.sub.2CO.sub.3, the reaction vessel is a 10 mL vial, the reaction temperature is 100 C., and the reaction time is 36 h.
115. The method of claim 83, comprising i) treating 1.0 eq. pimelic acid with 12 mol % ligand L2 in the presence of 10 mol % Pd(OAc).sub.2; and ii) addition of 2.0 eq. Ag.sub.2CO.sub.3, 2.0 eq. BQ3, and 1.0 eq. K.sub.2HPO.sub.4 at 100 C. in HFIP for 36 h in an 8 mL vial.
116. A method for the total synthesis of Myrotheciumone A. comprising the following steps: (1) reaction of MeI (2.0 eq.) and K.sub.2CO.sub.3 (3.0 eq.), in acetone, and refluxed for 3 hr; (2) reaction with Ph.sub.3PCH.sub.3Br (2.9 eq.) and tBuOK (2.4 eq.), in toluene, at r.t. overnight; (3) reaction with mCPBA (1.2 eq.), in CH.sub.2Cl.sub.2, at r.t. overnight; (4) reaction with TMSOTf (2.0 eq.) and 2,6-lutidine (2.0 eq.), in toluene, at 78 C. to r.t. overnight; (5) reaction with cat. Pivalic acid (10 mol %) and triethyl orthoacetate, neat, at 155 C., overnight and further reaction with cat. p-TsOH (10 mol %), in toluene, and refluxed overnight; (6) reaction with cat. PtO.sub.2, under H.sub.2 (4-layered ballon), in AcOH, at r.t. overnight; (7) reaction with 15% aq. NaOH, and refluxed overnight; (8) reaction with Pd(OAc).sub.2 (10 mol %), Ligand L2 (12 mol %), BQ3 (2.0 eq.), Ag.sub.2CO.sub.3 (2.0 eq.), K.sub.2HPO.sub.4 (0.35 eq.), and CsOAc (0.40 eq.), in HFIP, at 100 C., for 36 h; and (9) reaction with (Ir[dF(CF.sub.3)ppy].sub.2(dtbpy))PF.sub.6 (1 mol %), Cs.sub.2CO.sub.3 (1.5 eq.), and NaBH.sub.4 (1.2 eq.), under 02 atmosphere, in CH.sub.2Cl.sub.2, at 40 C., 4100 W Blue LED lamps, for 40 h.
117. A method for the total synthesis of Pedicellosine comprising the following steps: (1) reaction of Pd(OAc).sub.2 (10 mol %), Ligand L2 (12 mol %), BQ3 (2.0 eq.), Ag.sub.2CO.sub.3 (2.0 eq.), K.sub.2HPO.sub.4 (0.35 eq.), and CsOAc (0.40 eq.), in HFIP, at 100 C., for 36 h; (2) reaction with BH.sub.3.Math.Me.sub.2S (1.6 eq.), in THF, at 0 C. to r.t. overnight; and (3) reaction with EDCI (1.5 eq.), DMAP (20 mol %), and 2,3-dihydroxybenzoic acid (1.5 eq.), in CH.sub.2Cl.sub.2, at r.t. overnight.
118. Any method of -lactonization via -CH activation, -lactonization via -CH activation, -lactonization via -CH activation, or total syntheses of natural products as disclosed herein.
Description
BRIEF DESCRIPTION OF THE FIGURES
[0011]
[0012]
[0013]
[0014]
DETAILED DESCRIPTION OF THE INVENTION
[0015] Disclosed herein is the development of site-selective CO bond formation reactions of dicarboxylic acids through lactonization, which was driven by the fact that lactones are ubiquitous in organic chemistry, and that the monolactonization of dicarboxylic acids would leave the remaining carboxyl group as a versatile handle for further synthetic elaborations (17). It was estimated that more than 3,000 -lactones exist in nature (18, 19), and the formation of lactones at methylene carbons is commonplace in natural products, as demonstrated in the structures of ginkgolide B, bilobalide, picrotoxinin, and cladantholide (20, 21). Benzo-fused lactones such as phthalides and isochromanones are also recurring structures in bioactive natural products, such as colletotrialide, fusarentin 6,7-dimethyl ether, and ajudazol B (22, 23) (
[0016] Herein disclosed are two distinct catalysts for site-selective - and -CH activation of dicarboxylic acids using quinoline-pyridone ligands, which lead to three modes of lactonization for the synthesis of - and -lactones from various dicarboxylic acids (
[0017] The development of the lactonization reaction began with exploratory studies using adipic acid 1 as the standard substrate. It was realized that bis-carboxylate chelation of the dicarboxylic acid could prevent the desired directed CH activation, and thus a highly efficient bidentate ligand would be required to overcome this potential hurdle. Building on the precedent that pyridine-pyridone type ligands could promote -methylene CH activation in a palladium-catalyzed, carboxylic acid-directed dehydrogenation reaction (13), a series of pyridine-pyridone type ligands were investigated for the desired CO bond forming reactivity (see The Experimental section). Following extensive optimization of reaction parameters, the five-membered chelating quinoline-pyridone ligand L1 emerged as the most effective at initiating the lactonization of 1 to provide -lactone 1a in 65% isolated yield (
[0018] The generality of these two modes of lactonization via -CH activation was investigated with a series of dicarboxylic acids with various substitutions and topologies. For -lactonization reactions via -CH activation with ligand L1 (
[0019] For 6-lactonization reactions via -CH activation (
[0020] Subsequently, whether the 7-methylene CH bonds of pimelic acid 2 could also be activated for -lactonization was investigated. This was believed to present a significant challenge for CH activation because activation of the competing -methylene CH bonds that would result in five-membered cyclopalladation was expected to be both kinetically and thermodynamically preferred (25). It was expected that overcoming this hurdle for CH activation could lead to two distinct site-selective lactonization pathways via - or -methylene CH activation. With this objective in mind, other types of quinoline-pyridone ligands were explored. It was discovered that ligand L2 provided the desired -lactone 2b in 62% isolated yield (
[0021] With the scope of the lactonization established, silver-free conditions for the three modes of lactonization reactions were sought and MnO.sub.2 was found to be a viable replacement for Ag.sub.2CO.sub.3 as the oxidant. Upon further fine-tuning of the reaction conditions (see The Experimental section), the lactonization reactions could be rendered silver-free across a series of substrates (
[0022] In light of the broad scope of lactones prepared by this methodology, two total syntheses as a means to demonstrate the synthetic utility offered by the fusion of dicarboxylic acids and CH lactonization (
[0023] It was concluded that site-selective - and -methylene CH activation of aliphatic acids with two quinoline-pyridone ligands L1 and L2 had been achieved. This led to the development of three modes of lactonization reaction for the syntheses of - and -lactones from a great variety of dicarboxylic acids. The utility of the methodology is demonstrated by the total syntheses of two natural products as disclosed herein.
REFERENCES
[0024] 1. L.-C. Kao, A. Sen, Platinum(II) Catalysed Selective Remote Oxidation of Unactivated CH Bonds in Aliphatic Carboxylic Acids. J. Chem. Soc., Chem. Commun., 1242-1243 (1991). [0025] 2. B. D. Dangel, J. A. Johnson, D. Sames, Selective functionalization of amino acids in water: A synthetic method via catalytic CH bond activation. J. Am. Chem. Soc. 123, 8149-8150 (2001). [0026] 3. R. Giri, N. Maugel, J. J. Li, D. H. Wang, S. P. Breazzano, L. B. Saunders, J. Q. Yu, Palladium-catalyzed methylation and arylation of sp.sup.2 and sp.sup.3 CH bonds in simple carboxylic acids. J. Am. Chem. Soc. 129, 3510-3511 (2007). [0027] 4. Z. Zhuang, C. bin Yu, G. Chen, Q. F. Wu, Y. Hsiao, C. L. Joe, J. X. Qiao, M. A. Poss, J. Q. Yu, Ligand-Enabled OC(sp.sup.3)-H Olefination of Free Carboxylic Acids. J. Am. Chem. Soc. 140, 10363-10367 (2018). [0028] 5. Z. Zhuang, A. N. Herron, Z. Fan, J. Q. Yu, Ligand-Enabled Monoselective -C(sp.sup.3)-H Acyloxylation of Free Carboxylic Acids Using a Practical Oxidant. J. Am. Chem. Soc. 142, 6769-6776 (2020). [0029] 6. Z. Zhuang, J. Q. Yu, Lactonization as a general route to -C(sp.sup.3)-H functionalization. Nature. 577, 656-659 (2020). [0030] 7. Z. Zhuang, A. N. Herron, J. Q. Yu, Synthesis of Cyclic Anhydrides via Ligand-Enabled CH Carbonylation of Simple Aliphatic Acids. Angewandte Chemie International Edition. 60, 16382-16387 (2021). [0031] 8. K. K. Ghosh, M. van Gemmeren, Pd-Catalyzed -C(sp.sup.3)-H Arylation of Propionic Acid and Related Aliphatic Acids. ChemistryA European Journal. 23, 17697-17700 (2017). [0032] 9. K. K. Ghosh, A. Uttry, A. Koldemir, M. Ong, M. van Gemmeren, Direct -C(sp.sup.3)-H acetoxylation of aliphatic carboxylic acids. Organic Letters. 21, 7154-7157 (2019). [0033] 10. K. K. Ghosh, A. Uttry, F. Ghiringhelli, A. Mondal, M. van Gemmeren, Ligand-Enabled -C(sp.sup.3)-H Olefination of Free Carboxylic Acids. Angewandte Chemie International Edition. 59, 12848-12852 (2020). [0034] 11. F. Ghiringhelli, A. Uttry, K. K. Ghosh, M. van Gemmeren, Direct - and -C(sp.sup.3)-H Alkynylation of Free Carboxylic Acids. Angewandte Chemie International Edition. 59, 23127-23131 (2020). [0035] 12. A. Uttry, S. Mal, M. van Gemmeren, Late-Stage -C(sp.sup.3)-H Deuteration of Carboxylic Acids. J. Am. Chem. Soc. 143, 10895-10901 (2021). [0036] 13. Z. Wang, L. Hu, N. Chekshin, Z. Zhuang, S. Qian, J. X. Qiao, J.-Q. Yu, Ligand-controlled divergent dehydrogenative reactions of carboxylic acids via CH activation. Science. 374, 1281-1285 (2021). [0037] 14. M. Cianfanelli, G. Olivo, M. Milan, R. J. M. Klein Gebbink, X. Ribas, M. Bietti, M. Costas, Enantioselective CH Lactonization of Unactivated Methylenes Directed by Carboxylic Acids. J. Am. Chem. Soc. 142, 1584-1593 (2020). [0038] 15. L. Vicens, M. Bietti, M. Costas, General Access to Modified -Amino Acids by Bioinspired Stereoselective -CH Bond Lactonization. Angewandte Chemie International Edition. 60, 4740-4746 (2021). [0039] 16. M. S. Chen, M. C. White, A Predictably Selective Aliphatic CH Oxidation Reaction for Complex Molecule Synthesis. Science. 318, 783-787 (2007). [0040] 17. J. Schwarz, B. Knig, Decarboxylative reactions with and without lighta comparison. Green Chemistry. 20, 323-361 (2018). [0041] 18. S. K. Sartori, M. A. N. Diaz, G. Diaz-Muoz, Lactones: Classification, synthesis, biological activities, and industrial applications. Tetrahedron. 84, 132001-132039 (2021). [0042] 19. M. Seitz, O. Reiser, Synthetic approaches towards structurally diverse -butyrolactone natural-product-like compounds. Current Opinion in Chemical Biology. 9 (2005), pp. 285-292. [0043] 20. H. T. Simonsen, C. Weitzel, S. B. Christensen, in Natural Products: Phytochemistry, Botany and Metabolism of Alkaloids, Phenolics and Terpenes (Springer Berlin Heidelberg, 2013), pp. 3069-3098. [0044] 21. K. Strmgaard, K. Nakanishi, Chemistry and biology of terpene trilactones from Ginkgo biloba. Angewandte Chemie International Edition. 43, 1640-1658 (2004). [0045] 22. G. Shabir, A. Saeed, H. R. El-Seedi, Natural isocoumarins: Structural styles and biological activities, the revelations carry on. Phytochemistry. 181, 112568-112787 (2021). [0046] 23. A. D. Kinghorn, H. Falk, S. Gibbons, J. Kobayashi, Eds., Progress in the Chemistry of Organic Natural Products (Springer Nature, 2017), vol. 104. [0047] 24. F. Zaragoza Drwald, Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design (Wiley, 2004). [0048] 25. G. Xia, J. Weng, L. Liu, P. Verma, Z. Li, J. Q. Yu, Reversing conventional site-selectivity in C(sp 3)-H bond activation. Nature Chemistry. 11, 571-577 (2019). [0049] 26. P. Novak, A. Correa, J. Gallardo-Donaire, R. Martin, Synergistic palladium-catalyzed C(sp.sup.3)-H Activation/C(sp.sup.3)-O bond formation: A direct, step-economical route to benzolactones. Angewandte Chemie International Edition. 50, 12236-12239 (2011). [0050] 27. J. M. Lee, S. Chang, Pt-Catalyzed sp.sup.3 CH bond activation of o-alkyl substituted aromatic carboxylic acid derivatives for the formation of aryl lactones. Tetrahedron Letters. 47, 1375-1379 (2006). [0051] 28. T. Lin, G. Wang, W. Shan, D. Zeng, R. Ding, X. Jiang, D. Zhu, X. Liu, S. Yang, H. Chen, Myrotheciumones: Bicyclic cytotoxic lactones isolated from an endophytic fungus of Ajuga decumbens. Bioorganic and Medicinal Chemistry Letters. 24, 2504-2507 (2014). [0052] S. N. Khan, M. K. Zaman, R. Li, Z. Sun, A General Method for Photocatalytic Decarboxylative Hydroxylation of Carboxylic Acids. Journal of Organic Chemistry. 85, 5019-5026 (2020). [0053] 30. S. Begum, T. K. Chakraborty, Cp2TiCl-Mediated Reductive Cyclization: Total Synthesis of Pestalotiolactone A, Myrotheciumone A, and Scabrol A. Journal of Organic Chemistry. 86, 11812-11821 (2021). [0054] 31. E. M. Mpondo, J. Garcia, A. J. Chulia, New Phthalides from Gentiana pedicellata. Planta Medica. 53, 297-298 (1987).
EMBODIMENTS
[0055] The application provides the following embodiments:
Embodiment 1
[0056] A method of - or -lactonization via -CH activation, comprising i) treating a dicarboxylic acid substrate with a quinoline-pyridone or pyridine-pyridone ligand in the presence of a Pd source; and ii) addition of p-xyloquinone (BQ3), an Ag salt, and K.sub.2HPO.sub.4 in a reaction vessel.
Embodiment 2
[0057] The method of embodiment 1, wherein the quinoline-pyridone or pyridine-pyridone ligand is selected from the group consisting of:
##STR00002##
Embodiment 3
[0058] The method of any one of embodiments 1-2, wherein the Pd source is Pd(OAc).sub.2.
Embodiment 4
[0059] The method of any one of embodiments 1-3, wherein the Ag salt is Ag.sub.2CO.sub.3.
Embodiment 5
[0060] The method of any one of embodiments 1-4, wherein the quinoline-pyridone ligand is L1.
Embodiment 6
[0061] The method of any one of embodiments 1-4, wherein the pyridine-pyridone ligand is L18.
Embodiment 7
[0062] The method of any one of embodiments 1-4, wherein the pyridine-pyridone ligand is L17.
Embodiment 8
[0063] The method of any one of embodiments 1-4, wherein the pyridine-pyridone ligand is L13.
Embodiment 9
[0064] The method of any one of embodiments 1-4, wherein the pyridine-pyridone ligand is L14.
Embodiment 10
[0065] The method of any one of embodiments 1-4, wherein the pyridine-pyridone ligand is L11.
Embodiment 11
[0066] The method of any one of embodiments 1-4, wherein the quinoline-pyridone ligand is L10.
Embodiment 12
[0067] The method of any one of embodiments 1-4, wherein the quinoline-pyridone ligand is L16.
Embodiment 13
[0068] The method of any one of embodiments 1-4, wherein the pyridine-pyridone ligand is L12.
Embodiment 14
[0069] The method of any one of embodiments 1-4, wherein the pyridine-pyridone ligand is L15.
Embodiment 15
[0070] The method of -CH lactonization via -CH activation of embodiment 1, wherein the dicarboxylic acid substrate is 1.0 eq. adipic acid, the quinoline-pyridone ligand is 12 mol % L1, the Pd source is 10 mol % Pd(OAc).sub.2, the Ag salt is 2.0 eq. Ag.sub.2CO.sub.3, with 2.0 eq. BQ3, 1.0 eq. K.sub.2HPO.sub.4 in HFIP at 100 C. for 36 h and the reaction vessel is an 8-10 mL vial.
Embodiment 16
[0071] The method of -lactonization via -CH activation of embodiment 1, wherein the dicarboxylic acid substrate is 1.0 eq. pimelic acid, the quinoline-pyridone ligand is 12 mol % L1, the Pd source is 10 mol % Pd(OAc).sub.2, the Ag salt is 2.0 eq. Ag.sub.2CO.sub.3, with 2.0 eq. BQ3, 1.0 eq. K.sub.2HPO.sub.4 in HFIP at 100 C. for 36 h and the reaction vessel is an 8-10 mL vial.
Embodiment 17
[0072] The method of either one of embodiments 15 or 16, wherein the 1.0 eq. K.sub.2HPO.sub.4 is replaced with 0.75 eq. K.sub.2HPO.sub.4.
Embodiment 18
[0073] The method of either one of embodiments 15 or 16, wherein the 1.0 eq. K.sub.2HPO.sub.4 is replaced with a mixture of 0.35 eq. K.sub.2HPO.sub.4 and 0.4 eq. CsOAc.
Embodiment 19
[0074] The method of either one of embodiments 15 or 16, wherein the 2.0 eq. Ag.sub.2CO.sub.3 is replaced with 4.0 eq. MnO.sub.2 and the 1.0 eq. K.sub.2HPO.sub.4 is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1.0:1.5:1.0, 0.75 eq. total).
Embodiment 20
[0075] A method of -lactonization via -CH activation comprising i) treating a dicarboxylic acid substrate with a quinoline-pyridone or pyridine-pyridone ligand in the presence of a Pd source; and ii) addition of BQ3, Ag.sub.2CO.sub.3 and K.sub.2HPO.sub.4 in a reaction vessel.
Embodiment 21
[0076] The method of embodiment 20, wherein the quinoline-pyridone or pyridine-pyridone ligand is selected from the group consisting of:
##STR00003## ##STR00004##
Embodiment 22
[0077] The method of embodiment 21, wherein the quinoline-pyridone ligand is L2.
Embodiment 23
[0078] The method of embodiment 21, wherein the quinoline-pyridone ligand is L9.
Embodiment 24
[0079] The method of embodiment 21, wherein the quinoline-pyridone ligand is L8.
Embodiment 25
[0080] The method of embodiment 21, wherein the quinoline-pyridone ligand is L7.
Embodiment 26
[0081] The method of embodiment 21, wherein the pyridine-pyridone ligand is L5.
Embodiment 27
[0082] The method of embodiment 21, wherein the pyridine-pyridone ligand is L4.
Embodiment 28
[0083] The method of embodiment 21, wherein the quinoline-pyridone ligand is L6.
Embodiment 29
[0084] The method of embodiment 21, wherein the quinoline-pyridone ligand is L1.
Embodiment 30
[0085] A method of -lactonization via -CH activation comprising i) treating a dicarboxylic acid substrate with L2 in the presence of a Pd source; and ii) addition of an oxidant and K.sub.2HPO.sub.4.
Embodiment 31
[0086] The method of embodiment 30, wherein the oxidant is 2.0 eq. Na.sub.2S.sub.2O.sub.8.
Embodiment 32
[0087] The method of embodiment 30, wherein the oxidant is 2.0 eq. K.sub.2S.sub.2O.sub.8.
Embodiment 33
[0088] The method of embodiment 30, wherein the oxidant is 2.0 eq. BzOO.sup.tBu.
Embodiment 34
[0089] The method of embodiment 30, wherein the oxidant is 2.0 eq. AcOO.sup.tBu.
Embodiment 35
[0090] The method of embodiment 30, wherein the oxidant is 2.0 eq. Ce(SO.sub.4).sub.2.
Embodiment 36
[0091] The method of embodiment 30, wherein the oxidant is 2.0 eq. CMHP.
Embodiment 37
[0092] The method of embodiment 30, wherein the oxidant is 2.0 eq. .sup.tBuOO.sup.tu.
Embodiment 38
[0093] The method of embodiment 30, wherein the oxidant is 2.0 eq. 1-iodo-3,5-bis(trifluoromethyl)benzene.
Embodiment 39
[0094] The method of embodiment 30, wherein the oxidant is 2.0 eq. methyl 4-iodobenzoate.
Embodiment 40
[0095] The method of embodiment 30, wherein the oxidant is 2.0 eq. 1,2,3,4,5-pentafluoro-6-iodobenzene.
Embodiment 41
[0096] The method of embodiment 30, wherein the oxidant is 2.0 eq. TBHP in H.sub.2O.
Embodiment 42
[0097] The method of embodiment 30, wherein the oxidant is 2.0 eq. H.sub.2O.sub.2 in H.sub.2O.
Embodiment 43
[0098] The method of embodiment 30, wherein the oxidant is selected from the group consisting of:
##STR00005## ##STR00006##
Embodiment 44
[0099] The method of embodiment 43, wherein the oxidant is BQ8.
Embodiment 45
[0100] The method of embodiment 43, wherein the oxidant is BQ5.
Embodiment 46
[0101] The method of embodiment 43, wherein the oxidant is BQ4.
Embodiment 47
[0102] The method of embodiment 43, wherein the oxidant is BQ6.
Embodiment 48
[0103] The method of embodiment 43, wherein the oxidant is BQ1.
Embodiment 49
[0104] The method of embodiment 43, wherein the oxidant is BQ12.
Embodiment 50
[0105] The method of embodiment 43, wherein the oxidant is BQ2.
Embodiment 51
[0106] The method of embodiment 43, wherein the oxidant is BQ9.
Embodiment 52
[0107] The method of embodiment 43, wherein the oxidant is BQ7.
Embodiment 53
[0108] The method of embodiment 43, wherein the oxidant is BQ11.
Embodiment 54
[0109] The method of embodiment 43, wherein the oxidant is BQ13.
Embodiment 55
[0110] The method of embodiment 30, wherein the oxidant is AgOAc.
Embodiment 56
[0111] The method of embodiment 30, wherein the oxidant is Ag2O.
Embodiment 57
[0112] The method of embodiment 30, wherein the oxidant is AgF.
Embodiment 58
[0113] The method of embodiment 30, wherein the oxidant is Ag.sub.2CO.sub.3.
Embodiment 59
[0114] The method of embodiment 30, wherein the oxidant is AgNO.sub.3.
Embodiment 60
[0115] The method of embodiment 30, wherein the oxidant is Ag.sub.3PO.sub.4.
Embodiment 61
[0116] The method of embodiment 30, wherein the oxidant is CuSO.sub.4.Math.5H.sub.2O.
Embodiment 62
[0117] The method of embodiment 30, wherein the oxidant is CuF.sub.2.
Embodiment 63
[0118] The method of embodiment 30, wherein the oxidant is CuO.
Embodiment 64
[0119] The method of embodiment 30, wherein the oxidant is Cu.sub.3(PO.sub.4).sub.2.
Embodiment 65
[0120] The method of embodiment 30, wherein the oxidant is CuBr.sub.2.
Embodiment 66
[0121] The method of embodiment 30, wherein the oxidant is CuCO.sub.3.
Embodiment 67
[0122] The method of embodiment 30, wherein the oxidant is a mixture of BQ3 and an Ag salt.
Embodiment 68
[0123] The method of embodiment 67, wherein the Ag salt is Ag.sub.2CO.sub.3.
Embodiment 69
[0124] The method of embodiment 67, wherein the Ag salt is Ag.sub.3PO.sub.4.
Embodiment 70
[0125] The method of embodiment 67, wherein the Ag salt is AgF.
Embodiment 71
[0126] The method of embodiment 67, wherein the Ag salt is Ag.sub.2O.
Embodiment 72
[0127] The method of embodiment 67, wherein the Ag salt is AgOAc.
Embodiment 73
[0128] The method of any one of embodiments 20-72, wherein the Pd source is Pd(OAc).sub.2.
Embodiment 74
[0129] The method of any one of embodiments 20-72, wherein the Pd source is Pd(TFA).sub.2.
Embodiment 75
[0130] The method of any one of embodiments 20-72, wherein the Pd source is Pd(MeCN).sub.4(BF.sub.4).sub.2.
Embodiment 76
[0131] The method of any one of embodiments 20-72, wherein the Pd source is Pd(MeCN).sub.4(OTf).sub.2.
Embodiment 77
[0132] The method of any one of embodiments 20-72, wherein the Pd source is PdCl.sub.2.
Embodiment 78
[0133] The method of any one of embodiments 20-72, wherein the Pd source is PdCl.sub.2(PhCN).sub.2.
Embodiment 79
[0134] The method of any one of embodiments 20-72, wherein the Pd source is Pd.sub.2(dba).sub.3.
Embodiment 80
[0135] The method of any one of embodiments 20-72, wherein the Pd source is PdCl.sub.2(MeCN).sub.2.
Embodiment 81
[0136] The method of any one of embodiments 20-80, wherein the dicarboxylic acid substrate is pimelic acid
Embodiment 82
[0137] The method of any one of embodiments 20-80, wherein the dicarboxylic acid substrate is 2,2,6,6-tetramethylpimelic acid.
Embodiment 83
[0138] The method of embodiment 20, wherein the dicarboxylic acid substrate is 1.0 eq. pimelic acid, the quinoline-pyridone ligand is 12 mol % L2, the Pd source is 10 mol % Pd(OAc).sub.2, the oxidant is 2.0 eq. BQ3 and 2.0 eq. of an Ag salt, and 1.0 eq. K.sub.2HPO.sub.4, the reaction vessel is a vial between 8-10 mL, the reaction temperature is between 80-100 C., and the reaction time is between 12-72 h.
Embodiment 84
[0139] The method of embodiment 83, wherein the Ag salt is Ag.sub.2CO.sub.3.
Embodiment 85
[0140] The method of embodiment 83, wherein the Ag salt is Ag.sub.3PO.sub.4.
Embodiment 86
[0141] The method of embodiment 83, wherein the Ag salt is AgF.
Embodiment 87
[0142] The method of embodiment 83, wherein the Ag salt is Ag.sub.2O.
Embodiment 88
[0143] The method of embodiment 83, wherein the Ag salt is AgOAc.
Embodiment 89
[0144] The method of embodiment 84, wherein the Ag.sub.2CO.sub.3 is replaced by K.sub.2S.sub.2O.sub.8.
Embodiment 90
[0145] The method of embodiment 84, wherein the Ag.sub.2CO.sub.3 is replaced with 0.5 eq. Ag.sub.2CO.sub.3 in addition to replacing the 2.0 eq. BQ3 with 0.5 eq. BQ3.
Embodiment 91
[0146] The method of embodiment 84, wherein the 2.0 eq. Ag.sub.2CO.sub.3 is replaced with 1.0 eq. Ag.sub.2CO.sub.3 in addition to replacing the 2.0 eq. BQ3 with 1.0 eq. BQ3.
Embodiment 92
[0147] The method of any one of embodiments 20-91, wherein the reaction temperature is 100 C.
Embodiment 93
[0148] The method of any one of embodiments 20-91, wherein the reaction temperature is 80 C.
Embodiment 94
[0149] The method of any one of embodiments 20-91, wherein the reaction temperature is 120 C.
Embodiment 95
[0150] The method of any one of embodiments 20-94, wherein the reaction time is 12 h.
Embodiment 96
[0151] The method of any one of embodiments 20-94, wherein the reaction time is 24 h.
Embodiment 97
[0152] The method of any one of embodiments 20-94, wherein the reaction time is 36 h.
Embodiment 98
[0153] The method of any one of embodiments 20-94, wherein the reaction time is 72 h.
Embodiment 99
[0154] The method of any one of embodiments 20-98, wherein the reaction vessel is a 10 mL vial.
Embodiment 100
[0155] The method of any one of embodiments 20-98, wherein the reaction vessel is an 8 mL vial, the reaction temperature is 100 C., and the reaction time is 36 h.
Embodiment 101
[0156] The method of embodiment 83, wherein the 1.0 eq. of K.sub.2HPO.sub.4 is replaced with 0.75 eq. K.sub.2HPO.sub.4 and the reaction vessel is an 8 mL vial, the reaction temperature is 100 C., and the reaction time is 36 h.
Embodiment 102
[0157] The method of embodiment 83, wherein the 1.0 eq. of K.sub.2HPO.sub.4 is replaced with 0.35 eq K.sub.21HPO.sub.4 and 0.4 eq. CsOAc, the reaction vessel is an 8 mL vial, the reaction temperature is 100 C., and the reaction time is 36 h.
Embodiment 103
[0158] The method of embodiment 83, wherein the 1.0 eq. of K.sub.2HPO.sub.4 is replaced with 0.35 eq K.sub.2HPO.sub.4 and 0.4 eq. CsOAc, L2 is replaced with L10, and the reaction vessel is an 8 mL vial, the reaction temperature is 100 C., and the reaction time is 36 h.
Embodiment 104
[0159] The method of embodiment 83, wherein the 1.0 eq. of K.sub.2HPO.sub.4 is replaced with 0.35 eq K.sub.2HPO.sub.4 and 0.4 eq. CsOAc, L2 is replaced with L10, the reaction vessel is an 8 mL vial, the reaction temperature is 100 C., and the reaction time is 48 h.
Embodiment 105
[0160] The method of embodiment 83, wherein the 2.0 eq. of an Ag salt is replaced with 2.0 eq. of MnO.sub.2.
Embodiment 106
[0161] The method of embodiment 83, wherein the 2.0 eq. of an Ag salt is replaced with 6.0 eq. of MnO.sub.2.
Embodiment 107
[0162] The method of embodiment 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:1.5:1, total 0.75 eq.).
Embodiment 108
[0163] The method of embodiment 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:1.5:1, total 1.0 eq.).
Embodiment 109
[0164] The method of embodiment 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:2:1, total 0.75 eq.).
Embodiment 110
[0165] The method of embodiment 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:2:1, total 1.0 eq.).
Embodiment 111
[0166] The method of embodiment 83, wherein the reaction time is 48 h.
Embodiment 112
[0167] The method of embodiment 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:1.5:1, total 0.75 eq.) and L2 is replaced with L10.
Embodiment 113
[0168] The method of embodiment 83, wherein the 2.0 eq. of an Ag salt is replaced with K.sub.2HPO.sub.4:KH.sub.2PO.sub.4:CsOAc (1:1.5:1, total 0.75 eq.), L2 is replaced with L10, and the reaction time is 48 h.
Embodiment 114
[0169] The method of embodiment 83, wherein, the oxidant is 2.0 eq. BQ3 and 2.0 eq. of Ag.sub.2CO.sub.3, the reaction vessel is a 10 mL vial, the reaction temperature is 100 C., and the reaction time is 36 h.
Embodiment 115
[0170] The method of embodiment 83, comprising i) treating 1.0 eq. pimelic acid with 12 mol % ligand L2 in the presence of 10 mol % Pd(OAc).sub.2; and ii) addition of 2.0 eq. Ag.sub.2CO.sub.3, 2.0 eq. BQ3, and 1.0 eq. K.sub.2HPO.sub.4 at 100 C. in HFIP for 36 h in an 8 mL vial.
Embodiment 116
[0171] A method for the total synthesis of Myrotheciumone A. comprising the following steps: [0172] (1) reaction of MeI (2.0 eq.) and K.sub.2CO.sub.3 (3.0 eq.), in acetone, and refluxed for 3 hr; [0173] (2) reaction with Ph.sub.3PCH.sub.3Br (2.9 eq.) and tBuOK (2.4 eq.), in toluene, at r.t. overnight; [0174] (3) reaction with mCPBA (1.2 eq.), in CH.sub.2Cl.sub.2, at r.t. overnight; [0175] (4) reaction with TMSOTf (2.0 eq.) and 2,6-lutidine (2.0 eq.), in toluene, at 78 C. to r.t. overnight; [0176] (5) reaction with cat. Pivalic acid (10 mol %) and triethyl orthoacetate, neat, at 155 C., overnight and further reaction with cat. p-TsOH (10 mol %), in toluene, and refluxed overnight; [0177] (6) reaction with cat. PtO.sub.2, under H.sub.2 (4-layered balloon), in AcOH, at r.t. overnight; (7) reaction with 15% aq. NaOH, and refluxed overnight; [0178] (8) reaction with Pd(OAc).sub.2 (10 mol %), Ligand L2 (12 mol %), BQ3 (2.0 eq.), Ag.sub.2CO.sub.3 (2.0 eq.), K.sub.2HPO.sub.4 (0.35 eq.), and CsOAc (0.40 eq.), in HFIP, at 100 C., for 36 h; and [0179] (9) reaction with (Ir[dF(CF.sub.3)ppy].sub.2(dtbpy))PF.sub.6 (1 mol %), Cs.sub.2CO.sub.3 (1.5 eq.), and NaBH.sub.4 (1.2 eq.), under O.sub.2 atmosphere, in CH.sub.2Cl.sub.2, at 40 C., 4100 W Blue LED lamps, for 40 h.
Embodiment 117
[0180] A method for the total synthesis of Pedicellosine comprising the following steps: [0181] (1) reaction of Pd(OAc).sub.2 (10 mol %), Ligand L2 (12 mol %), BQ3 (2.0 eq.), Ag.sub.2CO.sub.3 (2.0 eq.), K.sub.2HPO.sub.4 (0.35 eq.), and CsOAc (0.40 eq.), in HFIP, at 100 C., for 36 h; [0182] (2) reaction with BH.sub.3.Math.Me.sub.2S (1.6 eq.), in THF, at 0 C. to r.t. overnight; and [0183] (3) reaction with EDCI (1.5 eq.), DMAP (20 mol %), and 2,3-dihydroxybenzoic acid (1.5 eq.), in CH.sub.2Cl.sub.2, at r.t. overnight.
Embodiment 118
[0184] The application provides any method of -lactonization via -CH activation, S-lactonization via CH activation, -lactonization via -CH activation, or total syntheses of natural products as disclosed herein.
Definitions
[0185] The phrase a or an entity as used herein refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. As such, the terms a (or an), one or more, and at least one can be used interchangeably herein.
[0186] The phrase as defined herein above refers to the broadest definition for each group as provided in the Summary of the Invention, the Detailed Description of the Invention, the Experimentals, or the broadest claim. In all other embodiments provided below, substituents which can be present in each embodiment and which are not explicitly defined retain the broadest definition provided in the Summary of the Invention.
[0187] As used in this specification, whether in a transitional phrase or in the body of the claim, the terms comprise(s) and comprising are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases having at least or including at least. When used in the context of a process, the term comprising means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound or composition, the term comprising means that the compound or composition includes at least the recited features or components, but may also include additional features or components.
[0188] As used herein, unless specifically indicated otherwise, the word or is used in the inclusive sense of and/or and not the exclusive sense of either/or.
[0189] The term independently is used herein to indicate that a variable is applied in any one instance without regard to the presence or absence of a variable having that same or a different definition within the same compound. Thus, in a compound in which R appears twice and is defined as independently selected from means that each instance of that R group is separately identified as one member of the set which follows in the definition of that R group. For example, each R.sup.1 and R.sup.2 is independently selected from carbon and nitrogen means that both R.sup.1 and R.sup.2 can be carbon, both R.sup.1 and R.sup.2 can be nitrogen, or R.sup.1 or R.sup.2 can be carbon and the other nitrogen or vice versa.
[0190] When any variable occurs more than one time in any moiety or formula depicting and describing compounds employed or claimed in the present invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such compounds result in stable compounds.
[0191] The symbols * at the end of a bond or a line drawn through a bond or drawn through a bond each refer to the point of attachment of a functional group or other chemical moiety to the rest of the molecule of which it is a part.
[0192] A bond drawn into ring system (as opposed to connected at a distinct vertex) indicates that the bond may be attached to any of the suitable ring atoms.
[0193] The term optional or optionally as used herein means that a subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, optionally substituted means that the optionally substituted moiety may incorporate a hydrogen or a substituent.
[0194] The phrase optional bond means that the bond may or may not be present, and that the description includes single, double, or triple bonds. If a substituent is designated to be a bond or absent, the atoms linked to the substituents are then directly connected.
[0195] The term about is used herein to mean approximately, in the region of, roughly, or around. When the term about is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term about is used herein to modify a numerical value above and below the stated value by a variance of 20%.
[0196] Certain compounds of Formulae I-X may exhibit tautomerism. Tautomeric compounds can exist as two or more interconvertable species. Prototropic tautomers result from the migration of a covalently bonded hydrogen atom between two atoms. Tautomers generally exist in equilibrium and attempts to isolate an individual tautomers usually produce a mixture whose chemical and physical properties are consistent with a mixture of compounds. The position of the equilibrium is dependent on chemical features within the molecule. For example, in many aliphatic aldehydes and ketones, such as acetaldehyde, the keto form predominates while; in phenols, the enol form predominates. Common prototropic tautomers include keto/enol (C(O)CHC(OH)CH), amide/imidic acid (C(O)NH
C(OH)N) and amidine (C(NR)NH
C(NHR)N) tautomers. The latter two are particularly common in heteroaryl and heterocyclic rings and the present invention encompasses all tautomeric forms of the compounds.
[0197] Technical and scientific terms used herein have the meaning commonly understood by one of skill in the art to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies and materials known to those of skill in the art. Standard reference works setting forth the general principles of pharmacology include Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10.sup.th Ed., McGraw Hill Companies Inc., New York (2001). Any suitable materials and/or methods known to those of skill can be utilized in carrying out the present invention. However, preferred materials and methods are described. Materials, reagents and the like to which reference are made in the following description and examples are obtainable from commercial sources, unless otherwise noted.
[0198] The definitions described herein may be appended to form chemically-relevant combinations, such as heteroalkylaryl, haloalkylheteroaryl, arylalkylheterocyclyl, alkylcarbonyl, alkoxyalkyl, and the like. When the term alkyl is used as a suffix following another term, as in phenylalkyl, or hydroxyalkyl, this is intended to refer to an alkyl group, as defined above, being substituted with one to two substituents selected from the other specifically-named group. Thus, for example, phenylalkyl refers to an alkyl group having one to two phenyl substituents, and thus includes benzyl, phenylethyl, and biphenyl. An alkylaminoalkyl is an alkyl group having one to two alkylamino substituents. Hydroxyalkyl includes 2-hydroxyethyl, 2-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 2,3-dihydroxybutyl, 2-(hydroxymethyl), 3-hydroxypropyl, and so forth. Accordingly, as used herein, the term hydroxyalkyl is used to define a subset of heteroalkyl groups defined below. The term -(ar)alkyl refers to either an unsubstituted alkyl or an aralkyl group. The term (hetero)aryl or (het)aryl refers to either an aryl or a heteroaryl group.
[0199] The term acyl as used herein denotes a group of formula C(O)R wherein R is hydrogen or lower alkyl as defined herein. The term or alkylcarbonyl as used herein denotes a group of formula C(O)R wherein R is alkyl as defined herein. The term C.sub.1-6 acyl refers to a group C(O)R contain 6 carbon atoms. The term arylcarbonyl as used herein means a group of formula C(O)R wherein R is an aryl group; the term benzoyl as used herein an arylcarbonyl group wherein R is phenyl.
[0200] The term alkyl as used herein denotes an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 12 carbon atoms. The term lower alkyl or C.sub.1-C.sub.6 alkyl as used herein denotes a straight or branched chain hydrocarbon residue containing 1 to 6 carbon atoms. C.sub.1-12 alkyl as used herein refers to an alkyl composed of 1 to 12 carbons. Examples of alkyl groups include, but are not limited to, lower alkyl groups include methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, t-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl.
[0201] When the term alkyl is used as a suffix following another term, as in phenylalkyl, or hydroxyalkyl, this is intended to refer to an alkyl group, as defined above, being substituted with one to two substituents selected from the other specifically-named group. Thus, for example, phenylalkyl denotes the radical RR, wherein R is a phenyl radical, and R is an alkylene radical as defined herein with the understanding that the attachment point of the phenylalkyl moiety will be on the alkylene radical. Examples of arylalkyl radicals include, but are not limited to, benzyl, phenylethyl, 3-phenylpropyl. The terms arylalkyl or aralkyl are interpreted similarly except R is an aryl radical. The terms (het)arylalkyl or (het)aralkyl are interpreted similarly except R is optionally an aryl or a heteroaryl radical.
[0202] When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, C.sub.1-6 alkyl is intended to encompass, C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, C.sub.6, C.sub.1-6, C.sub.1-5, C.sub.1-4, C.sub.1-3, C.sub.1-2, C.sub.2-6, C.sub.2-5, C.sub.2-4, C.sub.2-3, C.sub.3-6, C.sub.3-5, C.sub.3-4, C.sub.4-6, C.sub.4-5, and C.sub.5-6 alkyl.
[0203] Alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (C.sub.1-20 alkyl). In some embodiments, an alkyl group has 1 to 15 carbon atoms (C.sub.1-15 alkyl). In some embodiments, an alkyl group has 1 to 14 carbon atoms (C.sub.1-14 alkyl). In some embodiments, an alkyl group has 1 to 13 carbon atoms (C.sub.1-13 alkyl). In some embodiments, an alkyl group has 1 to 12 carbon atoms (C.sub.1-12 alkyl). In some embodiments, an alkyl group has 1 to 11 carbon atoms (C.sub.1-11 alkyl). In some embodiments, an alkyl group has 1 to 10 carbon atoms (C.sub.1-10 alkyl). In some embodiments, an alkyl group has 1 to 9 carbon atoms (C.sub.1-9 alkyl). In some embodiments, an alkyl group has 1 to 8 carbon atoms (C.sub.1-8 alkyl). In some embodiments, an alkyl group has 1 to 7 carbon atoms (C.sub.1-7 alkyl). In some embodiments, an alkyl group has 1 to 6 carbon atoms (C.sub.1-6 alkyl). In some embodiments, an alkyl group has 1 to 5 carbon atoms (C.sub.1-5 alkyl). In some embodiments, an alkyl group has 1 to 4 carbon atoms (C.sub.1-4 alkyl). In some embodiments, an alkyl group has 1 to 3 carbon atoms (C.sub.1-3 alkyl). In some embodiments, an alkyl group has 1 to 2 carbon atoms (C.sub.1-2 alkyl). In some embodiments, an alkyl group has 1 carbon atom (C.sub.1 alkyl). In some embodiments, an alkyl group has 2 to 6 carbon atoms (C.sub.2-6 alkyl). Examples of C.sub.1-6 alkyl groups include methyl (C.sub.1), ethyl (C.sub.2), n-propyl (C.sub.3), isopropyl (C.sub.3), n-butyl (C.sub.4), tert-butyl (C.sub.4), sec-butyl (C.sub.4), iso-butyl (C.sub.4), n-pentyl (C.sub.5), 3-pentanyl (C.sub.5), amyl (C.sub.5), neopentyl (C.sub.5), 3-methyl-2-butanyl (C.sub.5), tertiary amyl (C.sub.5), and n-hexyl (C.sub.6). Additional examples of alkyl groups include n-heptyl (C.sub.7), n-octyl (C.sub.8) and the like.
[0204] Alkenyl or olefin refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 10 carbon atoms and 1, 2, 3, or 4 carbon-carbon double bonds (C.sub.2-10 alkenyl). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (C.sub.2-9 alkenyl). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (C.sub.2-8 alkenyl). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (C.sub.2-7 alkenyl). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (C.sub.2-6 alkenyl). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (C.sub.2-5 alkenyl). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (C.sub.2-4 alkenyl). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (C.sub.2-3 alkenyl). In some embodiments, an alkenyl group has 2 carbon atoms (C.sub.2 alkenyl). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C.sub.2-4 alkenyl groups include ethenyl (C.sub.2), 1-propenyl (C.sub.3), 2-propenyl (C.sub.3), 1-butenyl (C.sub.4), 2-butenyl (C.sub.4), butadienyl (C.sub.4), and the like. Examples of C.sub.2-6 alkenyl groups include the aforementioned C.sub.2-4 alkenyl groups as well as pentenyl (C.sub.5), pentadienyl (C.sub.5), hexenyl (C.sub.6), and the like. Additional examples of alkenyl include heptenyl (C.sub.7), octenyl (C.sub.8), octatrienyl (C.sub.8), and the like.
[0205] Alkynyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 10 carbon atoms and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds) (C.sub.2-10 alkynyl). In some embodiments, an alkynyl group has 2 to 9 carbon atoms (C.sub.2-9 alkynyl). In some embodiments, an alkynyl group has 2 to 8 carbon atoms (C.sub.2-8 alkynyl). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (C.sub.2-7 alkynyl). In some embodiments, an alkynyl group has 2 to 6 carbon atoms (C.sub.2-6 alkynyl). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (C.sub.2-5 alkynyl). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (C.sub.2-4 alkynyl). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (C.sub.2-3 alkynyl). In some embodiments, an alkynyl group has 2 carbon atoms (C.sub.2 alkynyl). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C.sub.2-4 alkynyl groups include, without limitation, ethynyl (C.sub.2), 1-propynyl (C.sub.3), 2-propynyl (C.sub.3), 1-butynyl (C.sub.4), 2-butynyl (C.sub.4), and the like. Examples of C.sub.2-6 alkenyl groups include the aforementioned C.sub.2-4 alkynyl groups as well as pentynyl (C.sub.5), hexynyl (C.sub.6), and the like. Additional examples of alkynyl include heptynyl (C.sub.7), octynyl (C.sub.8), and the like.
[0206] The terms haloalkyl or halo-lower alkyl or lower haloalkyl refers to a straight or branched chain hydrocarbon residue containing 1 to 6 carbon atoms wherein one or more carbon atoms are substituted with one or more halogen atoms.
[0207] The term alkylene or alkylenyl as used herein denotes a divalent saturated linear hydrocarbon radical of 1 to 10 carbon atoms (e.g., (CH.sub.2).sub.n) or a branched saturated divalent hydrocarbon radical of 2 to 10 carbon atoms (e.g., CHMe- or CH.sub.2CH(i-Pr)CH.sub.2), unless otherwise indicated. Except in the case of methylene, the open valences of an alkylene group are not attached to the same atom. Examples of alkylene radicals include, but are not limited to, methylene, ethylene, propylene, 2-methyl-propylene, 1,1-dimethyl-ethylene, butylene, 2-ethylbutylene.
[0208] The term alkoxy as used herein means an O-alkyl group, wherein alkyl is as defined above such as methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, t-butyloxy, pentyloxy, hexyloxy, including their isomers. Lower alkoxy as used herein denotes an alkoxy group with a lower alkyl group as previously defined. C.sub.1-10 alkoxy as used herein refers to an O-alkyl wherein alkyl is C.sub.1-10.
[0209] The term hydroxyalkyl as used herein denotes an alkyl radical as herein defined wherein one to three hydrogen atoms on different carbon atoms is/are replaced by hydroxyl groups.
[0210] The terms alkylsulfonyl and arylsulfonyl as used herein refers to a group of formula S(O).sub.2R wherein R is alkyl or aryl respectively and alkyl and aryl are as defined herein. The term heteroalkylsulfonyl as used herein refers herein denotes a group of formula S(O).sub.2R wherein R is heteroalkyl as defined herein.
[0211] The terms alkylsulfonylamino and arylsulfonylamino as used herein refers to a group of formula NR'S(O).sub.2R wherein R is alkyl or aryl respectively, R is hydrogen or C.sub.1-3 alkyl, and alkyl and aryl are as defined herein.
[0212] The term cycloalkyl as used herein refers to a saturated carbocyclic ring containing 3 to 8 carbon atoms, i.e. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. C.sub.3-7 cycloalkyl as used herein refers to an cycloalkyl composed of 3 to 7 carbons in the carbocyclic ring.
[0213] The term carboxy-alkyl as used herein refers to an alkyl moiety wherein one, hydrogen atom has been replaced with a carboxyl with the understanding that the point of attachment of the heteroalkyl radical is through a carbon atom. The term carboxy or carboxyl refers to a CO.sub.2H moiety.
[0214] The term heteroaryl or heteroaromatic as used herein means a monocyclic or bicyclic radical of 5 to 12 ring atoms having at least one aromatic ring containing four to eight atoms per ring, incorporating one or more N, O, or S heteroatoms, the remaining ring atoms being carbon, with the understanding that the attachment point of the heteroaryl radical will be on an aromatic ring. As well known to those skilled in the art, heteroaryl rings have less aromatic character than their all-carbon counter parts. Thus, for the purposes of the invention, a heteroaryl group need only have some degree of aromatic character. Examples of heteroaryl moieties include monocyclic aromatic heterocycles having 5 to 6 ring atoms and 1 to 3 heteroatoms include, but is not limited to, pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl, pyrazolyl, imidazolyl, oxazol, isoxazole, thiazole, isothiazole, triazoline, thiadiazole and oxadiaxoline which can optionally be substituted with one or more, preferably one or two substituents selected from hydroxy, cyano, alkyl, alkoxy, thio, lower haloalkoxy, alkylthio, halo, lower haloalkyl, alkylsulfinyl, alkylsulfonyl, halogen, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl, nitro, alkoxycarbonyl and carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylcarbamoyl, alkylcarbonylamino and arylcarbonylamino. Examples of bicyclic moieties include, but are not limited to, quinolinyl, isoquinolinyl, benzofuryl, benzothiophenyl, benzoxazole, benzisoxazole, benzothiazole and benzisothiazole. Bicyclic moieties can be optionally substituted on either ring; however the point of attachment is on a ring containing a heteroatom.
[0215] The term heterocyclyl, heterocycloalkyl or heterocycle as used herein denotes a monovalent saturated cyclic radical, consisting of one or more rings, preferably one to two rings, including spirocyclic ring systems, of three to eight atoms per ring, incorporating one or more ring heteroatoms (chosen from N, O or S(O).sub.0-2), and which can optionally be independently substituted with one or more, preferably one or two substituents selected from hydroxy, oxo, cyano, lower alkyl, lower alkoxy, lower haloalkoxy, alkylthio, halo, lower haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, unless otherwise indicated. Examples of heterocyclic radicals include, but are not limited to, azetidinyl, pyrrolidinyl, hexahydroazepinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl, oxazolidinyl, thiazolidinyl, isoxazolidinyl, morpholinyl, piperazinyl, piperidinyl, tetrahydropyranyl, thiomorpholinyl, quinuclidinyl and imidazolinyl.
[0216] Heterocyclyl or heterocyclic refers to a group or radical of a 3- to 14-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (3-14 membered heterocyclyl). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (monocyclic heterocyclyl) or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system (bicyclic heterocyclyl) or tricyclic system (tricyclic heterocyclyl)), and can be saturated or can contain one or more carbon-carbon double or triple bonds. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings. Heterocyclyl also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system.
[0217] In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-10 membered heterocyclyl). In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-8 membered heterocyclyl). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-6 membered heterocyclyl). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0218] Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azirdinyl, oxiranyl, and thiiranyl. Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, dioxolanyl, oxathiolanyl and dithiolanyl. Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing 1 heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazinanyl. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro-1,8-naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, 1H-benzo[e][1,4]diazepinyl, 1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl, 5,6-dihydro-4H-furo[3,2-b]pyrrolyl, 6,7-dihydro-5H-furo[3,2-b]pyranyl, 5,7-dihydro-4H-thieno[2,3-c]pyranyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 4,5,6,7-tetrahydro-1H-pyrrolo-[2,3-b]pyridinyl, 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl, 1,2,3,4-tetrahydro-1,6-naphthyridinyl, and the like. [00207]Aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (C.sub.6-14 aryl). In some embodiments, an aryl group has 6 ring carbon atoms (C.sub.6 aryl; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (C.sub.10 aryl; e.g., naphthyl such as 1-naphthyl (-naphthyl) and 2-naphthyl (-naphthyl)). In some embodiments, an aryl group has 14 ring carbon atoms (C.sub.14 aryl; e.g., anthracyl). Aryl also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.
[0219] Heteroaryl refers to a radical of a 5-14 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-14 membered heteroaryl). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. Heteroaryl includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. Heteroaryl also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused polycyclic (aryl/heteroaryl) ring system. Polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).
[0220] In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-10 membered heteroaryl). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-8 membered heteroaryl). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-6 membered heteroaryl). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0221] Exemplary 5-membered heteroaryl groups containing 1 heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryl groups containing 2 heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing 3 heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing 4 heteroatoms include, without limitation, tetrazolyl. Exemplary 6-membered heteroaryl groups containing 1 heteroatom include, without limitation, pyridinyl. Exemplary 6-membered heteroaryl groups containing 2 heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing 1 heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary tricyclic heteroaryl groups include, without limitation, phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl and phenazinyl.
[0222] Saturated refers to a ring moiety that does not contain a double or triple bond, i.e., the ring contains all single bonds.
[0223] Alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups may be optionally substituted. Optionally substituted refers to a group which may be substituted or unsubstituted. In general, the term substituted means that at least one hydrogen present on a group is replaced with a non-hydrogen substituent, and which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Heteroatoms such as nitrogen, oxygen, and sulfur may have hydrogen substituents and/or non-hydrogen substituents which satisfy the valencies of the heteroatoms and results in the formation of a stable compound.
[0224] Exemplary non-hydrogen substituents wherein a moiety is optionally substituted as used herein means the moiety may be substituted with any additional moiety selected from, but not limited to, the group consisting of halogen, CN, NO.sub.2, N.sub.3, SO.sub.2H, SO.sub.3H, OH, OR.sup.aa, N(R.sup.bb).sub.2, N(OR.sup.cc)R.sup.bb, SH, SR.sup.aa, C(O)R.sup.aa, CO.sub.2H, CHO, CO.sub.2R.sup.aa, OC(O)R.sup.aa, OCO.sub.2R.sup.aa, C(O)N(R.sup.bb).sub.2, OC(O)N(R.sup.bb).sub.2, NR.sup.bbC(O)R.sup.aa, NR.sup.bbCO.sub.2R.sup.aa, NR.sup.bbC(O)N(R.sup.bb).sub.2, C(NR.sup.bb)R.sup.aa, C(NR.sup.bb)OR.sup.aa, OC(NR.sup.bb)R.sup.aa, OC(NR.sup.bb)OR.sup.aa, C(NR.sup.bb)N(R.sup.bb).sub.2, OC(NR.sup.bb)N(R.sup.bb).sub.2, NR.sup.bbC(NR.sup.bb)N(R.sup.bb).sub.2, C(O)NR.sup.bbSO.sub.2R.sup.aa, NR.sup.bbSO.sub.2R.sup.aa, SO.sub.2N(R.sup.bb).sub.2, SO.sub.2R.sup.aa, S(O)R.sup.aa, OS(O)R.sup.aa, B(OR.sup.cc).sub.2, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-14 carbocyclyl, 3- to 14-membered heterocyclyl, C.sub.6-14 aryl, and 5- to 14-membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups, or two geminal hydrogens on a carbon atom are replaced with the group O; each instance of R.sup.aa is, independently, selected from the group consisting of C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-14 carbocyclyl, 3- to 14-membered heterocyclyl, C.sub.6-14 aryl, and 5- to 14-membered heteroaryl, or two R.sup.aa groups are joined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups; each instance of R.sup.bb is, independently, selected from the group consisting of hydrogen, OH, OR.sup.aa, N(R.sup.cc).sub.2, CN, C(O)R.sup.aa, C(O)N(R).sub.2, CO.sub.2R.sup.aa, SO.sub.2R.sup.aa, SO.sub.2N(R.sup.cc)2, SOR.sup.aa, C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-14 carbocyclyl, 3- to 14-membered heterocyclyl, C.sub.6_t.sub.4 aryl, and 5- to 14-membered heteroaryl, or two R.sup.bb groups are joined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups; each instance of R.sup.cc is, independently, selected from the group consisting of hydrogen, C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-14 carbocyclyl, 3- to 14-membered heterocyclyl, C.sub.6-14 aryl, and 5- to 14-membered heteroaryl, or two R.sup.cc groups are joined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups; and each instance of R.sup.dd is, independently, selected from the group consisting of halogen, CN, NO.sub.2, N.sub.3, SO.sub.2H, SO.sub.3H, OH, OC.sub.1-6 alkyl, ON(C.sub.1-6 alkyl).sub.2, N(C.sub.1-6 alkyl).sub.2, N(OC.sub.1-6 alkyl)(C.sub.1-6 alkyl), N(OH)(C.sub.1-6 alkyl), NH(OH), SH, SC.sub.1-6 alkyl, C(O)(C.sub.1-6 alkyl), CO.sub.2H, CO.sub.2(C.sub.1-6 alkyl), OC(O)(C.sub.1-6 alkyl), OCO.sub.2(C.sub.1-6 alkyl), C(O)NH.sub.2, C(O)N(C.sub.1-6 alkyl).sub.2, OC(O)NH(C.sub.1-6 alkyl), NHC(O)(C.sub.1-6 alkyl), N(C.sub.1-6 alkyl)C(O)(C.sub.1-6 alkyl), NHCO.sub.2(C.sub.1-6 alkyl), NHC(O)N(C.sub.1-6 alkyl).sub.2, NHC(O)NH(C.sub.1-6 alkyl), NHC(O)NH.sub.2, C(NH)O(C.sub.1-6 alkyl), OC(NH)(C.sub.1-6 alkyl), OC(NH)OC.sub.1-6 alkyl, C(NH)N(C.sub.1-6 alkyl).sub.2, C(NH)NH(C.sub.1-6 alkyl), C(NH)NH.sub.2, OC(NH)N(C.sub.1-6 alkyl).sub.2, OC(NH)NH(C.sub.1-6 alkyl), OC(NH)NH.sub.2, NHC(NH)N(C.sub.1-6 alkyl).sub.2, NHC(NH)NH.sub.2, NHSO.sub.2(C.sub.1-6 alkyl), SO.sub.2N(C.sub.1-6 alkyl).sub.2, SO.sub.2NH(C.sub.1-6 alkyl), SO.sub.2NH.sub.2, SO.sub.2C.sub.1-6 alkyl, B(OH).sub.2, B(OC.sub.1-6 alkyl).sub.2, C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 carbocyclyl, C.sub.6-10 aryl, 3- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl; or two geminal R.sup.dd substituents on a carbon atom may be joined to form O.
[0225] Halo or halogen refers to fluorine (fluoro, F), chlorine (chloro, Cl), bromine (bromo, Br), or iodine (iodo, I).
[0226] As used herein, the term composition is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combination of the specified ingredients.
[0227] Salt includes any and all salts. Pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19. Pharmaceutically acceptable salts include those derived from inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N.sup.+(C.sub.1-4alkyl).sub.4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
[0228] Unless otherwise indicated, compounds described herein can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC). Compounds described herein can be in the form of individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.
[0229] Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, replacement of .sup.19F with .sup.18F, replacement of a carbon by a .sup.13C- or .sup.14C-enriched carbon, and/or replacement of an oxygen atom with .sup.18O, are within the scope of the disclosure. Other examples of isotopes include .sup.15N, .sup.18O, .sup.17O, .sup.31P, .sup.32P, .sup.35S, .sup.18F, .sup.36Cl and .sup.123I. Compounds with such isotopically enriched atoms are useful, for example, as analytical tools or probes in biological assays.
[0230] Certain isotopically-labelled compounds (e.g., those labeled with .sup.13H and .sup.14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., .sup.13C) isotopes are particularly preferred for their ease of preparation and detectability.
[0231] Certain isotopically-labelled compounds of Formula (I) can be useful for medical imaging purposes, for example, those labeled with positron-emitting isotopes like .sup.11C or .sup.18F can be useful for application in Positron Emission Tomography (PET) and those labeled with gamma ray emitting isotopes like .sup.123I can be useful for application in Single Photon Emission Computed Tomography (SPECT). Further, substitution with heavier isotopes such as deuterium (i.e., .sup.2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Further, substitution with heavier isotopes such as deuterium (i.e., .sup.2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements), and hence, may be preferred in some circumstances. Additionally, isotopic substitution at a site where epimerization occurs may slow or reduce the epimerization process and thereby retain the more active or efficacious form of the compound for a longer period of time. Isotopically labeled compounds of Formula (I), in particular those containing isotopes with longer half-lives (t.sub.1/2>1 day), can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopically labeled reagent for a non-isotopically labeled reagent.
EXPERIMENTALS
[0232] Compounds of the invention can be made by a variety of methods depicted in the illustrative synthetic reactions described below in the Examples section.
[0233] The starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989, Volumes 1-5 and Supplementals; and Organic Reactions, Wiley & Sons: New York, 1991, Volumes 1-40. It should be appreciated that the synthetic reaction schemes shown in the Examples section are merely illustrative of some methods by which the compounds of the invention can be synthesized, and various modifications to these synthetic reaction schemes can be made and will be suggested to one skilled in the art having referred to the disclosure contained in this application.
[0234] The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.
[0235] Unless specified to the contrary, the reactions described herein are typically conducted under an inert atmosphere at atmospheric pressure at a reaction temperature range of from about 78 C. to about 150 C., often from about 0 C. to about 125 C., and more often and conveniently at about room (or ambient) temperature, e.g., about 20 C.
[0236] Various substituents on the compounds of the invention can be present in the starting compounds, added to any one of the intermediates or added after formation of the final products by known methods of substitution or conversion reactions. If the substituents themselves are reactive, then the substituents can themselves be protected according to the techniques known in the art. A variety of protecting groups are known in the art, and can be employed. Examples of many of the possible groups can be found in Protective Groups in Organic Synthesis by Green et al., John Wiley and Sons, 1999. For example, nitro groups can be added by nitration and the nitro group can be converted to other groups, such as amino by reduction, and halogen by diazotization of the amino group and replacement of the diazo group with halogen. Acyl groups can be added by Friedel-Crafts acylation. The acyl groups can then be transformed to the corresponding alkyl groups by various methods, including the Wolff-Kishner reduction and Clemmenson reduction. Amino groups can be alkylated to form mono- and di-alkylamino groups; and mercapto and hydroxy groups can be alkylated to form corresponding ethers. Primary alcohols can be oxidized by oxidizing agents known in the art to form carboxylic acids or aldehydes, and secondary alcohols can be oxidized to form ketones. Thus, substitution or alteration reactions can be employed to provide a variety of substituents throughout the molecule of the starting material, intermediates, or the final product, including isolated products.
GENERAL CONDITIONS
1. General Information
[0237] Pd(OAc).sub.2 was purchased from Strem. Solvents were obtained from Sigma-Aldrich, Alfa-Aeser, and Acros, and used directly without further purification. Other reagents were purchased at the highest commercial quality and used without further purification, unless otherwise stated. Analytical thin layer chromatography was performed on 0.25 mm silica gel 60F254 or Merck pre-coated aluminiumbacked silica gel F254 plates. 1H NMR spectra were recorded on Bruker AMX-400, Bruker AV-500, or Bruker DRX-600 instruments. The following abbreviations (or combinations thereof) were used to explain multiplicities: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad. Coupling constants, J, were reported in Hertz unit (Hz). 13C NMR spectra were recorded on Bruker AMX-400, Bruker AV-500, or Bruker DRX-600 and were fully decoupled by broad band proton decoupling. Chemical shifts were referenced to the appropriate residual solvent peaks. Column chromatography was performed using E. Merck silica (60, particle size 0.043-0.063 mm), and pTLC was performed on Merck silica plates (60F254). High-resolution mass spectra (HRMS) were recorded on an Agilent Mass spectrometer using ESI-TOF (electrospray ionization-time of flight).
2. Experimental Section for the Lactonization Reaction
2.1 Optimization Data for the Lactonization Reactions
1. Ligand Investigation for -Directed, -Lactonization:
TABLE-US-00001 TABLE S1
2. Fine-Tuning of Reaction Conditions for -Directed, -Lactonization:
TABLE-US-00002 TABLE S2
3. Ligand Investigation for -Directed, -Lactonization:
TABLE-US-00003 TABLE S3
4. Investigation of Oxidants for -Directed, -Lactonization:
TABLE-US-00004 TABLE S4
5. Investigation of Palladium Source for -Directed, -Lactonization:
TABLE-US-00005 TABLE S5
6. General Control Experiments for -Directed, -Lactonization:
TABLE-US-00006 TABLE S6
7. Investigation of Other Oxidants for -Directed, -Lactonization:
TABLE-US-00007 TABLE S7
8. Investigation of Reaction Conditions with Silver Salts and BQ3 for -Directed, -Lactonization:
TABLE-US-00008 TABLE S8
TABLE-US-00009 TABLE S9
9. Further Fine-Tuning of Reaction Conditions for -Directed, -Lactonization:
TABLE-US-00010 TABLE S10
10 Optimization for Silver-Free Reaction Conditions Using MnO.SUB.2 .as Oxidant for -Directed, -Lactonization:
TABLE-US-00011 TABLE S11
2.2 Reaction Procedures of the -Directed, -CH Lactonization Reaction
General Procedure for the -Directed, -CH Lactonization Reaction Using Ag.sub.2CO.sub.3 as Oxidant
[0239] To a 2-dram vial was added the substrate (0.1 mmol), Pd(OAc).sub.2 (10 mol %, 0.01 mmol), ligand (12 mol %, 0.012 mmol), p-xyloquinone (0.2 mmol), Ag.sub.2CO.sub.3 (0.2 mmol), K.sub.2HPO.sub.4 (0.035 mmol) and CsOAc (0.04 mmol, preferably added from a stock solution in HFIP as CsOAc is hygroscopic). HFIP (1.0 mL, or the volume needed to make up to 1.0 mL if a stock solution of CsOAc was used) and a stir-bar was then added, followed by sealing the reaction vessel with a PTFE septum inserted between the vial and its cap. (Note: Pd(OAc).sub.2, ligand, p-xyloquinone, CsOAc, and the substrate could all be prepared as a stock solution in HFIP. The use of stock solution is recommended for setting up a series of reactions to maximize work efficiency). The reaction mixture was sonicated for 30 seconds before stirring at 200 rpm and 100 C. (heating block temperature) for 36 hours. The reaction mixture was then cooled to room temperature and diluted with dichloromethane (1.0 mL), followed by addition of deionized water (2.0 mL), aq. 6M HCl (0.3 mL), brine (1.0 mL) and then shaken vigorously. The lower organic layer was carefully pipetted and filtered through a short plug of Celite. The remaining aqueous layer was extracted with CH.sub.2Cl.sub.2 (1.0 mL) twice and the organic layer was pipetted and filtered as mentioned. The combined organic layer was then evaporated to dryness. The crude was then taken into CDCl.sub.3 (0.6 mL) with CH.sub.2Br.sub.2 (10.0 L) as the internal standard to determine the assay yield of the reaction by .sup.1H NMR spectroscopy. The isolation of the product was carried out with aqueous extractions of the organic layer (in 0.6 mL CDCl.sub.3 diluted with 2.0 mL CH.sub.2Cl.sub.2) with sat. aq. NaHCO.sub.3 solution (1.0 mL each, 3 times). The collected aqueous layer was then acidified by aq. 6M HCl to pH2 and extracted with EtOAc (1.0 mL, 3 times). The combined EtOAc layers was dried with anhydrous MgSO.sub.4, filtered, and evaporated to dryness. The product was either further purified by column chromatography (General procedure for gradient elution unless stated otherwise: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH, collecting 1.0-2.0 mL fractions. It was observed that the R.sub.f values of carboxylic acids obtained by TLC analysis could not be directly used as a guide for column chromatography. Hence, the gradient elution method was employed for their purification.) or pTLC (exact eluent composition mentioned below for each example) or subject to further derivatization into benzyl esters for isolation if purification of the lactone acid was found to be not straightforward.
General Procedure for the -Directed, -CH Lactonization Reaction Using MnO.SUB.2 .as Oxidant
[0240] To a 2-dram vial was added the substrate (0.1 mmol), Pd(OAc).sub.2 (10 mol %, 0.01 mmol), ligand (12 mol %, 0.012 mmol), p-xyloquinone (0.2 mmol), MnO.sub.2 (0.4 mmol), K.sub.2HPO.sub.4 (0.021 mmol), KH.sub.2PO.sub.4 (0.032 mmol), CsOAc (0.021 mmol, preferably added from a stock solution in HFIP as CsOAc is hygroscopic). HFIP (1.0 mL, or the volume needed to make up to 1.0 mL if a stock solution of CsOAc was used) and a stir-bar was then added, followed by sealing the reaction vessel with a PTFE septum inserted between the vial and its cap. (Note: Pd(OAc).sub.2, ligand, p-xyloquinone, CsOAc, and the substrate could all be prepared as a stock solution in HFIP. The use of stock solution is recommended for setting up a series of reactions to maximize work efficiency). The reaction mixture was sonicated for 30 seconds before stirring at 200 rpm and 100 C. (heating block temperature) for 36-48 hours. The reaction mixture was then cooled to room temperature and diluted with dichloromethane (1.0 mL), followed by addition of deionized water (2.0 mL), aq. 6M HCl (0.3 mL), brine (1.0 mL) and then shaken vigorously. The lower organic layer was carefully pipetted and filtered through a short plug of Celite. The remaining aqueous layer was extracted with CH.sub.2Cl.sub.2 (1.0 mL) twice and the organic layer was pipetted and filtered as mentioned. The combined organic layer was then evaporated to dryness. The crude was then taken into CDCl.sub.3 (0.6 mL) with CH.sub.2Br.sub.2 (10.0 L) as the internal standard to determine the assay yield of the reaction by .sup.1H NMR spectroscopy. The isolation of the product was carried out with aqueous extractions of the organic layer (in 0.6 mL CDCl.sub.3 diluted with 2.0 mL CH.sub.2Cl.sub.2) with sat. aq. NaHCO.sub.3 solution (1.0 mL each, 3 times). The collected aqueous layer was then acidified by aq. 6M HCl to pH2 and extracted with EtOAc (1.0 mL, 3 times). The combined EtOAc layers was dried with anhydrous MgSO.sub.4, filtered, and evaporated to dryness. The product was either further purified by column chromatography (General procedure for gradient elution unless stated otherwise: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH, collecting 1.0-2.0 mL fractions. It was observed that the R.sub.f values of carboxylic acids obtained by TLC analysis could not be directly used as a guide for column chromatography. Hence, the gradient elution method was employed for their purification.) or pTLC (exact eluent composition mentioned below for each example) or subject to further derivatization into benzyl esters for isolation if purification of the lactone acid was found to be not straightforward.
General Procedure for Benzyl Ester Formation
[0241] To the product obtained after aqueous extraction with sat. NaHCO.sub.3 solution as mentioned above was added dry CH.sub.2Cl.sub.2 (2.0 mL), BnOH (1.2 eq.), DMAP (1.2 eq.) and EDCI (1.2 eq.) sequentially at room temperature. The reaction mixture was stirred at room temperature overnight, and completion of the reaction was confirmed by TLC analysis of the reaction mixture. The reaction mixture was then quenched by the addition of water and extracted with CH.sub.2Cl.sub.2 (3 times), and the desired product was purified by pTLC (exact eluent composition mentioned below for each example).
Guide for Reaction Set-Up, Work-Up, and Expected Observations (Applicable to Both -Directed and -Directed Lactonization Reactions).
[0242] Scenario: Setting up 4 reactions for the conversion of pimelic acid 2 to lactone 2b. [0243] 1. Weigh Pd(OAc).sub.2 (5.0 eq., to be dissolved in 1.0 mL HFIP), pimelic acid 2 (5.0 eq., to be dissolved in 1.0 mL HFIP), Ligand L2 (5.0 eq., to be dissolved in 1.0 mL HFIP. Vial is labelled Li in the picture, but it is ligand L2 that was used), BQ3 (4.0 eq., to be dissolved in 0.8 mL HFIP), and CsOAc (5.0 eq., to be dissolved into 1.0 mL HFIP) into 5 separate vials. [0244] 2. Weigh Ag.sub.2CO.sub.3 (2.0 eq. each), and K.sub.2HPO.sub.4 (0.35 eq. each) into 4 separate 2-dram vials, whereby each serves as the reaction vessel. [0245] 3. Add the required volume of HFIP into the vials containing Pd(OAc).sub.2 (1.0 mL), pimelic acid 2 (1.0 mL), ligand L2 (1.0 mL), BQ3 (0.8 mL), and CsOAc (1.0 mL). It is recommended to sonicate the mixture to facilitate dissolution of the solids to obtain homogenous solutions. [0246] 4. Use an autopipette or a syringe to add 0.2 mL each of the Pd(OAc).sub.2, pimelic acid 2, ligand L2, p-xyloquinone, and CsOAc solutions into the 4 reaction vessels. [0247] 5. Add one stir bar to each of the reaction vessel. [0248] 6. Prepare 4 vial caps with PTFE septum (glossy side of the septum should be in contact with the reaction vessel). [0249] 7. Put on the caps. Make sure the caps are tightly screwed to the vial and the reaction vessels should therefore be sealed. Tightening too much is not recommended as it would deform the PTFE septum and lead to solvent leakage. [0250] 8. Sonicate the reaction mixture, whereby the reaction mixtures will then acquire a milky appearance. Make sure the caps are still tightly screwed to the vial afterwards. [0251] 9. Load the reaction vessels onto the heating block, block temperature 100 C., stirring rate 200 rpm, for 36 hours (Do not let the reactions run for longer than 36 hours, as yields were found to decrease with extended reaction time, please see optimization data above). [0252] 10. Colour of the reaction mixture changes from bright yellow before heating, to brown/crimson with ligand L2 after 15 minutes of heating at 100 C. (block temperature). With ligand L1, the colour changes from bright yellow to olive green (5 minutes), and then to brown/crimson (15-30 minutes) (not shown here). [0253] 11. After 36 hours, cool the reaction mixture to room temperature, dilute with dichloromethane (1.0 mL), followed by addition of deionized water (2.0 mL), aq. 6M aq. HCl (0.3 mL), brine (1.0 mL) and then shaken vigorously. The lower organic layer was carefully pipetted and filtered through a short plug of Celite. [0254] 12. The combined organic layer was then evaporated to dryness. The crude was then taken into CDCl.sub.3 (0.6 mL) with CH.sub.2Br.sub.2 (10.0 L) as the internal standard to determine the assay yield of the reaction by .sup.1H NMR spectroscopy.
Determination of Assay Yield by 1H NMR Spectroscopy of the Crude Reaction Mixture:
[0255] For 10.0 L of CH.sub.2Br.sub.2, the no. of mmol of CH.sub.2Br.sub.2 is [(10.0*2.477)/173.83]=0.142 mmol. Since each mole of CH.sub.2Br.sub.2 contains 2 moles of H, the no. of mmol of H is 0.284 mmol. [0256] Setting the integral of the resonance of the CH.sub.2Br.sub.2 standard to 0.284, the integral of each CH resonance of any species on the crude .sup.1H NMR would reflect the no. of mmol of that species. [0257] For the case of the lactone product 2b, the resonance at 4.5 ppm corresponds to H2a as shown on the structure of the product. [0258] Setting the integral of the CH.sub.2Br.sub.2 standard to 284 would then reflect the percentage NMR yield of the product, because: [(Observed integral of the resonance of H2a when the integral of the standard is set to 0.284)/0.1]*100=Percentage NMR yield of the product.
2.3 Characterization Data of Products Obtained from -Directed, -CH Lactonization Reaction
##STR00076##
2-(5-Oxotetrahydrofuran-2-yl)acetic acid 1a
[0259] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 50% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 65% (9.4 mg, 0.065 mmol, colorless oil).
[0260] .sup.1H NMR (400 MHz, CDCl.sub.3) 4.90 (dddd, J=9.1, 7.8, 6.9, 6.1 Hz, 1H), 2.85 (dd, J=16.6, 6.9 Hz, 1H), 2.72 (dd, J=16.6, 6.1 Hz, 1H), 2.67-2.55 (m, 2H), 2.49 (dt, J=12.8, 7.8 Hz, 1H), 1.99 (dtd, J=12.8, 9.1, 7.7 Hz, 1H).
[0261] .sup.13C NMR (100 MHz, CDCl.sub.3) 176.9, 175.0, 76.1, 39.8, 28.6, 27.6.
[0262] HRMS (ESI-TOF) Calculated for C.sub.6H.sub.6O.sub.4 [MH].sup.: 143.0350, found 143.0344.
##STR00077##
Benzyl 2-(4-methyl-5-oxotetrahydrofuran-2-yl)acetate 4a
[0263] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.30). Isolated yield 60% over 2 steps (14.9 mg, 0.60 mmol, colourless oil, d.r.=1.5:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0264] NMR for minor isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 7.43-7.32 (m, 5H), 5.15 (s, 2H), 4.97-4.88 (m, 1H), 2.83 (dd, J=16.1, 6.7 Hz, 1H), 2.74-2.59 (m, 2H), 2.26-2.07 (m, 2H), 1.29 (d, J=7.3 Hz, 3H).
[0265] .sup.13C NMR (151 MHz, CDCl.sub.3) 179.4, 169.5, 135.5, 128.8, 128.6, 128.5, 74.0, 67.0, 40.0, 35.1, 33.8, 15.9.
[0266] NMR for major isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 7.41-7.30 (m, 5H), 5.15 (s, 2H), 4.82-4.71 (m, 1H), 2.88 (dd, J=16.3, 6.9 Hz, 1H), 2.74-2.59 (m, 2H), 1.65-1.55 (m, 2H), 1.27 (d, J=7.0 Hz, 3H).
[0267] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.8, 169.5, 135.5, 128.8, 128.6, 128.5, 74.1, 67.0, 40.2, 37.0, 35.8, 15.1.
[0268] HRMS (ESI-TOF) Calculated for C.sub.14H17O.sub.4 [M+H].sup.+: 249.1127, found 249.1131.
##STR00078##
2-(4-Ethyl-5-oxotetrahydrofuran-2-yl)acetic acid 5a
[0269] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 60% (10.3 mg, 0.060 mmol, colorless oil, d.r.=1.4:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0270] NMR for minor isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 4.98-4.86 (m, 1H), 2.90-2.77 (m, 1H), 2.74-2.64 (m, 1H), 2.64-2.54 (m, 1H), 2.24-2.13 (m, 2H), 1.89-1.82 (m, 1H), 1.59-1.53 (m, 1H), 1.01 (t, J=7.5 Hz, 3H).
[0271] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.9, 175.2, 74.2, 40.6, 39.9, 32.7, 24.0, 11.7.
[0272] NMR for major isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 4.78-4.72 (m, 1H), 2.89-2.78 (m, 1H), 2.74-2.64 (m, 1H), 2.64-2.55 (m, 2H), 1.97-1.89 (m, 1H), 1.68-1.60 (m, 1H), 1.53-1.46 (m, 1H), 0.99 (t, J=7.5 Hz, 3H).
[0273] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.3, 175.2, 74.0, 42.2, 40.0, 34.3, 23.3, 11.7. HRMS (ESI-TOF) Calculated for C.sub.8H.sub.11O.sub.4, for [MH].sup.: 171.0657, found 171.0664.
##STR00079##
2-(4-Isopropyl-5-oxotetrahydrofuran-2-yl)acetic acid 6a
[0274] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 55% (10.3 mg, 0.055 mmol, colorless oil, d.r. 1.3:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.1C NMR data reported as a mixture of diastereomers.
[0275] NMR for minor isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 4.85 (dt, J=14.0, 6.6 Hz, 1H), 2.82 (dd, J=16.5, 6.7 Hz, 1H), 2.75-2.65 (m, 1H), 2.65-2.57 (m, 1H), 2.34-2.25 (m, 1H), 2.23-2.14 (m, 1H), 2.05 (ddd, J=14.0, 9.9, 5.4 Hz, 1H), 1.09-0.99 (m, 3H), 0.96 (d, J=6.8 Hz, 3H).
[0276] .sup.13C NMR (151 MHz, CDCl.sub.3) 177.4, 175.0, 74.2, 45.3, 40.2, 29.3, 29.0, 20.8, 18.7.
[0277] NMR for major isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 4.73 (dq, J=10.5, 6.3 Hz, 1H), 2.87 (dd, J=16.5, 7.0 Hz, 1H), 2.75-2.65 (m, 1H), 2.65-2.57 (m, 1H), 2.43 (ddd, J=13.1, 8.8, 5.8 Hz, 1H), 2.23-2.14 (m, 1H), 1.78-1.67 (m, 1H), 1.09-0.99 (m, 3H), 0.92 (d, J=6.8 Hz, 3H).
[0278] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.2, 175.0, 73.7, 46.9, 39.9, 30.3, 27.6, 20.6, 18.4. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.15O.sub.4 [M+H].sup.+: 187.0970, Found: 187.0972.
##STR00080##
2-(4-Benzyl-5-oxotetrahydrofuran-2-yl)acetic acid 7a
[0279] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 60% (14.0 mg, 0.060 mmol, colorless oil, d.r=1.4:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0280] NMR for minor isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 7.35-7.15 (m, 5H), 4.79-4.65 (m, 1H), 3.18 (dd, J=13.9, 4.5 Hz, 1H), 3.03-2.92 (m, 1H), 2.83-2.71 (m, 2H), 2.65-2.54 (m, 1H), 2.22 (dt, J=13.1, 7.6 Hz, 1H), 2.03 (ddd, J=13.8, 9.3, 5.1 Hz, 1H).
[0281] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.3, 175.3, 138.0, 129.0, 128.9, 127.1, 74.2, 40.9, 39.9, 36.5, 32.2.
[0282] NMR for major isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 7.35-7.15 (m, 5H), 4.79-4.65 (m, 1H), 3.27 (dd, J=14.1, 4.3 Hz, 1H), 3.03-2.92 (m, 1H), 2.83-2.71 (m, 2H), 2.64-2.54 (m, 1H), 2.49-2.40 (m, 1H), 1.71-1.61 (m, 1H).
[0283] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.3, 175.3, 138.3, 129.0, 128.9, 126.9, 74.2, 42.6, 39.8, 36.1, 34.3. HRMS (ESI-TOF) Calculated for C.sub.13H.sub.15O.sub.4 [M+H].sup.+: 235.0970, found 235.0967.
##STR00081##
Benzyl 2-(4-(tert-butyl)-5-oxotetrahydrofuran-2-yl)acetate 8a
[0284] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.30). Isolated yield 50% over 2 steps (14.5 mg, 0.050 mmol, colourless oil, d.r.=1.5:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0285] NMR for minor isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 7.43-7.28 (m, 5H), 5.30-5.07 (m, 2H), 4.83 (dtd, J=8.1, 6.5, 5.0 Hz, 1H), 2.81 (dd, J=16.1, 6.4 Hz, 1H), 2.64-2.58 (m, 1H), 2.45 (dd, J=9.9, 7.6 Hz, 1H), 2.34 (dt, J=13.5, 7.9 Hz, 1H), 2.03 (ddd, J=13.5, 9.9, 5.0 Hz, 1H), 1.05 (s, 9H).
[0286] .sup.13C NMR (151 MHz, CDCl.sub.3) 177.0, 169.6, 135.5, 128.8, 128.6, 128.5, 73.6, 67.0, 48.9, 40.5, 31.7, 30.2, 27.5.
[0287] NMR for major isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 7.43-7.28 (m, 5H), 5.30-5.07 (m, 2H), 4.67 (dtd, J=10.4, 6.5, 5.6 Hz, 1H), 2.88 (dd, J=16.3, 6.7 Hz, 1H), 2.70-2.64 (m, 1H), 2.50 (dd, J=12.6, 8.6 Hz, 1H), 2.43-2.38 (m, 1H), 1.75 (td, J=12.6, 10.5 Hz, 1H), 1.05 (s, 9H).
[0288] .sup.13C NMR (151 MHz, CDCl.sub.3) 176.1, 169.6, 135.5, 128.8, 128.7, 128.5, 73.0, 67.0, 50.7, 40.2, 33.0, 31.7, 27.3.
[0289] HRMS (ESI-TOF) Calculated for C.sub.17H.sub.23O.sub.4 [M+H].sup.+: 291.1596, Found: 291.1600.
##STR00082##
Benzyl 2-(4-(1,3-dioxoisoindolin-2-yl)-5-oxotetrahydrofuran-2-yl)acetate 9a
[0290] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (30% EA/hexanes, R.sub.f=0.30). Isolated yield 25% over 2 steps (9.5 mg, 0.025 mmol, colourless oil, d.r.=2:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0291] NMR for minor diastereomer: .sup.1H NMR (400 MHz, CDCl.sub.3) 8.01-7.82 (m, 2H), 7.82-7.72 (m, 2H), 7.46-7.31 (m, 5H), 5.36-5.11 (m, 4H), 2.96-2.85 (m, 2H), 2.85-2.73 (m, 1H), 2.61-2.44 (m, 1H).
[0292] .sup.13C NMR (100 MHz, CDCl.sub.3) 172.2, 169.2, 167.0, 135.4, 134.7, 131.8, 128.9, 128.7, 128.6, 124.0, 74.1, 67.2, 46.7, 39.6, 31.3.
[0293] NMR for major diastereomer: .sup.1H NMR (400 MHz, CDCl.sub.3) 8.01-7.82 (m, 2H), 7.82-7.72 (m, 2H), 7.46-7.31 (m, 5H), 5.36-5.11 (m, 3H), 4.99 (tdd, J=8.3, 6.9, 3.6 Hz, 1H), 3.12 (ddd, J=16.5, 6.8, 1.7 Hz, 1H), 2.96-2.85 (m, 1H), 2.85-2.73 (m, 1H), 2.61-2.44 (m, 1H).
[0294] .sup.13C NMR (100 MHz, CDCl.sub.3) 171.2, 169.2, 167.0, 135.4, 134.7, 131.7, 128.8, 128.7, 128.6, 124.0, 73.7, 67.1, 48.2, 40.3, 32.4.
[0295] HRMS (ESI-TOF) Calculated for C.sub.21H.sub.18NO.sub.6 [M+H].sup.+: 380.1134, Found: 380.1133.
##STR00083##
2-(4,4-Dimethyl-5-oxotetrahydrofuran-2-yl)acetic acid 10a
[0296] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 84% (14.4 mg, 0.084 mmol, off white solid).
[0297] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.83 (ddt, J=10.0, 7.1, 6.0 Hz, 1H), 2.86 (dd, J=16.6, 7.1 Hz, 1H), 2.68 (dd, J=16.6, 6.0 Hz, 1H), 2.32 (dd, J=12.8, 6.0 Hz, 1H), 1.85 (dd, J=12.8, 9.9 Hz, 1H), 1.29 (s, 3H), 1.29 (s, 3H).
[0298] .sup.13C NMR (126 MHz, CDCl.sub.3) 181.4, 175.0, 72.5, 43.1, 40.5, 40.0, 25.1, 24.5. HRMS (ESI-TOF) Calculated for C.sub.8H.sub.13O.sub.4 [M+H].sup.+: 173.0814, Found: 173.0809.
##STR00084##
2-(4,4-Diethyl-5-oxotetrahydrofuran-2-yl)acetic acid 11a
[0299] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 66% (13.2 mg, 0.066 mmol, off white solid).
[0300] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.79 (dddd, J=9.4, 7.0, 6.9, 6.1 Hz, 1H), 2.84 (dd, J=16.5, 7.0 Hz, 1H), 2.66 (dd, J=16.5, 6.1 Hz, 1H), 2.27 (dd, J=13.2, 6.9 Hz, 1H), 1.88 (dd, J=13.2, 9.4 Hz, 1H), 1.75-1.51 (m, 4H), 0.96 (t, J=7.5 Hz, 3H), 0.90 (t, J=7.5 Hz, 3H).
[0301] .sup.13C NMR (126 MHz, CDCl.sub.3) 180.4, 175.3, 72.7, 48.8, 40.6, 37.5, 29.3, 28.4, 8.9, 8.8. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.17O.sub.4 [M+H].sup.+: 201.1127, Found: 201.1135.
##STR00085##
Benzyl 2-((2R*,3S*)-3-methyl-5-oxotetrahydrofuran-2-yl)acetate 12a
[0302] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (10% EA/hexanes, R.sub.f=0.30). Isolated yield 70% over 2 steps (17.4 mg, 0.070 mmol, colourless oil, d.r.>20:1).
[0303] .sup.1H NMR (500 MHz, CDCl.sub.3) 7.49-7.29 (m, 5H), 5.16 (s, 2H), 4.49 (td, J=7.0, 5.7 Hz, 1H), 2.77-2.65 (m, 3H), 2.33 (ddd, J=15.3, 8.5, 7.0 Hz, 1H), 2.22 (dd, J=17.3, 9.1 Hz, 1H), 1.15 (d, J=6.6 Hz, 3H).
[0304] .sup.13C NMR (126 MHz, CDCl.sub.3) 175.7, 169.7, 135.5, 128.8, 128.6, 128.6, 82.6, 67.1, 39.0, 36.7, 35.9, 17.5.
[0305] HRMS (ESI-TOF) Calculated for C.sub.14H.sub.17O.sub.4 [M+H].sup.+: 249.1127, Found: 249.1131.
##STR00086##
Benzyl 2-((2R*,3R*)-3-(tert-butyl)-5-oxotetrahydrofuran-2-yl)acetate 13a
[0306] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (10% EA/hexanes, R.sub.f=0.50). Isolated yield 76% over 2 steps (22.0 mg, 0.076 mmol, colourless oil, d.r.>20:1).
[0307] .sup.1H NMR (400 MHz, CDCl.sub.3) 7.68-7.30 (m, 5H), 5.43-5.01 (m, 2H), 4.79 (ddd, J=6.6, 5.5, 4.4 Hz, 1H), 2.78-2.68 (m, 2H), 2.63 (dd, J=18.4, 10.0 Hz, 1H), 2.40 (dd, J=18.4, 5.4 Hz, 1H), 2.09 (ddd, J=10.0, 5.5, 5.4 Hz, 1H), 0.90 (s, 9H).
[0308] .sup.13C NMR (100 MHz, CDCl.sub.3) 176.6, 169.5, 135.4, 128.8, 128.6, 128.6, 77.8, 67.0, 49.5, 41.3, 32.5, 30.4, 26.8.
[0309] HRMS (ESI-TOF) Calculated for C.sub.17H.sub.23O.sub.4 [M+H].sup.+: 291.1596, Found: 291.1602.
##STR00087##
2-(4-Oxo-5-oxaspiro[2.4]heptan-6-yl)acetic acid 14a
[0310] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 62% (10.5 mg, 0.062 mmol, off white solid).
[0311] .sup.1H NMR (500 MHz, CDCl.sub.3) 5.00 (dddd, J=7.6, 7.0, 6.8, 6.5 Hz, 1H), 2.93 (dd, J=16.5, 6.8 Hz, 1H), 2.76 (dd, J=16.5, 6.5 Hz, 1H), 2.48 (dd, J=12.9, 7.6 Hz, 1H), 2.14 (dd, J=12.9, 7.0 Hz, 1H), 1.35 (ddd, J=10.5, 6.5, 3.6 Hz, 1H), 1.26 (ddd, J=10.5, 6.6, 3.7 Hz, 1H), 1.08-0.89 (m, 2H).
[0312] .sup.13C NMR (126 MHz, CDCl.sub.3) 179.4, 175.0, 73.4, 40.3, 35.4, 20.3, 16.0, 14.9. HRMS (ESI-TOF) Calculated for C.sub.8H.sub.11O.sub.4 [M+H].sup.+: 171.0657, Found: 171.0661.
##STR00088##
2-(5-Oxo-6-oxaspiro[3.4]octan-7-yl)acetic acid 15a
[0313] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 65% (12.0 mg, 0.065 mmol, off white solid).
[0314] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.74 (dq, J=8.3, 6.4 Hz, 1H), 2.82 (dd, J=16.5, 7.1 Hz, 1H), 2.68-2.64 (m, 2H), 2.64-2.60 (m, 1H), 2.60-2.53 (m, 1H), 2.46 (dtd, J=11.5, 7.3, 2.6 Hz, 1H), 2.15 (dq, J=11.4, 4.5 Hz, 1H), 2.13-2.08 (m, 1H), 2.08-2.04 (m, 1H), 2.04-2.02 (m, 1H), 2.02-1.98 (m, 2H).
[0315] .sup.13C NMR (126 MHz, CDCl.sub.3) 180.5, 175.1, 72.9, 44.3, 41.6, 39.9, 31.8, 29.6, 16.6. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.3O.sub.4 [M+H].sup.+: 185.0814, Found: 185.0816.
##STR00089##
Benzyl 2-(1-Oxo-2-oxaspiro[4.4]nonan-3-yl)acetate 16a
[0316] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.30). Isolated yield 55% over 2 steps (15.9 mg, 0.055 mmol, colourless oil).
[0317] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.50-7.28 (m, 5H), 5.15 (s, 2H), 4.80 (dddd, J=9.4, 6.9, 6.3, 6.0 Hz, 1H), 2.89 (dd, J=16.2, 6.9 Hz, 1H), 2.65 (dd, J=16.2, 6.3 Hz, 1H), 2.33 (dd, J=12.7, 6.0 Hz, 1H), 2.17 (dtd, J=12.9, 6.9, 1.8 Hz, 1H), 1.96-1.87 (m, 1H), 1.87-1.84 (m, 2H), 1.84-1.80 (m, 1H), 1.79-1.71 (m, 1H), 1.71-1.62 (m, 2H), 1.62-1.54 (m, 1H).
[0318] .sup.13C NMR (151 MHz, CDCl.sub.3) 181.9, 169.7, 135.5, 128.8, 128.6, 128.5, 73.4, 67.0, 50.1, 42.9, 40.3, 37.6, 36.9, 25.6, 25.5.
[0319] HRMS (ESI-TOF) Calculated for C.sub.1H.sub.21O.sub.4 [M+H].sup.+: 289.1440, Found: 289.1446.
##STR00090##
Benzyl 2-(1-oxo-2-oxaspiro[4.5]decan-3-yl)acetate 17a
[0320] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.35). Isolated yield 65% over 2 steps (20.0 mg, 0.065 mmol, colourless oil).
[0321] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.49-7.29 (m, 5H), 5.16 (s, 2H), 4.82 (dddd, J=10.3, 6.8, 6.4, 6.3 Hz, 1H), 2.88 (dd, J=16.2, 6.8 Hz, 1H), 2.66 (dd, J=16.2, 6.4 Hz, 1H), 2.48 (dd, J=13.0, 6.3 Hz, 1H), 1.88-1.80 (m, 1H), 1.80-1.75 (m, 1H), 1.73 (dd, J=9.7, 4.1 Hz, 1H), 1.71-1.66 (m, 1H), 1.66-1.62 (m, 1H), 1.62-1.58 (m, 2H), 1.48 (dt, J=13.9, 4.5 Hz, 1H), 1.42-1.36 (m, 1H), 1.36-1.30 (m, 1H), 1.28-1.18 (m, 1H).
[0322] .sup.13C NMR (151 MHz, CDCl.sub.3) 181.0, 169.7, 135.5, 128.8, 128.6, 128.6, 73.1, 67.0, 45.0, 40.6, 39.3, 34.4, 31.7, 25.4, 22.3, 22.2.
[0323] HRMS (ESI-TOF) Calculated for C.sub.18H.sub.23O.sub.4 [M+H].sup.+: 303.1596, Found: 303.1599.
##STR00091##
2-(8-(tert-Butyl)-1-oxo-2-oxaspiro[4.5]decan-3-yl)acetic acid 18a
[0324] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 67% (18.0 mg, 0.067 mmol, off white solid, d.r.=2.5:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0325] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.91-4.68 (m, 1H), 2.95-2.77 (m, 1H), 2.75-2.61 (m, 1H), 2.52 (dd, J=13.0, 6.5 Hz, 0.4H), 2.20-2.13 (m, 1H), 1.98-1.92 (m, 1H), 1.92-1.87 (m, 1H), 1.87-1.81 (m, 1H), 1.81-1.73 (m, 1H), 1.72-1.65 (m, 0.5H), 1.65-1.57 (m, 2H), 1.57-1.50 (m, 0.4H), 1.46-1.33 (m, 2H), 1.15-1.04 (m, 1H), 0.99-0.92 (m, 1H), 0.89-0.83 (m, 9H).
[0326] .sup.13C NMR (126 MHz, CDCl.sub.3) 181.5, 179.1, 175.4, 175.3, 72.9, 72.1, 47.7, 47.2, 45.2, 44.6, 42.4, 40.4, 40.3, 38.4, 35.0, 34.9, 34.9, 32.6, 32.6, 32.0, 27.7, 27.5, 23.4, 23.3, 22.7, 22.7. HRMS (ESI-TOF) Calculated for C.sub.15H.sub.25O.sub.4 [M+H].sup.+: 269.1753, Found: 269.1758.
##STR00092##
2-(1-Oxo-2,8-dioxaspiro[4.5]decan-3-yl)acetic acid 19a
[0327] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 68% (14.5 mg, 0.068 mmol, off white solid).
[0328] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.85 (dddd, J=9.7, 6.8, 6.2, 6.0 Hz, 1H), 4.07 (dt, J=11.7, 4.7 Hz, 1H), 3.93 (ddd, J=12.0, 5.4, 4.0 Hz, 1H), 3.63 (ddd, J=12.0, 9.2, 3.0 Hz, 1H), 3.52 (td, J=11.7, 3.1 Hz, 1H), 2.88 (dd, J=16.7, 6.8 Hz, 1H), 2.71 (dd, J=16.6, 6.0 Hz, 1H), 2.58 (dd, J=13.0, 6.2 Hz, 1H), 2.26-2.02 (m, 1H), 1.94 (ddd, J=13.4, 9.2, 4.0 Hz, 1H), 1.85 (dd, J=13.0, 9.7 Hz, 1H), 1.69-1.56 (m, 1H), 1.56-1.47 (m, 1H).
[0329] .sup.13C NMR (126 MHz, CDCl.sub.3) 179.3, 174.5, 72.7, 64.1, 63.8, 42.2, 40.0, 39.9, 33.8, 32.1. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.13O.sub.5 [MH].sup.: 213.0763, Found: 213.0767.
##STR00093##
Benzyl 2--oxo-1,3-dihydroisobenzofuran-1-yl)acetate 20a
[0330] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.40). Isolated yield 65% over 2 steps (18.3 mg, 0.065 mmol, colourless oil).
[0331] .sup.1H NMR (400 MHz, CDCl.sub.3) 7.90 (dt, J=7.6, 1.0 Hz, 1H), 7.64 (td, J=7.6, 1.0 Hz, 1H), 7.54 (tt, J=7.6, 0.8 Hz, 1H), 7.42 (dt, J=7.6, 0.8 Hz, 1H), 7.40-7.31 (m, 5H), 5.90 (dd, J=7.1, 6.2 Hz, 1H), 5.31-5.12 (m, 2H), 3.00 (dd, J=16.5, 7.1 Hz, 1H), 2.91 (dd, J=16.5, 6.2 Hz, 1H).
[0332] .sup.13C NMR (100 MHz, CDCl.sub.3) 170.0, 169.2, 148.8, 135.3, 134.4, 129.7, 128.8, 128.7, 128.7, 126.0, 126.0, 122.2, 77.0, 67.2, 39.7.
[0333] HRMS (ESI-TOF) Calculated for C.sub.1H.sub.15O.sub.4 [M+H].sup.+: 283.0970, Found: 283.0973.
##STR00094##
Benzyl 2-((3aR*,7aS*)-3-oxooctahydroisobenzofuran-1-yl)acetate 21a
[0334] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (10% EA/hexanes, R.sub.f=0.30). Isolated yield 63% over 2 steps (18.2 mg, 0.063 mmol, colourless oil, d.r.=2:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0335] .sup.1H NMR (400 MHz, CDCl.sub.3) 7.43-7.30 (m, 8H), 4.75 (td, J=7.1, 4.2 Hz, 0.5H), 4.59 (td, J=7.0, 3.0 Hz, 1H), 2.86 (dd, J=16.6, 7.6 Hz, 0.5H), 2.82-2.69 (m, 1.5H), 2.74-2.58 (m, 2.5H), 2.48 (dq, J=11.6, 5.7 Hz, 0.5H), 2.31-2.20 (m, 1H), 1.99 (dt, J=14.2, 4.6 Hz, 1H), 1.89-1.77 (m, 1H), 1.77-1.46 (m, 5.5H), 1.38-1.19 (m, 3H), 1.16-1.05 (m, 1H).
[0336] .sup.13C NMR (100 MHz, CDCl.sub.3) 177.8, 177.8, 170.0, 169.8, 135.5, 135.5, 128.8, 128.7, 128.7, 128.7, 128.6, 128.5, 79.0, 76.8, 67.0, 67.0, 41.7, 39.3, 38.6, 38.1, 38.1, 34.5, 27.2, 23.5, 23.1, 23.0, 23.0, 22.9, 22.8, 22.6.
[0337] HRMS (ESI-TOF) Calculated for C.sub.17H.sub.21O.sub.4 [M+H].sup.+: 289.1440, Found: 289.1446.
##STR00095##
Benzyl 2-((1S*,3aS*,7aS*)-3-oxooctahydroisobenzofuran-1-yl)acetate 22a
[0338] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (10% EA/hexanes, R.sub.f=0.30). Isolated yield 60% over 2 steps (17.3 mg, 0.060 mmol, colourless oil, d.r.=5:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0339] .sup.1H NMR (500 MHz, CDCl.sub.3) 7.48-7.29 (m, 5H), 5.34-5.05 (m, 2H), 4.51 (ddd, J=10.2, 7.5, 4.9 Hz, 1H), 2.76 (dd, J=16.1, 7.5 Hz, 1H), 2.71 (dd, J=16.1, 4.9 Hz, 1H), 2.26-2.09 (m, 1H), 2.02 (ddd, J=13.3, 11.2, 3.3 Hz, 1H), 1.93-1.78 (m, 3H), 1.63 (dtd, J=13.3, 10.2, 2.7 Hz, 1H), 1.31-1.16 (m, 4H).
[0340] .sup.13C NMR (126 MHz, CDCl.sub.3) 176.3, 169.8, 135.5, 128.8, 128.6, 128.6, 80.0, 67.1, 48.9, 46.2, 38.4, 27.6, 25.3, 25.0, 25.0.
[0341] HRMS (ESI-TOF) Calculated for C.sub.17H.sub.21O.sub.4 [M+H].sup.+: 289.1440, Found: 289.1452.
##STR00096##
Benzyl (3aR*,6S*,6aS*)-2-oxohexahydro-2H-cyclopenta[b]furan-6-carboxylate 23a
[0342] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (30% EA/hexanes, R.sub.f=0.50). Isolated yield 20% over 2 steps (5.5 mg, 0.020 mmol, colourless oil).
[0343] .sup.1H NMR (500 MHz, CDCl.sub.3) 7.41-7.31 (m, 5H), 5.20 (dd, J=6.6, 2.2 Hz, 1H), 5.15 (s, 2H), 3.14 (td, J=7.1, 2.2 Hz, 1H), 2.97 (ddddd, J=9.9, 9.4, 6.6, 6.5, 2.9 Hz, 1H), 2.81 (dd, J=18.4, 9.9 Hz, 1H), 2.33 (dd, J=18.4, 2.9 Hz, 1H), 2.18-2.11 (m, 1H), 2.11-2.03 (m, 1H), 1.96 (dt, J=12.4, 6.3 Hz, 1H), 1.55-1.47 (m, 1H).
[0344] .sup.13C NMR (126 MHz, CDCl.sub.3) 176.8, 172.7, 135.7, 128.8, 128.6, 128.3, 87.0, 67.0, 51.1, 38.5, 35.4, 32.6, 28.7.
[0345] HRMS (ESI-TOF) Calculated for C.sub.15H.sub.17O.sub.4 [M+H].sup.+: 261.1127, Found: 261.1130.
##STR00097##
2-(6-Oxotetrahydro-2H-pyran-2-yl)acetic acid 2a
[0346] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography. Five parallel reactions were carried out to obtain enough material for effective purification, as purification at 0.1 mmol scale was found difficult. (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield from the parallel reactions 25% (20.0 mg, 0.125 mmol, off white solid).
[0347] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.76 (dddd, J=10.7, 7.3, 5.7, 4.4 Hz, 1H), 2.81 (dd, J=16.4, 7.3 Hz, 1H), 2.75-2.55 (m, 2H), 2.48 (ddd, J=17.8, 9.0, 7.2 Hz, 1H), 2.05 (dq, J=13.7, 4.4 Hz, 1H), 2.00-1.80 (m, 2H), 1.62 (dddd, J=13.7, 10.9, 10.7, 5.8 Hz, 1H).
[0348] .sup.13C NMR (126 MHz, CDCl.sub.3) 175.0, 171.6, 76.4, 40.5, 29.4, 27.5, 18.4. HRMS (ESI-TOF) Calculated for C.sub.7H.sub.11O.sub.4 [MH].sup.: 157.0507, Found: 157.0501.
##STR00098##
2-(5-Ethyl-6-oxotetrahydro-2H-pyran-2-yl)acetic acid 24a
[0349] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 31% (5.8 mg, 0.031 mmol, colourless oil, d.r.=1:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0350] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.79-4.66 (m, 1H), 2.93-2.72 (m, 1H), 2.69-2.58 (m, OH), 2.45-2.32 (m, 1H), 2.20-2.13 (m, OH), 2.09-2.01 (m, 1H), 2.00-1.80 (m, 1H), 1.75-1.61 (m, 1H), 1.61-1.53 (m, OH), 1.53-1.44 (m, OH), 1.05-0.94 (m, 2H).
[0351] .sup.13C NMR (126 MHz, CDCl.sub.3) 174.9, 174.9, 173.2, 173.2, 77.0, 73.9, 42.1, 40.7, 39.8, 39.6, 28.6, 26.5, 24.9, 24.8, 23.9, 22.8, 11.7, 11.2.
[0352] HRMS (ESI-TOF) Calculated for C.sub.9H.sub.14O.sub.4Na [M+Na].sup.+: 209.0790, Found: 209.0797.
##STR00099##
2-(5-Isopropyl-6-oxotetrahydro-2H-pyran-2-yl)acetic acid 25a
[0353] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 30% (6.0 mg, 0.030 mmol, colourless oil, d.r.: 2.2:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0354] NMR for minor diastereomer: .sup.1H NMR (500 MHz, CDCl.sub.3) 4.79-4.71 (m, 1H), 2.84-2.74 (m, 1H), 2.68-2.56 (m, 1H), 2.41-2.33 (m, 1H), 2.26 (tt, J=13.2, 6.8 Hz, 1H), 2.06-1.99 (m, 1H), 1.71-1.57 (m, 2H), 1.04-0.90 (m, 6H).
[0355] .sup.13C NMR (126 MHz, CDCl.sub.3) 174.4, 174.3, 73.7, 44.0, 39.9, 28.1, 26.9, 20.8, 18.6, 18.4.
[0356] NMR for major diastereomer: .sup.1H NMR (500 MHz, CDCl.sub.3) 4.71-4.63 (m, 1H), 2.84-2.74 (m, 1H), 2.68-2.56 (m, 1H), 2.51 (dp, J=11.0, 5.6 Hz, 1H), 2.43 (ddd, J=11.0, 6.9, 3.6 Hz, 1H), 2.12-2.06 (m, 1H), 1.92 (ddd, J=13.6, 7.0, 3.0 Hz, 1H), 1.71-1.57 (m, 4H), 1.04-0.90 (m, 6H).
[0357] .sup.13C NMR (126 MHz, CDCl.sub.3) 174.3, 172.9, 73.7, 46.7, 40.8, 29.2, 28.5, 20.0, 20.0, 18.1. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.17O.sub.4 [M+H].sup.+: 201.1127,
[0358] Found: 201.1134.
##STR00100##
2-(5,5-Dimethyl-6-oxotetrahydro-2H-pyran-2-yl)acetic acid 26a
[0359] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 31% (5.7 mg, 0.031 mmol, off white solid).
[0360] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.82-4.68 (m, 1H), 2.79 (dd, J=16.3, 7.1 Hz, 1H), 2.65 (dd, J=16.3, 5.7 Hz, 1H), 2.02-1.90 (m, 1H), 1.87-1.78 (m, 2H), 1.78-1.70 (m, 1H), 1.31 (s, 3H), 1.29 (s, 3H).
[0361] .sup.13C NMR (126 MHz, CDCl.sub.3) 177.2, 174.8, 77.4, 40.8, 38.1, 34.4, 27.9, 27.8, 25.8. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.3O.sub.4 [MH].sup.: 185.0814, Found: 185.0815.
##STR00101##
Benzyl 2-(4-methyl-6-oxotetrahydro-2H-pyran-2-yl)acetate 27a
[0362] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.30). Isolated yield 38% over 2 steps (10.4 mg, 0.040 mmol, colourless oil, d.r.: 1.9:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0363] NMR for minor diastereomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 7.44-7.31 (m, 5H), 5.33-5.05 (m, 2H), 4.87 (ddd, J=10.5, 6.7, 4.1 Hz, 1H), 2.93-2.78 (m, 1H), 2.66-2.56 (m, 2H), 2.24-2.15 (m, 2H), 1.83 (ddd, J=14.9, 9.4, 6.2 Hz, 1H), 1.67 (dt, J=14.2, 5.0 Hz, 1H), 1.10 (d, J=6.3 Hz, 3H).
[0364] .sup.13C NMR (151 MHz, CDCl.sub.3) 171.7, 169.7, 135.6, 128.8, 128.6, 128.5, 73.4, 67.0, 40.4, 37.4, 34.7, 24.0, 21.4.
[0365] NMR for major diastereomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 7.44-7.31 (m, 5H), 5.33-5.05 (m, 2H), 4.74 (dtd, J=12.2, 6.4, 3.0 Hz, 1H), 2.93-2.78 (m, 1H), 2.75-2.66 (m, 1H), 2.66-2.56 (m, 1H), 2.13-2.06 (m, 2H), 2.05-1.97 (m, 1H), 1.27 (dt, J=13.7, 11.5 Hz, 1H), 1.03 (d, J=6.3 Hz, 3H).
[0366] .sup.13C NMR (151 MHz, CDCl.sub.3) 170.7, 169.7, 135.6, 128.8, 128.6, 128.5, 76.5, 66.9, 40.9, 38.0, 36.6, 26.7, 21.7.
[0367] HRMS (ESI-TOF) Calculated for C.sub.15H.sub.19O.sub.4 [M+H].sup.+: 263.1283, Found: 263.1288.
##STR00102##
Benzyl 2-(4-isopropyl-6-oxotetrahydro-2H-pyran-2-yl)acetate 28a
[0368] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.35). Isolated yield 48% over 2 steps (14.0 mg, 0.048 mmol, colourless oil, d.r.: 3.2:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0369] NMR for minor diastereomer: .sup.1H NMR (500 MHz, CDCl.sub.3) 7.45-7.29 (m, 5H), 5.16 (s, 2H), 4.79-4.74 (m, 1H), 2.90-2.79 (m, 1H), 2.70-2.57 (m, 1H), 2.53 (dd, J=15.8, 5.4 Hz, 1H), 2.29 (dd, J=15.8, 10.9 Hz, 1H), 1.83-1.71 (m, 3H), 1.59 (m, 1H), 0.93-0.86 (m, 6H).
[0370] .sup.13C NMR (126 MHz, CDCl.sub.3) 172.7, 169.7, 135.6, 128.8, 128.6, 128.5, 73.7, 67.0, 40.2, 35.3, 33.1, 32.3, 30.9, 19.5, 19.3.
[0371] NMR for major diastereomer: .sup.1H NMR (500 MHz, CDCl.sub.3) 7.45-7.29 (m, 5H), 5.16 (s, 2H), 4.70 (dtd, J=12.4, 6.4, 2.7 Hz, 1H), 2.90-2.79 (m, 1H), 2.70-2.57 (m, 2H), 2.16 (dd, J=17.8, 10.5 Hz, 1H), 2.00 (ddt, J=13.6, 4.2, 2.2 Hz, 1H), 1.83-1.71 (m, 1H), 1.51 (h, J=6.7 Hz, 1H), 1.28 (dt, J=14.1, 12.2 Hz, 1H), 0.93-0.86 (m, 6H).
[0372] .sup.13C NMR (126 MHz, CDCl.sub.3) 171.3, 169.7, 135.6, 128.8, 128.6, 128.5, 76.4, 66.9, 40.9, 37.8, 33.8, 32.4, 32.0, 19.3, 19.2.
[0373] HRMS (ESI-TOF) Calculated for C.sub.17H.sub.22O.sub.4Na [M+Na].sup.+: 313.1416, Found: 313.1429.
##STR00103##
Benzyl 2-(4-(tert-butyl)-6-oxotetrahydro-2H-pyran-2-yl)acetate 29a
[0374] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.30). Isolated yield 50% over 2 steps (15.2 mg, 0.050 mmol, colourless oil, d.r.: 5:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0375] .sup.1H NMR (500 MHz, CDCl.sub.3) 7.53-7.33 (m, 5H), 5.18 (s, 2H), 4.71 (ddt, J=11.6, 6.4, 3.2 Hz, 1H), 2.86 (dd, J=16.0, 6.6 Hz, 1H), 2.67 (dd, J=15.9, 6.1 Hz, 1H), 2.68-2.61 (m, 1H), 2.26 (dd, J=17.8, 10.4 Hz, 1H), 2.00 (ddt, J=13.6, 4.3, 2.3 Hz, 1H), 1.87-1.74 (m, 1H), 1.31 (dt, J=13.3, 11.8 Hz, 1H), 0.89 (s, 9H).
[0376] .sup.13C NMR (126 MHz, CDCl.sub.3) 171.6, 169.6, 135.5, 128.7, 128.5, 128.4, 76.3, 66.8, 41.5, 40.8, 32.3, 31.7, 30.1, 26.5.
[0377] HRMS (ESI-TOF) Calculated for C.sub.18H.sub.25O.sub.4 [M+H].sup.+: 305.1753, Found: 305.1754.
##STR00104##
Benzyl 2-(1-oxoisochroman-3-yl)acetate 30a
[0378] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.30). Isolated yield 71% over 2 steps (21.0 mg, 0.071 mmol, off white solid).
[0379] .sup.1H NMR (400 MHz, CDCl.sub.3) 8.09 (dd, J=7.8, 1.4 Hz, 1H), 7.55 (td, J=7.5, 1.4 Hz, 1H), 7.45-7.31 (m, 6H), 7.23 (d, J=7.6 Hz, 1H), 5.18 (s, 2H), 5.00 (p, J=6.9 Hz, 1H), 3.08-2.98 (m, 3H), 2.79 (dd, J=16.2, 6.9 Hz, 1H).
[0380] .sup.13C NMR (100 MHz, CDCl.sub.3) 169.6, 165.0, 138.5, 135.5, 134.1, 130.5, 128.8, 128.6, 128.5, 128.0, 127.6, 125.0, 74.7, 67.0, 39.9, 32.9.
[0381] HRMS (ESI-TOF) Calculated for C.sub.18H.sub.17O.sub.4 [M+H].sup.+: 297.1127, Found: 297.1131.
##STR00105##
2-(5-Oxo-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isochromen-7-yl)acetic acid 31a
[0382] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 75% (18.7 mg, 0.075 mmol, off white solid).
[0383] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.36 (s, 1H), 6.81 (d, J=0.9 Hz, 1H), 6.08-6.04 (m, 2H), 4.91 (dddd, J=11.3, 7.4, 5.5, 4.0 Hz, 1H), 3.06-2.94 (m, 2H), 2.85-2.74 (m, 2H).
[0384] .sup.13C NMR (151 MHz, CD.sub.3OD) 173.4, 166.9, 154.3, 149.0, 137.5, 119.2, 109.6, 108.4, 103.6, 76.7, 40.4, 33.4.
[0385] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.10O.sub.6Na [M+Na].sup.+: 273.0375, found 273.0384.
##STR00106##
2-(6,7-Dimethoxy-1-oxoisochroman-3-yl)acetic acid 32a
[0386] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 75% (19.9 mg, 0.075 mmol, off white solid).
[0387] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.49 (s, 1H), 6.91 (s, 1H), 4.94 (dddd, J=11.3, 7.4, 5.6, 4.0 Hz, 1H), 3.92 (s, 3H), 3.86 (s, 3H), 3.09-2.97 (m, 2H), 2.87-2.76 (m, 2H).
[0388] .sup.13C NMR (151 MHz, CD.sub.3OD) 173.4, 167.4, 155.9, 150.0, 135.6, 117.6, 112.7, 111.0, 77.0, 56.7, 56.5, 40.5, 33.0.
[0389] HRMS (ESI-TOF) Calculated for C.sub.1H.sub.15O.sub.6 [M+H].sup.+: 267.0869, found 267.0875.
##STR00107##
2-(7-Methoxy-1-oxoisochroman-3-yl)acetic acid 33a
[0390] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 80% (18.9 mg, 0.08 mmol, off white solid).
[0391] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.49 (d, J=2.7 Hz, 1H), 7.26 (d, J=8.3 Hz, 1H), 7.17 (dd, J=8.4, 2.8 Hz, 1H), 4.93 (dddd, J=11.1, 7.5, 5.6, 3.5 Hz, 1H), 3.83 (s, 3H), 3.07-2.93 (m, 2H), 2.86-2.74 (m, 2H).
[0392] .sup.13C NMR (151 MHz, CD.sub.3OD) 172.7, 165.8, 159.2, 131.5, 128.7, 125.2, 121.0, 112.8, 76.0, 54.6, 39.4, 31.2.
[0393] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.13O.sub.5 [M+H].sup.+: 237.0763, found 237.0762.
##STR00108##
2-(7-(2,5-Dioxopyrrolidin-1-yl)-1-oxoisochroman-3-yl)acetic acid 34a
[0394] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 80% (24.3 mg, 0.08 mmol, off white solid).
[0395] .sup.1H NMR (600 MHz, DMSO) 7.88-7.84 (m, 1H), 7.55-7.51 (m, 2H), 4.93 (dddd, J=9.4, 7.6, 4.7, 3.2 Hz, 1H), 3.17-3.07 (m, 2H), 2.86-2.72 (m, 6H).
[0396] .sup.13C NMR (151 MHz, DMSO) 176.9, 171.1, 163.7, 139.2, 132.4, 132.0, 128.6, 127.8, 124.9, 75.2, 39.3, 31.4, 28.6.
[0397] HRMS (ESI-TOF) Calculated for C.sub.15H.sub.14NO.sub.6 [M+H].sup.+: 304.0821, found 304.0820.
##STR00109##
2-(8-Methyl-1-oxoisochroman-3-yl)acetic acid 35a
[0398] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 85% (18.7 mg, 0.085 mmol, off white solid).
[0399] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.44 (t, J=7.6 Hz, 1H), 7.25 (d, J=7.7 Hz, 1H), 7.18 (d, J=7.5 Hz, 1H), 4.84 (dddd, J=11.0, 7.4, 5.6, 3.3 Hz, 1H), 3.12-2.97 (m, 2H), 2.85-2.71 (m, 2H), 2.61 (s, 3H).
[0400] .sup.13C NMR (151 MHz, CD.sub.3OD) 173.6, 166.6, 143.8, 141.8, 134.3, 132.1, 126.7, 124.3, 76.2, 40.4, 34.6, 22.2.
[0401] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.3O.sub.4 [M+H].sup.+: 221.0814, found 221.0813.
##STR00110##
2-(6-Methyl-1-oxoisochroman-3-yl)acetic acid 36a
[0402] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 80% (17.6 mg, 0.08 mmol, off white solid).
[0403] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.95 (s, 1H), 7.19 (dd, J=8.0, 1.7 Hz, 1H), 7.06 (s, 1H), (p, J=6.9 Hz, 1H), 3.02 (d, J=7.3 Hz, 2H), 2.97 (dd, J=16.5, 6.7 Hz, 1H), 2.79 (dd, J=16.5, 6.2 Hz, 1H), 2.40 (s, 3H).
[0404] .sup.13C NMR (151 MHz, CDCl.sub.3) 174.8, 165.4, 145.3, 138.5, 130.6, 129.0, 128.2, 122.1, 74.5, 39.7, 32.8, 21.9.
[0405] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.3O.sub.4 [M+H].sup.+: 221.0814, found 221.0816.
##STR00111##
2-(5-Methyl-1-oxoisochroman-3-yl)acetic acid 37a
[0406] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 80% (17.6 mg, 0.080 mmol, off white solid).
[0407] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.87 (dd, J=7.8, 1.3 Hz, 1H), 7.48 (d, J=7.5 Hz, 1H), 7.31 (t, J=7.7 Hz, 1H), 4.93 (dddd, J=11.5, 6.9, 5.9, 3.3 Hz, 1H), 3.17 (dd, J=16.7, 3.3 Hz, 1H), 2.94-2.87 (m, 1H), 2.85 (dd, J=16.7, 11.5 Hz, 2H), 2.34 (s, 3H).
[0408] .sup.13C NMR (151 MHz, CD.sub.3OD) 173.4, 167.6, 139.3, 137.0, 136.6, 128.7, 128.2, 125.7, 76.2, 40.5, 30.5, 18.8.
[0409] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.13O.sub.4 [M+H].sup.+: 221.0814, found 221.0824.
##STR00112##
2-(6-Fluoro-1-oxoisochroman-3-yl)acetic acid 38a
[0410] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 68% (15.2 mg, 0.068 mmol, off white solid).
[0411] .sup.1H NMR (600 MHz, CD.sub.3OD) 8.07 (dd, J=8.6, 5.7 Hz, 1H), 7.20-7.09 (m, 2H), 4.98 (dddd, J=10.0, 7.3, 5.6, 4.2 Hz, 1H), 3.17-3.03 (m, 2H), 2.90-2.75 (m, 2H).
[0412] .sup.13C NMR (151 MHz, CD.sub.3OD) 173.4, 167.5 (d, J=254.8 Hz), 166.2, 144.3, 134.1 (d, J=10.1 Hz), 122.4, 116.2 (d, J=22.6 Hz), 115.8 (d, J=22.6 Hz), 76.8, 40.5, 33.1. .sup.19F NMR (471 MHz, CD.sub.3OD) 5-106.01.
[0413] HRMS (ESI-TOF) Calculated for C.sub.11H.sub.10FO.sub.4 [M+H].sup.+: 225.0563, found 225.0560.
##STR00113##
2-(6-Chloro-1-oxoisochroman-3-yl)acetic acid 39a
[0414] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 78% (18.7 mg, 0.078 mmol, off white solid).
[0415] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.98 (d, J=8.2 Hz, 1H), 7.47-7.42 (m, 2H), 4.97 (dddd, J=10.2, 7.3, 5.6, 4.5 Hz, 1H), 3.17-3.05 (m, 2H), 2.88-2.77 (m, 2H).
[0416] .sup.13C NMR (151 MHz, CD.sub.3OD) 173.2, 166.2, 142.8, 141.4, 132.6, 129.2, 128.9, 124.6, 76.8, 40.4, 33.1.
[0417] HRMS (ESI-TOF) Calculated for C.sub.11H.sub.10ClO.sub.4 [M+H].sup.+: 241.0268, found 241.0264.
##STR00114##
2-(1-Oxo-6-phenylisochroman-3-yl)acetic acid 40a
[0418] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 75% (21.2 mg, 0.075 mmol, off white solid).
[0419] .sup.1H NMR (600 MHz, CD.sub.3OD) 8.07 (d, J=8.1 Hz, 1H), 7.71-7.66 (m, 3H), 7.63-7.60 (m, 1H), 7.51-7.45 (m, 2H), 7.44-7.38 (m, 1H), 5.00 (dddd, J=11.0, 7.3, 5.5, 3.6 Hz, 1H), 3.23-3.09 (m, 2H), 2.90-2.80 (m, 2H).
[0420] .sup.13C NMR (151 MHz, CD.sub.3OD) 173.4, 167.2, 148.3, 141.4, 140.8, 131.6, 130.1, 129.6, 128.3, 127.4, 127.2, 124.5, 76.9, 40.5, 33.5.
[0421] HRMS (ESI-TOF) Calculated for C.sub.17H.sub.15O.sub.4 [M+H].sup.+: 283.0970, found 283.0966.
##STR00115##
2-(1-Oxo-3,4-dihydro-1H-benzo[g]isochromen-3-yl)acetic acid 41a
[0422] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 85% (21.8 mg, 0.085 mmol, off white solid).
[0423] .sup.1H NMR (600 MHz, CD.sub.3OD) 8.63 (s, 1H), 8.01 (d, J=8.2 Hz, 111), 7.90 (dd, J=8.3, 1.1 Hz, 1H), 7.80 (s, 1H), 7.64 (ddd, J=8.3, 6.8, 1.2 Hz, 1H), 7.55 (ddd, J=8.1, 6.8, 1.2 Hz, 1H), 5.03 (dddd, J=11.0, 7.2, 5.4, 3.3 Hz, 1H), 3.33-3.27 (m, 2H), 3.21 (ddd, J=16.0, 11.0, 1.5 Hz, 1H), 2.93-2.76 (m, 2H).
[0424] .sup.13C NMR (151 MHz, CD.sub.3OD) 173.4, 167.5, 137.5, 135.2, 133.5, 133.0, 130.5, 130.3, 128.5, 127.7, 127.2, 123.7, 77.2, 40.6, 33.8.
[0425] HRMS (ESI-TOF) Calculated for C.sub.15H.sub.13O.sub.4 [M+H].sup.+: 257.0814, found 257.0819.
##STR00116##
2-(1-Oxo-7-(trifluoromethyl)isochroman-3-yl)acetic acid 42a
[0426] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 85% (23.3 mg, 0.085 mmol, off white solid).
[0427] .sup.1H NMR (600 MHz, CDCl.sub.3) 8.37 (s, 1H), 7.81 (dd, J=8.2, 2.0 Hz, 1H), 7.44 (d, J=9.5 Hz, 1H), 5.02 (dddd, J=9.9, 7.0, 6.1, 4.7 Hz, 1H), 3.22-3.12 (m, 2H), 3.02 (dd, J=16.6, 7.0 Hz, 1H), 2.85 (dd, J=16.6, 6.1 Hz, 1H).
[0428] .sup.13C NMR (151 MHz, CDCl.sub.3) 174.9, 163.7, 142.1, 131.0 (q, J=33.0 Hz), 130.6 (q, J=3.6 Hz), 128.5, 127.7 (q, J=3.9 Hz), 125.5, 123.5 (q, J=272.3 Hz), 74.4, 39.5, 32.7.
[0429] .sup.19F NMR (376 MHz, CDCl.sub.3) 65.56.
[0430] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.10O.sub.4F.sub.3 [M+H].sup.+: 275.0531, found 275.0529.
##STR00117##
2-(4-Oxo-6,7-dihydro-4H-thieno[3,2-c]pyran-6-yl)acetic acid 43a
[0431] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 30% (6.4 mg, 0.03 mmol, off white solid).
[0432] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.40-7.34 (m, 2H), 5.04 (dddd, J=11.3, 7.4, 5.6, 3.7 Hz, 1H), 3.34 (dd, J=16.5, 3.7 Hz, 1H), 3.13 (dd, J=17.0, 11.3 Hz, 1H), 2.85 (qd, J=16.2, 6.5 Hz, 2H).
[0433] .sup.13C NMR (151 MHz, CD.sub.3OD) 173.7, 163.4, 151.4, 128.5, 127.1, 125.9, 78.0, 40.6, 29.9. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.9O.sub.4S [M+H].sup.+: 213.0222, found 213.0221.
2.4 Synthesis and Characterization of Substrates for -Directed, -CH Lactonization Reaction General Procedure A for the Preparation of -Substituted Hexanedioic Acids:
##STR00118##
[0434] A solution of nBuLi (2.5M in hexanes, 2.1 eq.) was added to a solution of DIPA (2.0 eq.) in THF (0.1M) at 0 C. The resultant solution was stirred at 0 C. for 30 minutes. A carboxylic acid (10.0 mmol, 1.0 eq.) was dissolved in THF (5.0 mL) and added dropwise to the LDA solution at 0 C., in which the solution was warmed to r.t and stirred for 2 hours. The reaction mixture was then cooled to 0 C. and a solution of 5-bromo-1-pentene (10.0 mmol, 1.0 eq.) in THF (5.0 mL) was added. The reaction was warmed to room temperature and stirred overnight. The completion of the reaction was confirmed by TLC analysis of the reaction mixture. The reaction was then quenched with aq. HCl (1.0 M) and extracted three times with EtOAc. The combined organic layer was dried with anhydrous MgSO.sub.4, filtered, and concentrated under vacuum. The crude obtained was directly used for the next step without further purification.
[0435] To the crude carboxylic acid obtained in the previous step was added a 3:2:2 ratio of H.sub.2O, MeCN, and EtOAc (0.3 M) at room temperature, followed by RuCl.sub.3.Math.xH.sub.2O (2.2 mol %). The reaction was stirred vigorously and NaIO.sub.4 (4.1 eq.) was added in portions over 1 hour. The reaction mixture was then stirred at room temperature overnight. The reaction mixture was then diluted with water and extracted with EtOAc three times. The combined organic layer was dried with anhydrous MgSO.sub.4, filtered, and concentrated under vacuum. The desired -substituted hexanedioic acids were obtained after purification by flash column chromatography on silica gel (specific elution conditions are described for each compound below).
General Procedure B for the Preparation of -Substituted Hexanedioic Acids:
##STR00119##
[0436] To a stirred suspension of dry potassium carbonate (16.0 mmol) in anhydrous acetone (45 mL) under N.sub.2 was added ethyl 2-oxocyclopentane-1-carboxylate (8.0 mmol) followed by alkyl-iodide or alkyl-bromide (24 mmol). The reaction was heated to 60 C. and stirred overnight. The cooled reaction mixture was diluted with diethyl ether (200 mL) and then filtered. The filtrate was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel to give the alkyl-keto ester.
[0437] 20% aq. KOH (6 mL) was added to a solution 1-alkyl-keto ester (6 mmol) in methanol (6 mL), then the mixture was refluxed and stirred overnight. The cold mixture was extracted with ether. And the aqueous phase solution was acidified with 6M aq. HCl to pH2 followed by another extraction with EtOAc (three times). The combined organic layer obtained from extraction of the acidic aqueous layer was dried with anhydrous MgSO.sub.4, filtered, and concentrated under vacuum. The desired product was obtained after recrystallization by Et.sub.2O and hexane.
[0438] A solution of nBuLi (2.5M in hexanes, 2.1 eq.) was added to a solution of DIPA (2.0 eq.) in THF (0.1M) at 0 C. The resultant solution was stirred at 0 C. for 30 minutes. A carboxylic acid (10.0 mmol, 1.0 eq.) was dissolved in THE (5.0 mL) and added dropwise to the LDA solution at 0 C., in which the solution was warmed to r.t and stirred for 2 hours. The reaction mixture was then cooled to 0 C. and a solution of 6-bromo-1-hexene (10.0 mmol, 1.0 eq.) in THE (5.0 mL) was added. The reaction was warmed to room temperature and stirred overnight. The completion of the reaction was confirmed by TLC analysis of the reaction mixture. The reaction was then quenched with aq. HCl (1.0 M) and extracted three times with EtOAc. The combined organic layer was dried with anhydrous MgSO.sub.4, filtered, and concentrated under vacuum. The crude obtained was directly used for the next step without further purification.
[0439] To the crude carboxylic acid obtained in the previous step was added a 3:2:2 ratio of H.sub.2O, MeCN, and EtOAc (0.3 M) at room temperature, followed by RuCl.sub.3.Math.xH.sub.2O (2.2 mol %). The reaction was stirred vigorously and NaIO.sub.4 (4.1 eq.) was added in portions over 1 hour. The reaction mixture was then stirred at room temperature overnight. The reaction mixture was then diluted with water and extracted with EtOAc three times. The combined organic layer was dried with anhydrous MgSO.sub.4, filtered, and concentrated under vacuum. The desired -substituted hexanedioic acids were obtained after purification by flash column chromatography on silica gel (specific elution conditions are described for each compound below).
General Procedure B for the Preparation of -Substituted Heptanedioic Acids:
##STR00120##
[0440] To a stirred suspension of dry potassium carbonate (16.0 mmol) in anhydrous acetone (45 mL) under N.sub.2 was added methyl or ethyl 2-oxocyclohexanecarboxylate (8.0 mmol) followed by alkyl-iodide or alkyl-bromide (24 mmol). The reaction was heated to 60 C. and stirred overnight. The cooled reaction mixture was diluted with diethyl ether and then filtered. The filtrate was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel to give the alkyl-keto ester.
[0441] 20% aq. KOH (6 mL) was added to a solution alkyl-keto ester (6 mmol) in methanol (6 mL), then the mixture was refluxed and stirred overnight. The cold mixture was extracted with ether. And the aqueous phase solution was acidified with 6M aq. HCl to pH2 followed by another extraction with EtOAc (three times). The combined organic layer obtained from extraction of the acidic aqueous layer was dried with anhydrous MgSO.sub.4, filtered, and concentrated under vacuum. The desired product was obtained after recrystallization by Et.sub.2O and hexane.
##STR00121##
[0442] 3-Alkylcyclohexanone (8.0 mmol) was dissolved in dimethylcarbonate (15.0 mL) and NaH (0.5 g, 12.2 mmol, 60% dispersion in mineral oil) was added. The reaction mixture was heated to reflux and stirred at this temperature (90 C.) for 3 hours. The reaction was then quenched with sat. NH.sub.4Cl and extracted with EtOAc. The combined organic layer was dried with anhydrous MgSO.sub.4, filtered, and evaporated to dryness to provide the crude -keto ester.
[0443] Sodium metal (1.0 g, 32.0 mmol) was divided into small pieces with a spatula and introduced portionwise to ice-cold anhydrous MeOH (30 mL) with vigorous stirring. After the complete addition of sodium metal, the crude -keto ester obtained above was dissolved in anhydrous MeOH (5.0 mL) and added dropwise to the ice-cold reaction mixture. The reaction mixture was warmed to room temperature, then heated to reflux, and stirred at this temperature overnight. Water (5.0 mL) was then added to the refluxing reaction mixture and stirring was continued at reflux for 2 hours. The reaction mixture was cooled to room temperature and the MeOH was removed under vacuum. The aqueous residue was extracted with EtOAc three times, and then acidified to pH2 with 6M aq. HCl followed by another extraction with EtOAc (three times). The combined organic layer obtained from extraction of the acidic aqueous layer was dried with anhydrous MgSO.sub.4, filtered, and concentrated under vacuum. The desired product was obtained after purification by flash column chromatography on silica gel (specific elution conditions are described for each compound below).
##STR00122##
2,2-Dimethylhexanedioic acid 10
[0444] This compound was prepared according to the general procedure A for the preparation of -substituted hexanedioic acids.
[0445] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA/hexanes+1% AcOH, gradient elution)
[0446] Isolated yield: 52% over 2 steps (0.91 g, 5.2 mmol, white solid)
[0447] .sup.1H NMR (500 MHz, DMSO) 12.03 (s, 2H), 2.32-2.04 (m, 2H), 1.75-1.37 (m, 411), 1.07 (s, 6H).
[0448] .sup.13C NMR (126 MHz, DMSO) 178.7, 174.3, 41.1, 39.5, 34.1, 25.0, 24.9, 20.2. HRMS (ESI-TOF) Calculated for C.sub.8H.sub.13O.sub.4 [MH].sup.: 173.0814,
[0449] Found: 173.0820.
##STR00123##
2,2-Diethylhexanedioic acid 11
[0450] This compound was prepared according to the general procedure A for the preparation of -substituted hexanedioic acids.
[0451] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA/hexanes+1% AcOH, gradient elution)
[0452] Isolated yield: 60% over 2 steps (1.21 g, 6.0 mmol, white solid)
[0453] .sup.1H NMR (500 MHz, DMSO) 12.04 (s, 2H), 2.19 (t, J=7.0 Hz, 2H), 1.55-1.40 (m, 6H), 1.40-1.28 (m, 2H), 0.73 (t, J=7.4 Hz, 6H).
[0454] .sup.13C NMR (126 MHz, DMSO) 177.8, 174.3, 48.4, 34.1, 32.3, 26.2, 19.1, 8.2. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.17O.sub.4 [MH].sup.: 201.1127,
[0455] Found: 201.1128.
##STR00124##
Ethyl 1-methyl-2-oxocyclopentane-1-carboxylate 53
[0456] This compound was prepared according to the general procedure B for the preparation of -substituted hexanedioic acids by the reaction with MeI. Quantative yield, (1.36 g, 8.0 mmol, colorless oil).
[0457] .sup.1H NMR (600 MHz, CDCl.sub.3) 4.20-4.07 (m, 2H), 2.54-2.50 (m, 1H), 2.50-2.39 (m, 1H), 2.35-2.26 (m, 1H), 2.10-2.00 (m, 1H), 1.97-1.81 (m, 2H), 1.30 (s, 3H), 1.24 (td, J=7.1, 0.5 Hz, 3H).
[0458] .sup.13C NMR (151 MHz, CDCl.sub.3) 216.1, 172.5, 61.5, 56.0, 37.8, 36.3, 19.7, 19.5, 14.2.
[0459] The data is consistent with those reported in the literature.(33)
##STR00125##
2-Methylhexanedioic acid 4
[0460] This compound was prepared according to the general procedure B for the preparation of -substituted hexanedioic acids. 87% yield, (0.84 g, 5.22 mmol, white solid).
[0461] .sup.1H NMR (600 MHz, CDCl.sub.3) 2.52-2.45 (m, 1H), 2.44-2.33 (m, 2H), 1.79-1.65 (m, 3H), 1.55-1.46 (m, 1H), 1.20 (dd, J=7.0, 1.0 Hz, 3H).
[0462] .sup.13C NMR (151 MHz, CDCl.sub.3) 182.5, 179.8, 47.0, 34.1, 31.1, 25.3, 22.7, 11.8. HRMS (ESI-TOF) Calculated for C.sub.7H.sub.11O.sub.4 [MH].sup.: 159.0657, found 159.0653.
##STR00126##
Ethyl 1-ethyl-2-oxocyclopentane-1-carboxylate SS2
[0463] This compound was prepared according to the general procedure B for the preparation of -substituted hexanedioic acids by the reaction with EtI. 95% yield, (1.4 g, 7.6 mmol, colorless oil).
[0464] .sup.1H NMR (600 MHz, CDCl.sub.3) 4.22-4.10 (m, 2H), 2.55-2.46 (m, 1H), 2.46-2.36 (m, 1H), 2.33-2.19 (m, 1H), 2.05-1.84 (m, 4H), 1.68-1.58 (m, 1H), 1.29-1.21 (m, 3H), 0.89 (t, J=7.5 Hz, 3H).
[0465] .sup.13C NMR (151 MHz, CDCl.sub.3) 215.3, 171.3, 77.4, 77.2, 77.0, 61.4, 61.0, 38.2, 38.2, 32.4, 26.9, 19.7, 14.2, 9.3.
[0466] The data is consistent with those reported in the literature.(33)
##STR00127##
2-Ethylhexanedioic acid 5
[0467] This compound was prepared according to the general procedure B for the preparation of -substituted hexanedioic acids. 85% yield, (0.89 g, 5.1 mmol, white solid).
[0468] .sup.1H NMR (600 MHz, CDCl.sub.3) 2.44-2.29 (m, 3H), 1.86-1.38 (m, 6H), 0.95 (t, J=7.4 Hz, 3H).
[0469] .sup.13C NMR (151 MHz, CDCl.sub.3) 182.5, 179.8, 47.0, 34.1, 31.1, 25.3, 22.7, 11.8. HRMS (ESI-TOF) Calculated for C.sub.8H.sub.13O.sub.4 [MH].sup.: 173.0814, found 173.0810.
##STR00128##
2-Isopropylhexanedioic acid 6
[0470] This compound was prepared according to the general procedure A for the preparation of -substituted hexanedioic acids.
[0471] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA/hexanes+1% AcOH, gradient elution)
[0472] Isolated yield: 42% over 2 steps (791 mg, 4.2 mmol, colourless oil)
[0473] .sup.1H NMR (600 MHz, DMSO) 12.03 (s, 1H), 2.28-2.12 (m, 1H), 1.97 (td, J=8.2, 4.8 Hz, OH), 1.78-1.69 (m, J=6.8 Hz, 1H), 1.52-1.33 (m, 2H), 0.87 (dd, J=6.8, 4.2 Hz, 3H).
[0474] .sup.13C NMR (151 MHz, DMSO) 176.3, 174.3, 51.9, 33.6, 29.9, 28.5, 22.9, 20.4, 19.9. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.15O.sub.4 [MH].sup.: 187.0970, Found: 187.0978.
##STR00129##
2-(tert-Butyl)hexanedioic acid 8
[0475] This compound was prepared according to the general procedure A for the preparation of -substituted hexanedioic acids.
[0476] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA/hexanes+1% AcOH, gradient elution)
[0477] Isolated yield: 35% over 2 steps (710 mg, 3.5 mmol, colourless oil)
[0478] .sup.1H NMR (500 MHz, DMSO) 12.00 (s, 2H), 2.36-2.09 (m, 2H), 1.99 (dd, J=11.3, 2.5 Hz, 1H), 1.53-1.39 (m, 3H), 1.36 (ddd, J=13.1, 10.6, 5.0 Hz, 1H), 0.90 (s, 9H).
[0479] .sup.13C NMR (126 MHz, DMSO) 176.1, 174.3, 55.5, 33.6, 32.1, 27.5, 26.6, 23.6. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.17O.sub.4 [MH].sup.: 201.1127, Found: 201.1124.
##STR00130##
Ethyl 1-benzyl-2-oxocyclopentane-1-carboxylate SS3
[0480] This compound was prepared according to the general procedure B for the preparation of -substituted hexanedioic acids by the reaction With BnBr. 95% yield, (2.34 g, 7.6 mmol, colorless oil).
[0481] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.29-7.19 (m, 3H), 7.17-7.12 (m, 2H), 4.22-4.15 (m, 2H), 3.20 (dd, J=13.8, 1.4 Hz, 1H), 3.13 (dd, J=13.9, 1.5 Hz, 1H), 2.45-2.40 (m, 1H), 2.40-2.33 (m, 1H), 2.09-1.84 (m, 3H), 1.65-1.57 (m, 1H), 1.29-1.23 (m, 3H).
[0482] .sup.13C NMR (151 MHz, CDCl.sub.3) 215.1, 171.1, 136.8, 130.3, 128.5, 127.0, 77.4, 77.2, 76.9, 61.7, 61.6, 39.1, 38.5, 31.9, 19.6, 14.2.
[0483] The data is consistent with those reported in the literature.(34)
##STR00131##
2-Benzylhexanedioic acid 7
[0484] This compound was prepared according to the general procedure B for the preparation of -substituted hexanedioic acids. 90% yield, (1.28 g, 5.4 mmol, white solid).
[0485] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.30-7.16 (m, 5H), 3.01 (dd, J=13.6, 7.4 Hz, 1H), 2.78-2.65 (m, 2H), 2.40-2.26 (m, 2H), 1.78-1.61 (m, 3H), 1.59-1.51 (m, 1H).
[0486] .sup.13C NMR (151 MHz, CDCl.sub.3) 181.5, 179.5, 138.9, 129.0, 128.6, 126.7, 47.2, 38.1, 33.9, 31.0, 22.5. HRMS (ESI-TOF) Calculated for C.sub.13H.sub.16O.sub.4Na [M+Na].sup.+: 259.0946, Found: 259.0947.
##STR00132##
Adipic Acid/Hexane-1,6-Dioic Acid 1
[0487] This compound is commercially available.
##STR00133##
(S)-2-(1,3-dioxoisoindolin-2-yl)hexanedioic acid 9
[0488] This compound was synthesized from commercially available L-homoglutamic acid using the following general procedure(35). Amino acid (5.0 mmol, 1.0 equiv), phthalic anhydride (5.0 mmol, 1.0 equiv), and triethylamine (0.5 mmol, 0.1 equiv) were dissolved in toluene (30 mL) in a dried round bottom flask equipped with a stir bar and a reflux condenser. The reaction mixture was heated to reflux for 4 h. The reaction mixture was cooled to room temperature and concentrated under vacuum. The residue was dissolved in EtOAc, transferred to a separatory funnel, and washed with 1 M HCl. The organic layer was dried with MgSO.sub.4, filtered through Celite, and concentrated to give the desired product quantitatively as a white powder (1.46 g, 5.0 mmol).
[0489] .sup.1H NMR (500 MHz, DMSO) 8.14-7.74 (m, 4H), 4.74 (dd, J=10.0, 5.4 Hz, 1H), 2.21 (hept, J=8.0 Hz, 2H), 2.09 (ddt, J=14.6, 12.6, 7.4 Hz, 2H), 1.46 (p, J=7.5 Hz, 2H).
[0490] .sup.13C NMR (126 MHz, DMSO) 174.1, 170.4, 167.4, 134.9, 131.1, 123.4, 51.4, 32.9, 27.5, 21.4. HRMS (ESI-TOF) Calculated for C.sub.14H.sub.14NO.sub.6 [M+H].sup.+: 292.0821, Found: 292.0821.
##STR00134##
3-Methylhexanedioic acid 12
[0491] This compound is commercially available.
##STR00135##
3-(tert-Butyl)hexanedioic acid 13
[0492] This compound is commercially available.
1--Carboxypropyl)cyclopropane-1-carboxylic acid 14
[0493] This compound was synthesized using the following procedure:
##STR00136##
[0494] A solution of nBuLi (2.5M in hexanes, 1.4 mL, 3.6 mmol, 1.2 eq.) was added to a solution of DIPA (0.46 mL, 3.3 mmol, 1.1 eq.) in THF (30 mL) at 0 C. The resultant solution was stirred at 0 C. for 30 minutes then cooled to 78 C. tert-Butyl cyclopropanecarboxylate (427 mg, 3.0 mmol, 1.0 eq.) was dissolved in THF (2.0 mL) and added dropwise to the LDA solution at 78 C., in which the solution was stirred at 78 C. for 4 hours. A solution of 5-bromo-1-pentene (0.36 mL, 3.0 mmol, 1.0 eq.) in THF (2.0 mL) was then added. The reaction was warmed to room temperature and stirred overnight. The completion of the reaction was confirmed by TLC analysis of the reaction mixture. The reaction was then quenched with aq. HCl (1.0 M) and extracted three times with EtOAc. The combined organic layer was dried with anhydrous MgSO.sub.4, filtered, and concentrated under vacuum. The crude product obtained was directly used for the next step without further purification.
[0495] To the crude product obtained in the previous step was added a 3:2:2 ratio of H.sub.2O, MeCN, and EtOAc (0.3 M) at room temperature, followed by RuCl.sub.3.Math.xH.sub.2O (14 mg, 2.2 mol %). The reaction was stirred vigorously and NaIO.sub.4 (2.7 g, 12.3 mmol, 4.1 eq.) was added in portions over 1 hour. The reaction mixture was then stirred at room temperature overnight. The reaction mixture was then diluted with water and extracted with EtOAc three times. The combined organic layer was dried with anhydrous MgSO.sub.4, filtered, and concentrated under vacuum. To the crude product was added aq. NaOH (10.0 mL, 1.0 M) and quickly extracted with EtOAc three times. The aqueous layer was acidified with aq. HCl (6.0 M) to pH2 and extracted with EtOAc three times. The combined organic layer was dried with anhydrous MgSO.sub.4, filtered, and concentrated. The residue was dissolved in DCM (10 mL) and trifluoroacetic acid (0.23 mL, 3.0 mmol, 1.0 eq.) was added and stirred at room temperature overnight. Evaporation of the volatiles provided the desired product as a white solid in 20% yield over 4 steps (103.0 mg, 0.6 mmol).
[0496] .sup.1H NMR (500 MHz, DMSO) 2.17 (t, J=7.5 Hz, 2H), 1.71-1.57 (m, 2H), 1.54-1.39 (m, 2H), 1.15-0.94 (m, 2H), 0.71-0.56 (m, 2H).
[0497] .sup.13C NMR (126 MHz, DMSO) 176.2, 174.3, 33.7, 32.8, 22.9, 22.6, 14.7. HRMS (ESI-TOF) Calculated for C.sub.8H.sub.11O.sub.4 [MH].sup.: 171.0657,
[0498] Found: 171.0661.
1--Carboxypropyl)cyclobutane-1-carboxylic acid 15
[0499] This compound was prepared according to the general procedure A for the preparation of -substituted hexanedioic acids.
[0500] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA/hexanes+1% AcOH, gradient elution) Isolated yield: 41% over 2 steps (0.76 g, 4.1 mmol, white solid)
[0501] .sup.1H NMR (500 MHz, DMSO) 12.05 (s, 2H), 2.32-2.23 (m, 2H), 2.19 (t, J=7.4 Hz, 2H), 1.87-1.71 (m, 4H), 1.71-1.62 (m, 2H), 1.41-1.30 (m, 2H).
[0502] .sup.13C NMR (126 MHz, DMSO) 177.8, 174.3, 46.8, 36.9, 33.7, 29.5, 20.2, 15.0. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.13O.sub.4 [MH].sup.: 185.0814,
[0503] Found: 185.0818.
##STR00137##
1--Carboxypropyl)cyclopentane-1-carboxylic acid 16
[0504] This compound was prepared according to the general procedure A for the preparation of -substituted hexanedioic acids.
[0505] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA/hexanes+1% AcOH, gradient elution) Isolated yield: 55% over 2 steps (1.10 g, 5.5 mmol, white solid)
[0506] .sup.1H NMR (500 MHz, DMSO) 12.02 (s, 2H), 2.17 (t, J=7.3 Hz, 2H), 2.00 (dt, J=12.0, 6.2 Hz, 2H), 1.69-1.45 (m, 6H), 1.45-1.20 (m, 4H).
[0507] .sup.13C NMR (126 MHz, DMSO) 178.5, 174.2, 53.1, 38.1, 35.3, 34.0, 24.6, 21.3. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.15O.sub.4 [MH].sup.: 199.0970, Found: 199.0978.
##STR00138##
1--Carboxypropyl)cyclohexane-1-carboxylic acid 17
[0508] This compound was prepared according to the general procedure A for the preparation of -substituted hexanedioic acids.
[0509] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA/hexanes+1% AcOH, gradient elution) Isolated yield: 56% over 2 steps (1.20 g, 5.6 mmol, white solid)
[0510] .sup.1H NMR (500 MHz, DMSO) 12.04 (s, 2H), 2.15 (dq, J=4.4, 2.3 Hz, 2H), 1.92 (d, J=12.2 Hz, 2H), 1.61-1.47 (m, 3H), 1.40 (d, J=3.7 Hz, 4H), 1.27 (dt, J=14.5, 10.3 Hz, 2H), 1.20 (td, J=9.5, 3.5 Hz, 1H), 1.13 (td, J=12.1, 3.1 Hz, 2H).
[0511] .sup.13C NMR (126 MHz, DMSO) 177.4, 174.2, 45.8, 39.3, 34.0, 33.6, 25.5, 22.9, 19.4. HRMS (ESI-TOF) Calculated for C.sub.11H.sub.17O.sub.4 [MH].sup.:
[0512] 213.1127, Found: 213.1125.
##STR00139##
4-(tert-Butyl)-1--carboxypropyl)cyclohexane-1-carboxylic acid 18
[0513] This compound was prepared according to the general procedure A for the preparation of -substituted hexanedioic acids.
[0514] Elution condition: (10% EA/hexanes+1% AcOH to 50% EA+1% AcOH, gradient elution) Isolated yield: 56% over 2 steps (1.51 g, 5.6 mmol, white solid, d.r.=2.7:1)
[0515] .sup.1H NMR (500 MHz, DMSO) 12.03 (s, 2H), 2.21-2.07 (m, 3.5H), 1.79-1.71 (m, 0.5H), 1.64-1.48 (m, 2.5H), 1.45-1.31 (m, 4H), 1.16-1.06 (m, 0.6H), 1.06-0.91 (m, 4H), 0.85-0.79 (m, 9H).
[0516] .sup.13C NMR (126 MHz, DMSO) 178.8, 177.1, 174.3, 174.2, 47.2, 47.0, 45.9, 43.8, 40.9, 34.3, 34.0, 34.0, 32.1, 32.1, 30.9, 27.3, 24.2, 21.5, 19.8, 19.5.
[0517] HRMS (ESI-TOF) Calculated for C.sub.15H.sub.25O.sub.4 [MH].sup.: 269.1753, Found: 269.1748.
##STR00140##
4--Carboxypropyl)tetrahydro-2H-pyran-4-carboxylic acid 19
[0518] This compound was prepared according to the general procedure A for the preparation of -substituted hexanedioic acids.
[0519] Elution condition: (40% EA/hexanes+1% AcOH to 100% EA+1% AcOH, gradient elution) Isolated yield: 70% over 2 steps (1.51 g, 7.0 mmol, white solid)
[0520] .sup.1H NMR (500 MHz, DMSO) 12.23 (s, 2H), 3.70 (dt, J=11.8, 3.8 Hz, 2H), 3.29 (dd, J=11.4, 2.3 Hz, 2H), 2.17 (t, J=6.9 Hz, 2H), 1.90 (d, J=13.2 Hz, 2H), 1.49-1.43 (m, 2H), 1.43-1.37 (m, 2H), 1.37-1.31 (m, 2H).
[0521] .sup.13C NMR (126 MHz, DMSO) 176.7, 174.2, 64.6, 43.8, 39.2, 33.7, 19.1. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.1505 [MH].sup.: 215.0919,
[0522] Found: 215.0914.
##STR00141##
Ethyl 1-methyl-2-oxocyclohexane-1-carboxylate SS4
[0523] This compound was prepared according to the general procedure B for the preparation of -substituted heptanedioic acids with the reaction of MeI and ethyl 2-oxocyclohexane-1-carboxylate. 73% yield, (1.1 g, 6.0 mmol, colorless oil).
[0524] .sup.1H NMR (600 MHz, CDCl.sub.3) 4.22-4.14 (m, 2H), 2.54-2.41 (m, 3H), 2.06-1.97 (m, 1H), 1.78-1.57 (m, 4H), 1.50-1.41 (m, 1H), 1.28 (s, 3H), 1.25 (t, J=7.1 Hz, 3H).
[0525] .sup.13C NMR (151 MHz, CDCl.sub.3) 208.5, 173.2, 61.4, 57.3, 40.8, 38.4, 27.7, 22.8, 21.4, 14.2.
[0526] The data is consistent with those reported in the literature.(33)
##STR00142##
2-Methylheptanedioic acid 44
[0527] This compound was prepared according to the general procedure B for the preparation of -substituted heptanedioic acids. 75% yield, (0.78 g, 4.5 mmol, white solid).
[0528] .sup.1H NMR (500 MHz, DMSO) 2.29 (h, J=6.9 Hz, 1H), 2.19 (t, J=7.3 Hz, 2H), 1.57-1.50 (m, 1H), 1.50-1.41 (m, 2H), 1.33 (dq, J=15.7, 6.8 Hz, 1H), 1.25 (qd, J=7.6, 3.7 Hz, 2H), 1.03 (d, J=6.9 Hz, 3H).
[0529] .sup.13C NMR (126 MHz, DMSO) 177.4, 174.4, 38.6, 33.6, 33.0, 26.3, 24.4, 17.0. HRMS (ESI-TOF) Calculated for C.sub.8H.sub.13O.sub.4, [MH].sup.: 173.0814, found: 173.0811.
##STR00143##
2-(2-Carboxyethyl)benzoic acid 20
[0530] This compound is commercially available.
##STR00144##
(1R*,2R*)-2-(2-Carboxyethyl)cyclohexane-1-carboxylic acid 21
[0531] This compound was prepared according to the following procedure.(36)
[0532] The compound 20 (0.2 g, 1.03 mmol) was dissolved in glacial acetic acid (10.0 mL) and PtO.sub.2 (40.0 mg) was added. The reaction vessel was purged with H.sub.2 and the hydrogenation reaction was carried out at room temperature with a balloon of H.sub.2 and stirred for 3 days. Analysis of an aliquot of the reaction mixture at this point suggested completion of reaction. The reaction mixture was filtered with a plug of Celite and the filtrate was evaporated to dryness to give the desired compound as a white solid in 97% yield (0.2 g, 1.00 mmol).
[0533] .sup.1H NMR (500 MHz, CDCl.sub.3) 2.62 (dt, J=8.1, 4.1 Hz, 1H), 2.41 (ddd, J=15.8, 10.0, 5.8 Hz, 1H), 2.32 (ddd, J=16.0, 9.7, 6.4 Hz, 1H), 1.98-1.85 (m, 1H), 1.83-1.73 (m, 2H), 1.73-1.61 (m, 4H), 1.60-1.43 (m, 2H), 1.41-1.30 (m, 2H).
[0534] .sup.13C NMR (126 MHz, CDCl.sub.3) 181.6, 180.4, 45.2, 36.7, 32.6, 28.1, 25.3, 23.9, 22.4. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.15O.sub.4 [MH].sup.: 199.0970, Found: 199.0968.
##STR00145##
(1R*,2S*)-2-(2-Carboxyethyl)cyclohexane-1-carboxylic acid 22
[0535] This compound was prepared according to the following procedure.(36)
[0536] The compound 21 (0.1 g, 0.50 mmol) was suspended in conc. HCl (1.0 mL) in a sealed tube and stirred at 180 C. overnight. The reaction mixture was diluted with H.sub.2O and extracted with EtOAc three times. The combined organic layer was dried with anhydrous MgSO.sub.4, filtered, and evaporated to dryness to give the desired compound as an off-white solid in 76% yield (75.0 mg, 0.38 mmol).
[0537] .sup.1H NMR (500 MHz, CDCl.sub.3) 2.48 (ddd, J=16.2, 10.8, 5.5 Hz, 1H), 2.28 (ddd, J=16.1, 10.5, 5.7 Hz, 1H), 2.08 (td, J=11.5, 3.5 Hz, 1H), 1.96 (d, J=13.7 Hz, 1H), 1.89-1.79 (m, 2H), 1.79-1.72 (m, 2H), 1.66-1.56 (m, 1H), 1.53-1.41 (m, 2H), 1.30-1.19 (m, 2H), 0.92 (td, J=12.3, 8.9 Hz, 1H).
[0538] .sup.13C NMR (126 MHz, CDCl.sub.3) 182.9, 180.6, 49.9, 38.3, 31.5, 30.4, 30.1, 29.8, 25.6, 25.4. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.15O.sub.4 [MH].sup.: 199.0970, Found: 199.0974.
##STR00146##
(1R*,3S*)-3-(Carboxymethyl)cyclopentane-1-carboxylic acid 23
[0539] This compound was prepared according to the following procedure.
[0540] Bicyclo[3.2.1]oct-2-ene (1.0 g, 9.24 mmol) was dissolved in a 3:2:2 ratio of H.sub.2O/MeCN/EtOAc (31 mL) at room temperature. RuCl.sub.3.Math.xH.sub.2O (42.0 mg, 0.20 mmol) was added, followed by portionwise addition of NaIO.sub.4 (8.1 g, 38.0 mmol) over 1 hour. The reaction mixture was stirred vigorously at room temperature overnight. The reaction mixture was diluted with H.sub.2O and extracted with EtOAc three times. The combined organic layer was dried with anhydrous MgSO.sub.4, filtered, and evaporated to dryness to give the desired compound as a pale grey solid in 83% yield (1.35 g, 7.6 mmol).
[0541] .sup.1H NMR (600 MHz, DMSO) 12.01 (s, 2H), 2.69 (dt, J=16.4, 8.1 Hz, 1H), 2.24 (dd, J=7.3, 2.0 Hz, 2H), 2.19-2.10 (m, 1H), 2.03 (dt, J=12.5, 7.5 Hz, 1H), 1.83-1.71 (m, 3H), 1.31 (dt, J=12.5, 9.5 Hz, 1H), 1.24-1.18 (m, 1H).
[0542] .sup.13C NMR (151 MHz, DMSO) 177.1, 173.9, 42.9, 39.4, 36.2, 36.0, 31.4, 28.3. HRMS (ESI-TOF) Calculated for C.sub.8H.sub.11O.sub.4 [MH].sup.: 171.0657,
[0543] Found: 171.0657.
General Method for the Preparation of Substituted Benzoic Acid Substrates
##STR00147##
Procedure A
[0544] To a solution of 2-bromobenzoic acid (14.0 mmol) in DMF (30 mL) were added K.sub.2CO.sub.3 (21.0 mmol) and benzylbromide (14.3 mmol), and the mixture was stirred at room temperature for 12 h. The mixture was partitioned between EtOAc and H.sub.2O, and extracted with EtOAc, and the organic layer was washed with H.sub.2O and brine, dried over MgSO.sub.4, filtered, and concentrated in vacuo to give benzyl 2-bromobenzoate quantitatively.
[0545] A suspension of benzyl 2-bromobenzoate (2 mmol), benzyl 4-trifluoroboratebutanoate potassium salt (3 mmol), K.sub.2CO.sub.3 (829 mg, 6 mmol), Pd(OAc).sub.2 (18 mg, 0.08 mmol), 1,1-bis(di-tert-butylphosphino)ferrocene (dtbpf, 56 mg, 0.12 mmol) in toluene (10 mL), was degassed with N.sub.2 during 5 min and distilled water (2 mL) was added. The mixture was placed into a pre-heated oil bath at 80 C. during 18 h and controlled by TLC until the starting material was consumed. Then, the system was cooled to room temperature, diluted with H.sub.2O (10 mL) and extracted with Et.sub.2O (330 mL). The organic phase was washed with 1 M HCl (10 mL) and brine (20 mL), dried over MgSO.sub.4 and filtered through a cotton pad. The volatiles were removed under vacuum and the crude material was purified by column chromatography affording benzyl 2-(4-(benzyloxy)-4-oxobutyl)benzoate.
Preparation of benzyl 4-trifluoroboratebutanoate potassium salt
##STR00148##
[0546] In air, CuI (228 mg, 1.2 mmol), PPh.sub.3 (409 mg, 1.56 mmol), LiOMe (912 mg, 24 mmol), and bis(pinacolato)diboron (4.57 g, 18 mmol) were added to a 50 ml round-bottom flask equipped with a stir bar. The vessel was evacuated and filled with N.sub.2 (three cycles). DMF (15 mL), the benzyl 4-bromobutanoate (12 mmol, 3.07 g) were added in turn by syringe. The resulting reaction mixture was stirred vigorously at room temperature for 18 h. The reaction mixture was then diluted with EtOAc, filtered through silica gel with copious washings (EtOAc), concentrated, and purified by column chromatography, affording benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butanoate (2.9 g, 79% yield) as a colorless oil. .sup.LH NMR (600 MHz, CDCl.sub.3) 7.39-7.28 (m, 5H), 5.11 (s, 2H), 2.41-2.35 (m, 2H), 1.81-1.73 (m, 2H), 1.23 (s, 12H), 0.82 (t, J=7.9 Hz, 2H). .sup.13C NMR (151 MHz, CDCl.sub.3) 173.6, 136.3, 128.6, 128.3, 128.2, 83.2, 66.1, 36.7, 24.9, 19.7. HRMS (ESI-TOF) Calculated for C.sub.25H.sub.25O.sub.4 [M+H].sup.+: 304.1960, found: 304.1963.
[0547] To a stirred solution of benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butanoate (1.2 g, 4 mmol) in CH.sub.3CN (10 mL) was added KHF.sub.2 (936 mg, 12 mmol) Then the mixture was added with water (3 mL) dropwise at ambient temperature and the reaction mixture was stirred for 4 h. Then the solvent was removed under vacuum and dried. The resulting mixture was purified by dissolving in hot CH.sub.3CN, and precipitation by adding Et.sub.2O. Collect the white solid washed with Et.sub.2O to afford benzyl 4-trifluoroboratebutanoate potassium salt (795 mg, 70% yield) as a white solid. .sup.1H NMR (600 MHz, DMSO) 7.60-7.16 (m, 5H), 5.04 (s, 2H), 2.33-2.03 (m, 2H), 1.83-1.32 (m, 2H), 0.40--0.18 (m, 2H). .sup.13C NMR (151 MHz, DMSO) 173.8, 136.6, 128.4, 127.9, 127.8, 73.6, 64.8, 37.3, 25.0, 21.7 (q, J=2.7 Hz). HRMS (ESI-TOF) Calculated for C.sub.11H.sub.13BF.sub.3O.sub.2 [MH].sup.: 244.0997, found: 244.0992.
Procedure B
[0548] A solution of benzyl 2-(4-(benzyloxy)-4-oxobutyl)benzoate (1 mmol) in EtOAc (10 mL) was treated with 10% Pd/C (100 mg) and the mixture was stirred for overnight at room temperature under H.sub.2. The mixture was passed through celite and the filtrate was concentrated under reduced pressure to give 2--carboxypropyl)benzoic acid.
Procedure C
[0549] A solution of benzyl 2-(4-(benzyloxy)-4-oxobutyl)benzoate (1 mmol) in toluene (10 mL) was added with Boron trifluoride diethyl etherate (2.4 mmol) and the mixture was placed into a pre-heated oil bath at 80 C. for 2 h. The mixture was concentrated under reduced pressure and purified by column chromatography (EtOAc/Hexanes/3% AcOH) to give 2--carboxypropyl)benzoic acid.
##STR00149##
Benzyl 2-(4-(benzyloxy)-4-oxobutyl)benzoate S30
[0550] S30 was prepared by Procedure A, 97% yield for two steps, (0.75 g, 1.94 mmol, yellow oil).
[0551] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.94-7.90 (m, 1H), 7.44-7.31 (m, 11H), 7.26-7.19 (m, 2H), 5.32 (s, 2H), 5.11 (s, 2H), 3.00-2.95 (m, 2H), 2.34 (t, J=7.5 Hz, 2H), 1.97-1.89 (m, 2H).
[0552] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.4, 167.4, 143.6, 136.2, 136.1, 132.2, 131.3, 131.0, 129.5, 128.8, 128.7, 128.5, 128.4, 128.4, 128.3, 128.3, 126.3, 77.4, 77.2, 76.9, 66.8, 66.27, 34.02, 33.7, 26.8.
[0553] HRMS (ESI-TOF) Calculated for C.sub.25H.sub.25O.sub.4 [M+H].sup.+: 389.1753, Found: 389.1749.
##STR00150##
2--Carboxypropyl)benzoic acid 30
[0554] 30 was prepared by Procedure B, 99% yield, (0.21 g, 0.99 mmol, white solid).
[0555] .sup.1H NMR (600 MHz, CDCl.sub.3) 8.00 (dd, J=8.1, 1.5 Hz, 1H), 7.49 (td, J=7.5, 1.5 Hz, 1H), 7.33-7.27 (m, 2H), 3.18-3.12 (m, 2H), 2.43-2.38 (m, 2H), 2.05-1.98 (m, 2H).
[0556] .sup.13C NMR (151 MHz, CDCl.sub.3) 181.1, 174.3, 144.1, 133.0, 131.7, 131.3, 129.2, 126.4, 77.4, 77.2, 77.0, 33.4, 32.6, 27.7.
[0557] HRMS (ESI-TOF) Calculated for C.sub.11H.sub.12O.sub.4Na [M+Na].sup.+: 231.0633, Found: 231.0640.
##STR00151##
Benzyl 6-(4-(benzyloxy)-4-oxobutyl)benzo[d][1,3]dioxole-5-carboxylate S31
[0558] S31 was prepared by Procedure A, 95% yield for two steps, (0.82 g, 1.90 mmol, yellow oil).
[0559] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.43-7.32 (m, 10H), 6.66 (s, 1H), 5.98 (s, 2H), 5.28 (s, 2H), 5.11 (s, 2H), 2.97-2.92 (m, 2H), 2.35 (t, 2H), 1.95-1.87 (m, 2H).
[0560] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.4, 166.3, 150.9, 146.0, 140.6, 136.2, 136.2, 128.7, 128.7, 128.4, 128.4, 128.3, 122.2, 111.0, 110.8, 101.8, 66.7, 66.3, 33.9, 33.9, 26.9.
[0561] HRMS (ESI-TOF) Calculated for C.sub.26H.sub.25O.sub.6 [M+H].sup.+: 433.1651, Found: 433.1646.
##STR00152##
6--Carboxypropyl)benzo[d][1,3]dioxole-5-carboxylic acid 31
[0562] 31 was prepared by Procedure B, 99% yield, (0.25 g, 0.99 mmol, white solid).
[0563] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.37 (s, 1H), 6.76 (s, 1H), 6.00 (s, 2H), 3.00-2.95 (m, 2H), 2.31 (t, J=7.6 Hz, 2H), 1.90-1.82 (m, 2H).
[0564] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.4, 170.0, 152.2, 147.3, 141.6, 124.0, 111.8, 111.5, 103.1, 34.7, 34.6, 28.2.
[0565] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.12O.sub.6Na [M+Na].sup.+: 275.0532, Found: 275.0530.
##STR00153##
Benzyl 2-(4-(benzyloxy)-4-oxobutyl)-4,5-dimethoxybenzoate S32
[0566] S32 was prepared by Procedure A, 95% yield for two steps, (0.85 g, 1.90 mmol, yellow oil).
[0567] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.50 (s, 1H), 7.44-7.41 (m, 2H), 7.40-7.30 (m, 9H), 6.66 (s, 1H), 5.31 (s, 2H), 5.11 (s, 2H), 3.87 (s, 3H), 3.87 (s, 3H), 2.98-2.92 (m, 2H), 2.31 (t, J=7.4 Hz, 2H), 1.95-1.87 (m, 2H).
[0568] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.5, 166.8, 152.1, 146.9, 138.5, 136.3, 136.2, 128.7, 128.7, 128.4, 128.4, 128.4, 128.3, 120.8, 113.9, 113.8, 66.7, 66.3, 56.2, 56.0, 33.9, 33.8, 27.0. HRMS (ESI-TOF) Calculated for C.sub.27H.sub.29O.sub.6 [M+H].sup.+: 449.1964, Found: 449.1956.
##STR00154##
2--Carboxypropyl)-4,5-dimethoxybenzoic acid 32
[0569] 32 was prepared by Procedure B, 99% yield, (0.27 g, 0.99 mmol, white solid).
[0570] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.52 (s, 1H), 6.84 (s, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.04-2.98 (m, 2H), 2.32 (t, J=7.4 Hz, 2H), 1.93-1.85 (m, 2H).
[0571] .sup.13C NMR (151 M1 Hz, CD.sub.3OD) 177.8, 170.7, 153.5, 148.1, 139.9, 122.7, 115.7, 115.2, 34.75, 34.2, 28.2.
[0572] HRMS (ESI-TOF) Calculated for C.sub.13H.sub.15O.sub.6 [MH].sup.: 267.0869, Found: 267.0858.
##STR00155##
Benzyl 2-(4-(benzyloxy)-4-oxobutyl)-4-methoxybenzoate S33
[0573] S33 was prepared by Procedure A, 74% yield for two steps, (0.62 g, 1.48 mmol, yellow oil).
[0574] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.47-7.41 (m, 3H), 7.40-7.30 (m, 8H), 7.12 (d, J=8.5 Hz, 1H), 6.97 (dd, J=8.4, 2.9 Hz, 1H), 5.33 (s, 2H), 5.11 (s, 2H), 3.80 (s, 3H), 2.93-2.87 (m, 2H), 2.34-2.28 (m, 2H), 1.94-1.86 (m, 2H).
[0575] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.5, 167.2, 157.7, 136.2, 136.0, 135.6, 132.4, 130.3, 128.8, 128.7, 128.5, 128.4, 128.4, 128.3, 118.3, 115.8, 115.8, 66.9, 66.2, 55.6, 33.9, 33.0, 27.0. HRMS (ESI-TOF) Calculated for C.sub.26H.sub.27O.sub.5 [M+H].sup.+: 419.1858, Found: 419.1860.
##STR00156##
2--Carboxypropyl)-5-methoxybenzoic acid 33
[0576] 33 was prepared by Procedure B, 99% yield, (0.24 g, 0.99 mmol, white solid).
[0577] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.41 (d, J=3.0 Hz, 1H), 7.20 (d, J=8.5 Hz, 1H), 7.03 (dd, J=8.5, 3.0 Hz, 1H), 3.80 (s, 3H), 2.97-2.91 (m, 2H), 2.32-2.27 (m, 2H), 1.90-1.82 (m, 2H).
[0578] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.5, 170.9, 159.2, 136.5, 133.3, 132.3, 118.8, 116.6, 55.82, 34.7, 33.8, 28.3.
[0579] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.13O.sub.5 [MH].sup.: 237.0763, found: 237.0766.
##STR00157##
2-Bromo-4-(2,5-dioxopyrrolidin-1-yl)benzoic acid SS9
[0580] The synthesis of 2-bromo-4-(2,5-dioxopyrrolidin-1-yl)benzoic acid SS9: A mixture of 864 mg (4 mmol) of 4-amino-2-bromobenzoic acid, 1 g (4 mmol) of succinic anhydride, 0.6 ml of ClSiMe.sub.3, and 1.5 ml DMF was heated for 1.5 h on a bath at 160-165 C. cooled to room temperature, and diluted with water. The precipitate was separated by filtration, washed with water, and dried in air to obtain 2-bromo-4-(2,5-dioxopyrrolidin-1-yl)benzoic acid (90% yield, 1.07 g, 3.6 mmol) as yellow solid.
[0581] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.85-7.80 (m, 2H), 7.40 (dd, J=8.5, 2.6 Hz, 1H), 2.88 (s, 4H).
[0582] .sup.13C NMR (151 MHz, CD.sub.3OD) 178.4, 168.5, 135.8, 135.1, 131.8, 130.6, 121.6, 29.4. HRMS (ESI-TOF) Calculated for C.sub.11H.sub.9BrNO.sub.4 [M+H].sup.+: 297.9715, Found: 297.9716.
##STR00158##
Benzyl 2-(4-(benzyloxy)-4-oxobutyl)-4-(2,5-dioxopyrrolidin-1-yl)benzoate S34
[0583] S34 was prepared by Procedure A, 77% yield for two steps, (0.75 g, 1.54 mmol, yellow oil).
[0584] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.88 (dd, J=2.0, 0.8 Hz, 1H), 7.44-7.30 (m, 12H), 5.31 (s, 2H), 5.12 (s, 2H), 3.03-2.99 (m, 2H), 2.88 (s, 4H), 2.36 (t, J=7.4 Hz, 2H), 1.98-1.90 (m, 2H).
[0585] .sup.13C NMR (151 MHz, CDCl.sub.3) 176.1, 173.3, 166.1, 144.5, 136.2, 135.8, 132.3, 130.3, 130.1, 130.1, 129.2, 128.8, 128.8, 128.6, 128.6, 128.5, 128.4, 67.1, 66.3, 34.0, 33.5, 28.5, 26.7. HRMS (ESI-TOF) Calculated for C.sub.29H.sub.28NO.sub.6 [M+H].sup.+: 486.1917, Found: 486.1910.
##STR00159##
2--Carboxypropyl)-4-(2,5-dioxopyrrolidin-1-yl)benzoic acid 34
[0586] 34 was prepared by Method B, 98% yield, (0.3 g, 0.98 mmol, white solid).
[0587] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.86 (d, J=2.2 Hz, 1H), 7.44-7.37 (m, 2H), 3.10-3.04 (m, 2H), 2.85 (s, 4H), 2.35 (t, J=7.5 Hz, 2H), 1.97-1.89 (m, 2H).
[0588] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.6, 175.9, 168.5, 143.7, 131.5, 130.7, 130.5, 129.9, 129.1, 33.2, 32.9, 28.0, 26.6.
[0589] HRMS (ESI-TOF) Calculated for C.sub.15H.sub.16NO.sub.6 [M+H].sup.+: 306.0978, Found: 306.0965.
##STR00160##
Benzyl 2-(4-(benzyloxy)-4-oxobutyl)-3-methylbenzoate S35
[0590] S35 was prepared by Procedure A, 83% yield for two steps, (0.67 g, 1.66 mmol, yellow oil).
[0591] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.47-7.41 (m, 2H), 7.40-7.30 (m, 8H), 7.20 (t, J=7.6 Hz, 1H), 7.05-6.98 (m, 2H), 5.35 (s, 2H), 5.10 (s, 2H), 2.58-2.53 (m, 2H), 2.27 (s, 3H), 2.24 (t, J=7.5 Hz, 2H), 1.90-1.82 (m, 2H)
[0592] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.2, 169.8, 138.5, 136.2, 135.6, 135.1, 133.7, 129.6, 129.1, 128.7, 128.7, 128.6, 128.4, 128.3, 128.1, 127.0, 67.1, 66.3, 33.8, 33.0, 26.5, 19.8. HRMS (ESI-TOF) Calculated for C.sub.26H.sub.27O.sub.4 [M+H].sup.+: 403.1909,
[0593] Found: 403.1906.
##STR00161##
2--Carboxypropyl)-6-methylbenzoic acid 35
[0594] 35 was prepared by Procedure B, 99% yield, (0.22 g, 0.99 mmol, white solid).
[0595] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.23 (t, J=7.6 Hz, 1H), 7.12-7.06 (m, 2H), 2.71-2.66 (m, 2H), 2.33 (s, 3H), 2.30 (t, J=7.4 Hz, 2H), 1.95-1.87 (m, 2H).
[0596] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.2, 173.8, 139.1, 136.3, 135.3, 130.1, 128.9, 127.9, 34.5, 33.9, 27.8, 19.8.
[0597] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.14O.sub.4Na [M+Na].sup.+: 245.0790, Found: 245.0795.
##STR00162##
Benzyl 2-(4-(benzyloxy)-4-oxobutyl)-4-methylbenzoate S36
[0598] S36 was prepared by Procedure A, 95% yield for two steps, (0.77 g, 1.90 mmol, yellow oil).
[0599] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.85 (d, J=8.0 Hz, 1H), 7.45-7.40 (m, 2H), 7.37 (dd, J=7.3, 1.0 Hz, 2H), 7.37-7.29 (m, 6H), 7.07-7.00 (m, 2H), 5.30 (s, 2H), 5.11 (s, 2H), 2.98-2.93 (m, 2H), 2.37-2.31 (m, 5H), 1.97-1.88 (m, 2H).
[0600] .sup.13C NMR (151 M1 Hz, CDCl.sub.3) 173.5, 167.3, 143.9, 142.8, 136.3, 132.1, 131.3, 128.7, 128.7, 128.4, 128.4, 128.3, 128.3, 127.0, 126.5, 66.6, 66.3, 34.1, 33.8, 26.9, 21.6.
[0601] HRMS (ESI-TOF) Calculated for C.sub.26H.sub.27O.sub.4 [M+H].sup.+: 403.1909, Found: 403.1914.
##STR00163##
2--Carboxypropyl)-4-methylbenzoic acid 36
[0602] 36 was prepared by Procedure B, 99% yield, (0.22 g, 0.99 mmol, white solid).
[0603] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.83-7.78 (m, 1H), 7.13-7.07 (m, 2H), 3.02-2.96 (m, 2H), 2.37-2.29 (m, 5H), 1.92-1.84 (m, 2H).
[0604] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.4, 170.9, 145.0, 143.8, 132.9, 132.3, 128.2, 127.8, 34.7, 34.7, 28.1, 25.0, 21.4.
[0605] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.14O.sub.4Na [M+Na].sup.+: 245.0790, Found: 245.0789.
##STR00164##
Benzyl 2-(4-(benzyloxy)-4-oxobutyl)-3-methylbenzoate S37
[0606] S37 was prepared by Procedure A, 98% yield for two steps, (0.79 g, 1.96 mmol, yellow oil).
[0607] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.70-7.65 (m, 1H), 7.45-7.40 (m, 2H), 7.38-7.30 (m, 8H), 7.29-7.26 (m, 1H), 7.13 (t, J=7.6 Hz, 1H), 5.31 (s, 2H), 5.12 (s, 2H), 2.93-2.87 (m, 2H), 2.37 (t, J=7.3 Hz, 2H), 2.33 (s, 3H), 1.90-1.81 (m, 2H).
[0608] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.4, 168.2, 141.3, 137.7, 136.2, 136.1, 134.1, 130.7, 128.7, 128.7, 128.5, 128.4, 128.4, 128.3, 127.9, 125.9, 125.9, 66.9, 66.3, 34.4, 29.4, 25.4, 19.8. HRMS (ESI-TOF) Calculated for C.sub.26H.sub.26O.sub.4Na [M+Na].sup.+: 425.1729,
[0609] Found: 425.1721.
##STR00165##
2--Carboxypropyl)-3-methylbenzoic acid 37
[0610] 37 was prepared by Procedure B, 99% yield, (0.22 g, 0.99 mmol, white solid).
[0611] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.62 (dd, J=7.9, 1.4 Hz, 1H), 7.31 (dt, J=7.6, 1.4 Hz, 1H), 7.14 (t, J=7.6 Hz, 1H), 2.99-2.94 (m, 2H), 2.41-2.35 (m, 5H), 1.88-1.79 (m, 2H).
[0612] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.4, 172.2, 142.0, 138.7, 134.6, 132.8, 129.1, 126.7, 35.1, 30.5, 30.4, 26.8, 19.8.
[0613] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.14O.sub.4Na [M+Na].sup.+: 245.0790, Found: 245.0798.
##STR00166##
Benzyl 2-(4-(benzyloxy)-4-oxobutyl)-4-fluorobenzoate S38
[0614] S38 was prepared by Procedure A, 98% yield for two steps, (0.80 g, 1.96 mmol, yellow oil).
[0615] .sup.1H NMR (600 MHz, CDCl.sub.3) 8.01-7.95 (m, 1H), 7.45-7.40 (m, 2H), 7.40-7.37 (m, 3H), 7.37-7.30 (m, 5H), 6.96-6.90 (m, 2H), 5.31 (s, 2H), 5.12 (s, 2H), 3.02-2.97 (m, 2H), 2.35 (t, J=7.4 Hz, 2H), 1.98-1.90 (m, 2H).
[0616] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.2, 166.3, 164.9 (d, J=253.6 Hz), 147.4 (d, J=8.8 Hz), 136.1 (d, J=29.7 Hz), 133.8 (d, J=9.3 Hz), 128.8, 128.7, 128.5, 128.4, 128.4, 125.5 (d, J=2.8 Hz), 117.9 (d, J=21.4 Hz), 113.4 (d, J=21.4 Hz), 66.9, 66.3, 33.9, 33.8, 26.5.
[0617] .sup.19F NMR (376 MHz, CDCl.sub.3) 109.70.
[0618] HRMS (ESI-TOF) Calculated for C.sub.25H.sub.24O.sub.4F [M+H].sup.+: 407.1659, Found: 407.1653.
##STR00167##
2--Carboxypropyl)-4-fluorobenzoic acid 38
[0619] 38 was prepared by Procedure B, 98% yield, (0.22 g, 0.98 mmol, white solid).
[0620] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.98 (dd, J=8.7, 6.0 Hz, 1H), 7.08-6.98 (m, 2H), 3.07-3.01 (m, 2H), 2.33 (t, J=7.5 Hz, 2H), 1.94-1.86 (m, 2H).
[0621] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.2, 169.8, 166.0 (d, J=251.4 Hz), 148.7 (d, J=8.6 Hz), 134.9 (d, J=9.3 Hz), 127.5 (d, J=3.0 Hz), 118.6 (d, J=21.6 Hz), 114.0 (d, J=21.8 Hz), 34.6, 34.6, 27.8.
[0622] .sup.19F NMR (376 MHz, CD.sub.3OD) 5-108.88.
[0623] HRMS (ESI-TOF) Calculated for C.sub.11H.sub.11O.sub.4FNa [M+Na].sup.+: 249.0539, Found: 249.0537.
##STR00168##
Benzyl 2-(4-(benzyloxy)-4-oxobutyl)-4-chlorobenzoate S39
[0624] S39 was prepared by Procedure A by using 2-bromo-4-chlorobenzoic acid (3 mmol) with other condition no change, 75% yield, (0.63 g, 1.50 mmol, yellow oil).
[0625] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.90-7.84 (m, 1H), 7.44-7.30 (m, 10H), 7.24-7.19 (m, 2H), 5.31 (s, 2H), 5.12 (s, 2H), 2.98-2.93 (m, 2H), 2.34 (t, J=7.4 Hz, 2H), 1.96-1.88 (m, 2H).
[0626] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.2, 166.5, 145.8, 138.4, 136.2, 131.2, 128.8, 128.7, 128.6, 128.5, 128.4, 127.8, 126.5, 67.0, 66.4, 33.9, 33.6, 26.6.
[0627] HRMS (ESI-TOF) Calculated for C.sub.25H.sub.24ClO.sub.4 [M+H].sup.+: 423.1363, Found: 423.1356.
##STR00169##
2--Carboxypropyl)-4-chlorobenzoic acid 39
[0628] 39 was prepared by Procedure C, 75% yield, (0.18 g, 0.75 mmol, white solid).
[0629] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.88 (d, J=8.3 Hz, 1H), 7.33 (d, J=2.2 Hz, 1H), 7.29 (dd, J=8.4, 2.2 Hz, 1H), 3.04-2.98 (m, 2H), 2.33 (t, J=7.4 Hz, 2H), 1.93-1.85 (m, 2H).
[0630] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.2, 169.9, 147.1, 138.8, 133.7, 131.9, 127.3, 34.6, 34.4, 27.9. HRMS (ESI-TOF) Calculated for C.sub.11H.sub.12ClO.sub.4 [M+H].sup.+: 243.0424, Found: 243.0424.
##STR00170##
Benzyl 3-(4-(benzyloxy)-4-oxobutyl)-[1,1-biphenyl]-4-carboxylate S40
[0631] To a solution of Pd.sub.2(dba).sub.3 (183 mg, 0.2 mmol), SPhos (164 mg, 0.4 mmol) in dioxane (8 mL) was added a solution of S39 (844 mg, 2 mmol) in dioxane (8 mL) and stirred for 10 minutes. K.sub.3PO.sub.4 (1.27 g, 6 mmol) and PhB(OH).sub.2 were added. The resulting mixture was heated to 100 C. and stirred for 15 hours. The reaction was cooled to room temperature and diluted with ethyl acetate. Then washed with brine and the organic phase was concentrated under reduced pressure and purified by column chromatography to give the product S40 (85% yield, 0.79 g, 1.7 mmol) as a yellow oil.
[0632] .sup.1H NMR (600 MHz, CDCl.sub.3) 8.03 (d, J=8.1 Hz, 1H), 7.61-7.56 (m, 2H), 7.49-7.42 (m, 6H), 7.41-7.29 (m, 10H), 5.35 (s, 2H), 5.11 (s, 2H), 3.09-3.04 (m, 2H), 2.38 (t, J=7.5 Hz, 2H), 2.03-1.95 (m, 2H).
[0633] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.4, 167.1, 145.0, 144.3, 140.0, 136.2, 136.1, 131.8, 130.0, 129.0, 128.8, 128.7, 128.5, 128.4, 128.4, 128.3, 128.2, 128.1, 128.0, 127.4, 124.9, 66.8, 66.3, 34.0, 34.0, 26.9. HRMS (ESI-TOF) Calculated for C.sub.31H.sub.29O.sub.4 [M+H].sup.+: 465.2066, Found: 465.2062.
##STR00171##
3--Carboxypropyl)-[1,1-biphenyl]-4-carboxylic acid 40
[0634] 40 was prepared by Procedure B, 99% yield, (0.28 g, 0.99 mmol, white solid).
[0635] .sup.1H NMR (600 MHz, CD.sub.3OD) 8.01 (d, J=8.1 Hz, 1H), 7.71-7.66 (m, 2H), 7.58-7.53 (m, 2H), 7.51-7.45 (m, 2H), 7.42-7.36 (m, 1H), 3.13 (t, J=7.7 Hz, 2H), 2.38 (t, J=7.4 Hz, 2H), 2.02-1.94 (m, 2H).
[0636] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.6, 171.1, 145.8, 145.4, 141.3, 132.8, 130.7, 130.0, 129.1, 128.16, 125.6, 34.8, 34.7, 28.2.
[0637] HRMS (ESI-TOF) Calculated for C.sub.17H.sub.15O.sub.4 [MH].sup.: 283.0970, Found: 283.0966.
##STR00172##
Benzyl 3-(4-(benzyloxy)-4-oxobutyl)-2-naphthoate S41
[0638] S41 was prepared by Procedure A, 91% yield for two steps, (0.80 g, 1.82 mmol, yellow oil).
[0639] .sup.1H NMR (600 MHz, CDCl.sub.3) 8.50 (s, 1H), 7.86 (ddq, J=8.2, 1.3, 0.6 Hz, 1H), 7.78-7.73 (m, 1H), 7.64 (d, J=0.8 Hz, 1H), 7.57-7.51 (m, 1H), 7.51-7.44 (m, 3H), 7.43-7.38 (m, 2H), 7.38-7.30 (m, 6H), 5.39 (s, 2H), 5.11 (s, 2H), 3.16-3.11 (m, 2H), 2.38 (t, J=7.5 Hz, 2H), 2.01 (tt, J=9.5, 6.7 Hz, 2H).
[0640] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.5, 167.5, 138.9, 136.2, 136.1, 135.1, 132.5, 131.3, 129.6, 128.8, 128.7, 128.6, 128.5, 128.4, 127.9, 127.2, 126.2, 67.0, 66.3, 34.0, 33.9, 26.8. HRMS (ESI-TOF) Calculated for C.sub.29H.sub.27O.sub.4 [M+H].sup.+: 439.1909,
[0641] Found: 439.1908.
##STR00173##
3--Carboxypropyl)-2-naphthoic acid 41
[0642] 41 was prepared by Procedure B, 99% yield, (0.26 g, 0.99 mmol, white solid).
[0643] .sup.1H NMR (600 MHz, CD.sub.3OD) 8.48 (s, 1H), 7.90 (d, J=8.2 Hz, 1H), 7.82 (d, J=8.3 Hz, 1H), 7.72 (s, 1H), 7.55 (ddd, J=8.2, 6.8, 1.3 Hz, 1H), 7.48 (ddd, J=8.1, 6.8, 1.2 Hz, 1H), 3.19-3.14 (m, 2H), 2.36 (t, J=7.5 Hz, 2H), 2.01-1.93 (m, 2H).
[0644] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.5, 171.0, 140.1, 136.4, 133.2, 132.7, 130.4, 129.7, 129.6, 129.2, 128.2, 127.2, 34.8, 34.7, 28.1.
[0645] HRMS (ESI-TOF) Calculated for C.sub.29H.sub.27O.sub.4 [M+H].sup.+: 439.1909, found: 439.1908.
##STR00174##
Benzyl 2-(4-(benzyloxy)-4-oxobutyl)-5-(trifluoromethyl)benzoate S42
[0646] S42 was prepared by Procedure A, 88% yield for two steps, (0.80 g, 1.76 mmol, yellow oil).
[0647] .sup.1H NMR (600 MHz, CDCl.sub.3) 8.18-8.15 (m, 1H), 7.64 (ddd, J=8.1, 2.2, 0.7 Hz, 1H), 7.46-7.30 (m, 11H), 5.35 (s, 2H), 5.11 (s, 2H), 3.05-2.99 (m, 2H), 2.34 (t, J=7.4 Hz, 2H), 1.97-1.89 (m, 2H).
[0648] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.1, 166.2, 147.6 (q, J=2.2 Hz), 136.1, 135.6, 131.9, 130.2, 128.9 (q, J=33.0 Hz), 128.7, 128.7, 128.6, 128.6, 128.5, 128.4, 128.4, 128.0 (q, J=4.1 Hz), 123.8 (q, J=272.3 Hz), 67.4, 66.4, 33.9, 33.6, 26.6.
[0649] .sup.19F NMR (376 MHz, CDCl.sub.3) 65.26.
[0650] HRMS (ESI-TOF) Calculated for C.sub.26H.sub.24F.sub.3O.sub.4 [M+H].sup.+: 457.1627, Found: 457.1624.
##STR00175##
2--Carboxypropyl)-5-(trifluoromethyl)benzoic acid 42
[0651] 42 was prepared by Procedure B, 99% yield, (0.27 g, 0.99 mmol, white solid).
[0652] .sup.1H NMR (600 MHz, CD.sub.3OD) 8.15 (d, J=2.0 Hz, 1H), 7.74 (ddd, J=8.0, 2.1, 0.8 Hz, 1H), 7.52 (d, J=8.1 Hz, 1H), 3.13-3.08 (m, 2H), 2.35 (t, J=7.4 Hz, 2H), 1.97-1.89 (m, 2H).
[0653] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.1, 169.3, 149.2, 133.2, 129.5 (q, J=33.0 Hz), 129.2 (q, J=3.6 Hz), 128.7 (q, J=3.9 Hz), 125.4 (q, J=271.3 Hz), 34.60, 34.5, 27.8.
[0654] .sup.19F NMR (376 MHz, CD.sub.3OD) 62.91.
[0655] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.12F.sub.3O.sub.4 [M+H].sup.+: 277.0688, Found: 277.0681.
##STR00176##
Benzyl 3-(4-(benzyloxy)-4-oxobutyl)thiophene-2-carboxylate S43
[0656] 43 was prepared by Procedure A, 85% yield for two steps, (0.67 g, 1.70 mmol, yellow oil).
[0657] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.43 (d, J=5.4 Hz, 1H), 7.42-7.27 (m, 10H), 7.03 (d, J=5.4 Hz, 1H), 5.28 (s, 2H), 5.11 (s, 2H), 3.26-3.20 (m, 2H), 2.39 (t, J=8.5 Hz, 2H), 2.07-1.99 (m, 2H).
[0658] .sup.13C NMR (151 MHz, CDCl.sub.3) 173.1, 163.2, 154.1, 136.2, 136.1, 129.6, 128.7, 128.7, 128.4, 128.4, 128.4, 128.0, 121.8, 66.3, 33.7, 28.7, 26.7.
[0659] HRMS (ESI-TOF) Calculated for C.sub.23H.sub.23O.sub.4S [M+H].sup.+: 395.1317, found: 395.1309.
##STR00177##
2--carboxypropyl)thiophene-3-carboxylic acid 43
[0660] S43 was prepared by Procedure C, 85% yield (182 mg, 0.85 mmol, white solid).
[0661] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.38 (d, J=5.4 Hz, 1H), 7.18 (dd, J=5.3, 0.8 Hz, 1H), 3.27-3.22 (m, 2H), 2.36 (t, J=7.4 Hz, 2H), 2.02-1.94 (m, 2H).
[0662] .sup.13C NMR (151 MHz, CD.sub.3OD) 177.0, 166.5, 155.0, 130.7, 129.8, 129.6, 122.8, 34.2, 29.4, 28.0. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.9O.sub.4S [MH].sup.: 213.0222, found: 213.0218.
##STR00178##
Pimelic Acid/Heptane-1,7-Dioic Acid 2
[0663] This compound is commercially available.
##STR00179##
Ethyl 1-ethyl-2-oxocyclohexane-1-carboxylate SS19
[0664] This compound was prepared according to the general procedure B for the preparation of -substituted heptanedioic acids with the reaction of EtI and methyl 2-oxocyclohexane-1-carboxylate. 75% yield, (1.19 g, 6.0 mmol, colorless oil).
[0665] .sup.1H NMR (600 MHz, CDCl.sub.3) 4.20 (q, J=7.3 Hz, 2H), 2.53-2.40 (m, 3H), 2.06-1.89 (m, 1H), 1.77-1.56 (m, 2H), 1.44-1.41 (m, 1H), 1.26 (t, J=7.1 Hz, 3H), 0.84 (t, J=7.6 Hz, 3H).
[0666] .sup.13C NMR (151 MHz, CDCl.sub.3) 208.4, 172.1, 61.3, 61.2, 41.3, 35.7, 27.8, 27.7, 22.7, 14.3, 8.9.
[0667] The data is consistent with those reported in the literature.(33)
##STR00180##
2-Ethylheptanedioic acid 24
[0668] This compound was prepared according to the general procedure B for the preparation of -substituted heptanedioic acids. 75% yield, (0.85 g, 4.5 mmol, white solid).
[0669] .sup.1H NMR (500 MHz, DMSO) 12.00 (s, 2H), 2.18 (t, J=7.3 Hz, 2H), 2.12 (tt, J=8.4, 5.4 Hz, 1H), 1.55-1.40 (m, 5H), 1.40-1.33 (m, 1H), 1.23 (p, J=7.7 Hz, 2H), 0.90-0.74 (m, 3H).
[0670] .sup.13C NMR (126 MHz, DMSO) 176.8, 174.4, 46.4, 33.5, 31.2, 26.5, 26.5, 24.8, 24.5, 11.7, 11.6. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.15O.sub.4 [MH].sup.: 187.0970, found: 187.0973.
##STR00181##
2-Isopropylheptanedioic acid 25
[0671] This compound was prepared according to the general procedure for the preparation of -substituted heptanedioic acids.
[0672] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA+1% AcOH, gradient elution) Isolated yield: 61% over 2 steps (1.23 g, 6.1 mmol, colourless oil)
[0673] .sup.1H NMR (500 MHz, DMSO) 11.98 (s, 2H), 2.18 (t, J=7.3 Hz, 2H), 1.95 (ddd, J=9.5, 7.4, 4.8 Hz, 1H), 1.73 (h, J=6.8 Hz, 1H), 1.56-1.44 (m, 2H), 1.42 (ddd, J=9.7, 6.0, 4.0 Hz, 2H), 1.29-1.13 (m, 2H), 0.91-0.82 (m, 6H).
[0674] .sup.13C NMR (126 MHz, DMSO) 176.4, 174.4, 174.3, 52.1, 33.6, 30.0, 28.8, 27.0, 24.6, 20.4, 20.0, 19.8.
[0675] HRMS (ESI-TOF) Calculated for C.sub.10H.sub.17O.sub.4 [MH].sup.: 201.1127, Found: 201.1125.
##STR00182##
2,2-Dimethylheptanedioic acid 26
[0676] This compound was prepared according to the general procedure for the preparation of -substituted heptanedioic acids.
[0677] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA+1% AcOH, gradient elution) Isolated yield: 57% over 2 steps (1.07 g, 5.7 mmol, white solid)
[0678] .sup.1H NMR (500 MHz, DMSO) 3.33 (s, 2H), 2.19 (t, J=7.3 Hz, 2H), 1.54-1.37 (m, 4H), 1.19 (tq, J=12.4, 6.0 Hz, 2H), 1.06 (s, 6H).
[0679] .sup.13C NMR (126 MHz, DMSO) 178.8, 174.4, 41.2, 39.9, 33.6, 25.0, 25.0, 24.1. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.15O.sub.4 [MH].sup.: 187.0970,
[0680] Found: 187.0972.
##STR00183##
3-Methylheptanedioic acid 27
[0681] This compound was prepared according to the general procedure for the preparation of -substituted heptanedioic acids:
[0682] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA+1% AcOH, gradient elution) Isolated yield: 20% over 2 steps (0.28 g, 1.6 mmol, pale yellow oil)
[0683] .sup.1H NMR (500 MHz, DMSO) 11.99 (s, 2H), 2.23-2.12 (m, 3H), 1.99 (dd, J=15.0, 8.0 Hz, 1H), 1.80 (dq, J=13.8, 6.9 Hz, 1H), 1.59-1.39 (m, 2H), 1.28 (ddt, J=13.2, 10.9, 5.6 Hz, 1H), 1.14 (dddd, J=13.2, 10.5, 7.7, 5.4 Hz, 1H), 0.88 (d, J=6.6 Hz, 3H).
[0684] .sup.13C NMR (126 MHz, DMSO) 174.4, 173.9, 41.3, 35.5, 33.8, 29.5, 22.0, 19.5. HRMS (ESI-TOF) Calculated for C.sub.8H.sub.13O.sub.4 [MH].sup.: 173.0814,
[0685] Found: 173.0815.
##STR00184##
3-Isopropylheptanedioic acid 28
[0686] This compound was prepared according to the general procedure for the preparation of -substituted heptanedioic acids:
[0687] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA+1% AcOH, gradient elution)
[0688] Isolated yield: 50% over 2 steps (0.81 g, 4 mmol, pale yellow oil).
[0689] .sup.1H NMR (500 MHz, DMSO) 11.97 (s, 2H), 2.25-2.09 (m, 3H), 2.01 (dd, J=15.3, 7.1 Hz, 1H), 1.71-1.60 (m, 2H), 1.53-1.39 (m, 2H), 1.28 (ddt, J=13.2, 11.0, 5.7 Hz, 1H), 1.14 (ddt, J=13.0, 9.9, 6.8 Hz, 1H), 0.80 (dd, J=13.6, 6.5 Hz, 6H).
[0690] .sup.13C NMR (126 MHz, DMSO) 174.7, 174.4, 40.0, 35.7, 33.9, 30.2, 29.4, 22.3, 19.2, 18.5. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.17O.sub.4 [MH].sup.: 201.1127, Found: 201.1127.
##STR00185##
3-(tert-Butyl)heptanedioic acid 29
[0691] This compound was prepared according to the general procedure for the preparation of -substituted heptanedioic acids:
[0692] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA+1% AcOH, gradient elution)
[0693] Isolated yield: 52% over 2 steps (0.9 g, 4.16 mmol, white solid).
[0694] .sup.1H NMR (500 MHz, DMSO) 11.97 (s, 2H), 2.29 (dd, J=16.2, 5.1 Hz, 1H), 2.25-2.10 (m, 2H), 1.94 (dd, J=16.2, 6.3 Hz, 1H), 1.62-1.51 (m, 2H), 1.51-1.42 (m, 1H), 1.42-1.33 (m, 1H), 0.98 (tdd, J=11.9, 8.1, 3.6 Hz, 1H), 0.82 (s, 9H).
[0695] .sup.13C NMR (126 MHz, DMSO) 175.3, 174.4, 44.0, 35.6, 33.9, 33.2, 33.1, 30.2, 27.3, 23.6. HRMS (ESI-TOF) Calculated for C.sub.11H.sub.19O.sub.4 [MH].sup.: 215.1283 Found: 215.1284.
2.5 Reaction Procedures of the -Directed, -CH Lactonization Reaction
General Procedure for the -Directed, -CH Lactonization Reaction Using Ag.sub.2CO.sub.3 as Oxidant
[0696] To a 2-dram vial was added the substrate (0.1 mmol), Pd(OAc).sub.2 (10 mol %, 0.01 mmol), ligand (12 mol %, 0.012 mmol), p-xyloquinone (0.2 mmol), Ag.sub.2CO.sub.3 (0.2 mmol), K.sub.2HPO.sub.4 (0.035 mmol) and CsOAc (0.04 mmol, preferably added from a stock solution in HFIP as CsOAc is hygroscopic). HFIP (1.0 mL, or the volume needed to make up to 1.0 mL if a stock solution of CsOAc was used) and a stir-bar was then added, followed by sealing the reaction vessel with a PTFE septum inserted between the vial and its cap. (Note: Pd(OAc).sub.2, ligand, p-xyloquinone, CsOAc, and the substrate could all be prepared as a stock solution in HFIP. The use of stock solution is recommended for setting up a series of reactions to maximize work efficiency). The reaction mixture was sonicated for 30 seconds before stirring at 200 rpm and 100 C. (heating block temperature) for 36 hours. The reaction mixture was then cooled to room temperature and diluted with dichloromethane (1.0 mL), followed by addition of deionized water (2.0 mL), aq. 6M HCl (0.3 mL), brine (1.0 mL) and then shaken vigorously. The lower organic layer was carefully pipetted and filtered through a short plug of Celite. The remaining aqueous layer was extracted with CH.sub.2Cl.sub.2 (1.0 mL) twice and the organic layer was pipetted and filtered as mentioned. The combined organic layer was then evaporated to dryness. The crude was then taken into CDCl.sub.3 (0.6 mL) with CH.sub.2Br.sub.2 (10.0 L) as the internal standard to determine the assay yield of the reaction by .sup.1H NMR spectroscopy. The isolation of the product was carried out with aqueous extractions of the organic layer (in 0.6 mL CDCl.sub.3 diluted with 2.0 mL CH.sub.2Cl.sub.2) with sat. aq. NaHCO.sub.3 solution (1.0 mL each, 3 times). The collected aqueous layer was then acidified by aq. 6M HCl to pH2 and extracted with EtOAc (1.0 mL, 3 times). The combined EtOAc layers was dried with anhydrous MgSO.sub.4, filtered, and evaporated to dryness. The product was either further purified by column chromatography (General procedure for gradient elution unless stated otherwise: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH, collecting 1.0-2.0 mL fractions. It was observed that the R.sub.f values of carboxylic acids obtained by TLC analysis could not be directly used as a guide for column chromatography. Hence, the gradient elution method was employed for their purification.) or pTLC (exact eluent composition mentioned below for each example) or subject to further derivatization into benzyl esters for isolation if purification of the lactone acid was found to be not straightforward.
General Procedure for the -Directed, -CH Lactonization Reaction Using MnO.SUB.2 .as Oxidant
[0697] To a 2-dram vial was added the substrate (0.1 mmol), Pd(OAc).sub.2 (10 mol %, 0.01 mmol), ligand (12 mol %, 0.012 mmol), p-xyloquinone (0.2 mmol), MnO.sub.2 (0.4 mmol), K.sub.2HPO.sub.4 (0.021 mmol), KH.sub.2PO.sub.4 (0.032 mmol), CsOAc (0.021 mmol, preferably added from a stock solution in HFIP as CsOAc is hygroscopic). HFIP (1.0 mL, or the volume needed to make up to 1.0 mL if a stock solution of CsOAc was used) and a stir-bar was then added, followed by sealing the reaction vessel with a PTFE septum inserted between the vial and its cap. (Note: Pd(OAc).sub.2, ligand, p-xyloquinone, CsOAc, and the substrate could all be prepared as a stock solution in HFIP. The use of stock solution is recommended for setting up a series of reactions to maximize work efficiency). The reaction mixture was sonicated for 30 seconds before stirring at 200 rpm and 100 C. (heating block temperature) for 36-48 hours. The reaction mixture was then cooled to room temperature and diluted with dichloromethane (1.0 mL), followed by addition of deionized water (2.0 mL), aq. 6M HCl (0.3 mL), brine (1.0 mL) and then shaken vigorously. The lower organic layer was carefully pipetted and filtered through a short plug of Celite. The remaining aqueous layer was extracted with CH.sub.2Cl.sub.2 (1.0 mL) twice and the organic layer was pipetted and filtered as mentioned. The combined organic layer was then evaporated to dryness. The crude was then taken into CDCl.sub.3 (0.6 mL) with CH.sub.2Br.sub.2 (10.0 L) as the internal standard to determine the assay yield of the reaction by .sup.1H NMR spectroscopy. The isolation of the product was carried out with aqueous extractions of the organic layer (in 0.6 mL CDCl.sub.3 diluted with 2.0 mL CH.sub.2Cl.sub.2) with sat. aq. NaHCO.sub.3 solution (1.0 mL each, 3 times). The collected aqueous layer was then acidified by aq. 6M HCl to pH2 and extracted with EtOAc (1.0 mL, 3 times). The combined EtOAc layers was dried with anhydrous MgSO.sub.4, filtered, and evaporated to dryness. The product was either further purified by column chromatography (General procedure for gradient elution unless stated otherwise: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH, collecting 1.0-2.0 mL fractions. It was observed that the R.sub.f values of carboxylic acids obtained by TLC analysis could not be directly used as a guide for column chromatography. Hence, the gradient elution method was employed for their purification.) or pTLC (exact eluent composition mentioned below for each example) or subject to further derivatization into benzyl esters for isolation if purification of the lactone acid was found to be not straightforward.
General Procedure for Benzyl Ester Formation
[0698] To the product obtained after aqueous extraction with sat. NaHCO.sub.3 solution as mentioned above was added dry CH.sub.2Cl.sub.2 (2.0 mL), BnOH (1.2 eq.), DMAP (1.2 eq.) and EDCI (1.2 eq.) sequentially at room temperature. The reaction mixture was stirred at room temperature overnight, and completion of the reaction was confirmed by TLC analysis of the reaction mixture. The reaction mixture was then quenched by the addition of water and extracted with CH.sub.2Cl.sub.2 (3 times), and the desired product was purified by pTLC (exact eluent composition mentioned below for each example).
2.6 Characterization Data of Products Obtained from -Directed, -CH Lactonization Reaction
##STR00186##
3-(4,4-Dimethyl-5-oxotetrahydrofuran-2-yl)-2,2-dimethylpropanoic acid 48b
[0699] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 100% (21.4 mg, 0.1 mmol, off white solid).
[0700] .sup.1H NMR (400 MHz, CDCl.sub.3) 4.53 (dq, J=9.9, 5.9 Hz, 1H), 2.19 (dd, J=12.7, 5.9 Hz, 1H), 1.93 (d, J=5.9 Hz, 2H), 1.73 (dd, J=12.7, 9.9 Hz, 1H), 1.31 (s, 3H), 1.29 (s, 3H), 1.25 (s, 3H), 1.24 (s, 3H).
[0701] .sup.13C NMR (100 MHz, CDCl.sub.3) 183.8, 182.0, 74.5, 45.9, 44.5, 41.4, 40.1, 26.1, 25.1, 25.1, 24.4. HRMS (ESI-TOF) Calculated for C.sub.11H.sub.17O.sub.4 [MH].sup.: 213.1127, Found: 213.1128
##STR00187##
3-(4,4-Dimethyl-5-oxotetrahydrofuran-2-yl)propanoic acid 26b
[0702] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 62% (11.4 mg, 0.062 mmol, off white solid).
[0703] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.48 (dddd, J=9.9, 8.9, 5.9, 4.1 Hz, 1H), 2.76-2.49 (m, 2H), 2.20 (dd, J=12.7, 5.9 Hz, 1H), 2.02 (dtd, J=15.3, 7.7, 4.1 Hz, 1H), 1.98-1.89 (m, 1H), 1.75 (dd, J=12.7, 9.9 Hz, 1H), 1.28 (s, 3H), 1.26 (s, 3H).
[0704] .sup.13C NMR (126 MHz, CDCl.sub.3) 181.8, 178.2, 75.9, 43.4, 40.6, 30.7, 30.1, 25.2, 24.6. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.3O.sub.4 [MH].sup.: 185.0814, Found: 185.0815.
##STR00188##
3-(4-Methyl-5-oxotetrahydrofuran-2-yl)propanoic acid 44b
[0705] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 61% (10.5 mg, 0.061 mmol, colorless oil, d.r=1.3:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0706] NMR for minor isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 4.61-4.54 (m, 1H), 2.61-2.48 (m, 3H), 2.18 2.09 (m, 1H), 1.98-1.90 (m, 3H), 1.28 (d, J=7.4 Hz, 3H).
[0707] .sup.13C NMR (151 MHz, CDCl.sub.3) 179.9, 178.5, 77.2, 35.5, 34.0, 30.4, 30.1, 15.9.
[0708] NMR for major isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 4.41 (dddd, J=10.1, 8.8, 5.5, 4.1 Hz, 1H), 2.77-2.64 (m, 2H), 2.61-2.48 (m, 2H), 2.08-1.98 (m, 2H), 1.52 (td, J=12.3, 10.4 Hz, 1H), 1.27 (d, J=7.1 Hz, 3H).
[0709] .sup.13C NMR (151 MHz, CDCl.sub.3) 179.4, 178.5, 77.2, 37.2, 36.0, 30.5, 30.1, 15.2.
[0710] HRMS (ESI-TOF) Calculated for C.sub.8H.sub.11O.sub.4 for [MH].sup.: 171.0657, found 171.0657.
##STR00189##
3-(4-Ethyl-5-oxotetrahydrofuran-2-yl)propanoic acid 24b
[0711] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 54% (10.0 mg, 0.054 mmol, colorless oil, d.r.=1.2:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0712] NMR for minor isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 4.59-4.50 (m, 1H), 2.66-2.51 (m, 3H), 2.15-2.06 (m, 2H), 2.07-2.00 (m, 2H), 1.88-1.82 (m, 1H), 1.58-1.42 (m, 1H), 1.01 (t, J=6.6 Hz, 3H).
[0713] .sup.13C NMR (151 MHz, CDCl.sub.3) 179.2, 178.3, 77.5, 40.7, 33.1, 30.7, 30.1, 24.1, 11.8.
[0714] NMR for major isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 4.42 (dddd, J=9.9, 8.6, 5.7, 4.1 Hz, 1H), 2.66-2.51 (m, 3H), 1.98-1.89 (m, 4H), 1.58-1.44 (m, 2H), 1.01 (t, J=6.6 Hz, 3H).
[0715] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.6, 178.3, 77.5, 42.5, 34.5, 30.6, 30.1, 23.4, 11.7. HRMS (ESI-TOF) Calculated C.sub.9H.sub.1304 for [MH].sup.: 185.0814, found 185.0812.
##STR00190##
3-(4-Isopropyl-5-oxotetrahydrofuran-2-yl)propanoic acid 25b
[0716] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 74% (14.8 mg, 0.074 mmol, colorless oil, d.r=1.1:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0717] NMR for minor diastereomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 4.51 (tt, J=9.0, 4.9 Hz, 1H), 2.64-2.58 (m, 1H), 2.58-2.48 (m, 2H), 2.25-2.21 (m, 1H), 2.16-2.12 (m, 1H), 2.00-1.88 (m, 3H), 1.07-0.98 (m, 3H), 0.91 (dd, J=6.8, 1.1 Hz, 3H).
[0718] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.5, 178.2, 77.6, 47.2, 31.1, 30.1, 29.6, 28.9, 20.6, 18.3.
[0719] NMR for major diastereomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 4.39 (tdd, J=9.8, 5.6, 4.2 Hz, 1H), 2.64-2.58 (m, 1H), 2.58-2.48 (m, 2H), 2.30 (ddd, J=12.8, 8.8, 5.7 Hz, 1H), 2.21-2.16 (m, 1H), 2.04 (dtd, J=15.2, 7.7, 4.1 Hz, 1H), 2.00-1.88 (m, 1H), 1.64 (td, J=12.4, 10.2 Hz, 1H), 1.07-0.98 (m, 3H), 0.94 (dd, J=6.8, 1.1 Hz, 3H).
[0720] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.2, 177.9, 77.1, 45.4, 30.6, 30.3, 30.1, 27.6, 20.8, 18.7. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.15O.sub.4 [MH].sup.: 199.0970, Found: 199.0972.
##STR00191##
3-(4-Benzyl-5-oxotetrahydrofuran-2-yl)propanoic acid 45b
[0721] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 57% (14.1 mg, 0.057 mmol, colorless oil, d.r.=1.2:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0722] NMR for minor isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 7.35-7.13 (m, 5H), 4.44-4.33 (m, 1H), 3.18 (dd, J=13.9, 4.5 Hz, 1H), 3.00-2.89 (m, 1H), 2.78 (dd, J=13.8, 9.4 Hz, 1H), 2.59-2.41 (m, 2H), 2.14 (dt, J=13.2, 7.5 Hz, 1H), 1.91-1.81 (m, 3H).
[0723] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.1, 177.9, 138.5, 128.9, 128.9, 126.9, 77.6, 42.9, 36.2, 34.6, 30.4, 29.9.
[0724] NMR for major isomer: .sup.1H NMR (600 MHz, CDCl.sub.3) 7.35-7.13 (m, 5H), 4.44-4.33 (m, 1H), 3.28 (dd, J=14.0, 4.3 Hz, 1H), 3.00-2.89 (m, 1H), 2.73 (dd, J=14.1, 9.5 Hz, 1H), 2.59-2.41 (m, 2H), 2.32 (ddd, J=12.7, 8.5, 5.6 Hz, 1H), 1.99-1.91 (m, 2H), 1.58 (td, J=12.3, 10.2 Hz, 1H).
[0725] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.1, 177.9, 138.5, 128.9, 128.9, 127.0, 77.6, 42.9, 36.2, 34.6, 30.4, 29.9.
[0726] HRMS (ESI-TOF) Calculated for C.sub.14H.sub.17O.sub.4 [M+H].sup.+: 249.1127, Found: 249.1134.
##STR00192##
Benzyl 3-(4-(tert-butyl)-5-oxotetrahydrofuran-2-yl)propanoate 46b
[0727] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (10% EA/hexanes, R.sub.f=0.30). Isolated yield 57% over 2 steps (17.3 mg, 0.057 mmol, colourless oil, d.r.=1:1). Diastereomers were not separable by column chromatography, .sup.1H and .sup.13C NMR data reported as a mixture of diastereomers.
[0728] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.41-7.29 (m, 10H), 5.26-4.97 (m, 4H), 4.43 (ddt, J=8.9, 8.0, 4.8 Hz, 1H), 4.29 (dddd, J=10.1, 8.4, 5.6, 4.3 Hz, 1H), 2.62-2.49 (m, 4H), 2.49-2.45 (m, 1H), 2.45-2.41 (m, 1H), 2.35-2.27 (m, 1H), 2.27-2.21 (m, 1H), 2.04 (dddd, J=14.3, 8.3, 7.3, 4.3 Hz, 1H), 1.98-1.88 (m, 4H), 1.66 (td, J=12.6, 10.5 Hz, 1H), 1.04 (s, 18H).
[0729] .sup.13C NMR (151 MHz, CDCl.sub.3) 177.2, 176.6, 172.7, 172.7, 135.9, 135.9, 128.7, 128.7, 128.5, 128.5, 128.4, 128.4, 76.7, 76.1, 66.6, 66.6, 50.9, 49.0, 32.9, 31.8, 31.7, 31.3, 30.7, 30.4, 30.4, 30.3, 27.5, 27.3.
[0730] HRMS (ESI-TOF) Calculated for C.sub.18H.sub.25O.sub.4 [M+H].sup.+: 305.1753, Found: 305.1754.
##STR00193##
3-(5-Oxotetrahydrofuran-2-yl)propanoic acid 2b
[0731] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 50% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 62% (9.8 mg, 0.062 mmol, colorless oil).
[0732] .sup.1H NMR (600 MHz, CDCl.sub.3) 4.57 (dddd, J=9.1, 7.4, 6.8, 4.7 Hz, 1H), 2.74-2.45 (m, 4H), 2.38 (dq, J=12.7, 6.9 Hz, 1H), 2.03 (dq, J=14.6, 7.8 Hz, 1H), 1.96 (dt, J=14.6, 7.4 Hz, 1H), 1.89 (dq, J=12.7, 9.1 Hz, 1H).
[0733] .sup.13C NMR (151 MHz, CDCl.sub.3) 176.9, 176.4, 79.6, 30.6, 29.7, 28.8, 28.1. HRMS (ESI-TOF) Calculated for C.sub.7H.sub.9O.sub.4 [MH].sup.: 157.0501, found: 157.0501.
##STR00194##
3-(5-Oxo-6-oxaspiro[3.4]octan-7-yl)propanoic acid 47b
[0734] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 60% (11.9 mg, 0.060 mmol, off white solid).
[0735] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.39 (tdd, J=8.7, 6.1, 4.1 Hz, 1H), 2.62-2.54 (m, 2H), 2.54-2.47 (m, 2H), 2.47-2.39 (m, 1H), 2.17-2.11 (m, 1H), 2.11-2.05 (m, 1H), 2.02-1.96 (m, 3H), 1.95-1.91 (m, 1H), 1.91-1.85 (m, 1H).
[0736] .sup.13C NMR (126 MHz, CDCl.sub.3) 180.9, 178.2, 76.3, 44.5, 41.9, 31.8, 30.6, 30.1, 29.7, 16.6. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.13O.sub.4 [MH].sup.: 197.0814, Found: 197.0813.
##STR00195##
Benzyl 3-((2S*,3S*)-3-isopropyl-5-oxotetrahydrofuran-2-yl)propanoate 28b
[0737] Following the general procedure for its synthesis and benzyl ester formation, the mixture of compound 28b and 28a was obtained as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.30). Total isolated yield 50% over 2 steps, (14.5 mg, 0.050 mmol, colourless oil, 28b:28a=2.5:1). A sample of the lactone 28b (7.0 mg, 0.024 mmol, colourless oil) was obtained by further purification (pTLC, 10% EA/hexanes, R.sub.f=0.17) for unambiguous characterization.
[0738] .sup.1H NMR (500 MHz, CDCl.sub.3) 7.54-7.29 (m, 5H), 5.24-5.02 (m, 2H), 4.29 (ddd, J=9.8, 6.5, 3.1 Hz, 1H), 2.76-2.47 (m, 3H), 2.31 (dd, J=18.0, 9.0 Hz, 1H), 2.10 (dtd, J=14.5, 7.9, 3.1 Hz, 1H), 1.98 (dddd, J=9.0, 7.9, 6.5, 6.5 Hz, 1H), 1.85 (dddd, J=14.5, 9.8, 7.5, 5.8 Hz, 1H), 1.71 (h, J=6.8 Hz, 1H), 0.94 (d, J=6.7 Hz, 3H), 0.90 (d, J=6.7 Hz, 3H).
[0739] .sup.13C NMR (126 MHz, CDCl.sub.3) 176.5, 172.8, 135.9, 128.7, 128.5, 128.4, 82.8, 66.6, 47.1, 32.3, 31.2, 30.8, 30.5, 20.6, 19.5.
[0740] HRMS (ESI-TOF) Calculated for C.sub.17H.sub.23O.sub.4 [M+H].sup.+: 291.1596, Found: 291.1597.
##STR00196##
3-((2S*,3S*)-3-(tert-butyl)-5-oxotetrahydrofuran-2-yl)propanoic acid 29b
[0741] Following the general procedure for its synthesis, the mixture of compounds 29b and 29a was obtained as the acid by column chromatography (Gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 70% EtOAc+1% AcOH). Total isolated yield 70% (15.0 mg, 0.070 mmol, colourless oil, 29b:29a=2:1). A sample of the lactone 29b (3.0 mg, 0.014 mmol, white solid) was obtained by further purification (Gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 50% EtOAc+1% AcOH, then continue elution using this eluant for the separation of the two lactones) for unambiguous characterization.
[0742] .sup.1H NMR (600 MHz, CDCl.sub.3) 4.44 (ddd, J=11.3, 4.5, 3.3 Hz, 1H), 2.72-2.52 (m, 3H), 2.42 (dd, J=18.6, 5.5 Hz, 1H), 2.03 (ddd, J=14.5, 7.4, 3.3 Hz, 1H), 1.98 (ddd, J=10.1, 5.5, 4.5 Hz, 1H), 1.87 (ddd, J=14.5, 11.3, 6.5 Hz, 1H), 0.92 (s, 9H).
[0743] .sup.13C NMR (151 MHz, CDCl.sub.3) 177.5, 176.9, 81.0, 50.4, 32.4, 32.1, 30.5, 30.0, 26.9. HRMS (ESI-TOF) Calculated for C.sub.11H.sub.17O.sub.4 [MH].sup.: 213.1127, Found: 213.1130.
##STR00197##
Benzyl 5-oxo-2-phenyltetrahydrofuran-3-carboxylate 49b
[0744] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (30% EA/hexanes, R.sub.f=0.20). Isolated yield 36% over 2 steps (Total yield 71% for both diastereomers), (10.7 mg, 0.036 mmol, off white solid).
##STR00198##
[0745] Cis-isomer: .sup.1H NMR (400 MHz, CDCl.sub.3) 7.36-7.28 (m, 6H), 7.25-7.21 (m, 2H), 7.10-7.00 (m, 2H), 5.75 (d, J=7.8 Hz, 1H), 4.79 (d, J=12.1 Hz, 1H), 4.52 (d, J=12.1 Hz, 1H), 3.76 (ddd, J=8.7, 7.8, 5.3 Hz, 1H), 3.11 (dd, J=17.7, 5.3 Hz, 1H), 2.82 (dd, J=17.7, 8.7 Hz, 1H).
[0746] .sup.13C NMR (100 MHz, CDCl.sub.3) 175.0, 169.7, 135.2, 134.7, 129.1, 128.7, 128.7, 128.7, 128.7, 125.8, 81.3, 67.4, 46.8, 31.7.
[0747] HRMS (ESI-TOF) Calculated for C.sub.18H.sub.17O.sub.4 [M+H].sup.+: 297.1127, Found: 297.1118.
[0748] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (30% EA/hexanes, R.sub.f=0.45). Isolated yield 35% over 2 steps (Total yield 71% for both diastereomers), (10.5 mg, 0.035 mmol, off white solid).
##STR00199##
[0749] Trans-isomer: .sup.1H NMR (400 MHz, CDCl.sub.3) 7.42-7.33 (m, 6H), 7.33-7.27 (m, 4H), 5.63 (d, J=7.3 Hz, 1H), 5.23 (d, J=12.1 Hz, 1H), 5.17 (d, J=12.2 Hz, 1H), 3.37 (ddd, J=9.4, 8.9, 7.3 Hz, 1H), 3.02 (dd, J=17.7, 8.9 Hz, 1H), 2.91 (dd, J=17.8, 9.4 Hz, 1H).
[0750] .sup.13C NMR (100 MHz, CDCl.sub.3) 174.2, 170.7, 138.0, 135.0, 129.1, 129.0, 128.9, 128.9 128.6, 125.6, 82.4, 67.7, 48.9, 32.4.
[0751] HRMS (ESI-TOF) Calculated for C.sub.18H.sub.17O.sub.4 [M+H].sup.+: 297.1127, Found: 297.1127.
##STR00200##
Benzyl 2-((2S*,3S*)-5-oxo-2-phenyltetrahydrofuran-3-yl)acetate 50b
[0752] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.25). Isolated yield 25% over 2 steps, (7.8 mg, 0.025 mmol, off white solid).
[0753] .sup.1H NMR (500 MHz, CDCl.sub.3) 7.42-7.30 (m, 10H), 5.12 (d, J=7.0 Hz, 1H), 5.12-5.05 (m, 2H), 2.91 (dd, J=16.7, 8.2 Hz, 1H), 2.84 (ddddd, J=8.2, 8.2, 8.1, 7.0, 5.6 Hz, 1H), 2.67 (dd, J=16.3, 5.6 Hz, 1H), 2.52 (dd, J=16.3, 8.1 Hz, 1H), 2.42 (dd, J=16.7, 8.2 Hz, 1H).
[0754] .sup.13C NMR (126 MHz, CDCl.sub.3) 175.6, 170.8, 137.6, 135.4, 129.1, 129.0, 128.9, 128.8, 128.6, 126.1, 85.5, 67.1, 41.2, 36.4, 34.9.
[0755] HRMS (ESI-TOF) Calculated for C.sub.19H.sub.19O.sub.4 [M+H].sup.+: 311.1283, Found: 311.1278.
##STR00201##
(3aS*,5S*,6aS*)-2-Oxohexahydro-2H-cyclopenta[b]furan-5-carboxylic acid 23b
[0756] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 66% (11.2 mg, 0.066 mmol, off white solid).
[0757] .sup.1H NMR (400 MHz, CDCl.sub.3) 4.97 (td, J=6.2, 2.4 Hz, 1H), 2.95 (dddd, J=8.8, 8.1, 6.5, 6.3 Hz, 1H), 2.91 (dddd, J=10.0, 8.1, 6.9, 6.2 Hz, 1H), 2.78 (dd, J=17.7, 10.0 Hz, 1H), 2.51 (d, J=17.7 Hz, 1H), 2.42 (ddd, J=15.0, 6.3, 2.4 Hz, 1H), 2.32 (ddd, J=15.1, 8.8, 6.2 Hz, 1H), 2.23 (dt, J=13.4, 8.1 Hz, 1H), 1.94 (dt, J=13.7, 6.9 Hz, 1H).
[0758] .sup.13C NMR (100 MHz, CDCl.sub.3) 179.6, 177.3, 85.5, 43.5, 38.8, 36.9, 35.9, 35.1. HRMS (ESI-TOF) Calculated for C.sub.8H.sub.9O.sub.4 [MH].sup.: 169.0501,
[0759] Found: 169.0499.
[0760] The relative configuration of 23b was determined from its reduced analogue 23b through treatment with BH.sub.3.Math.THF.
##STR00202##
[0761] Compound 23b (50.0 mg, 0.30 mmol) was dissolved in anhydrous THF (2.0 mL), the reaction mixture was cooled to 0 C. and a solution of BH.sub.3.Math.THF (0.9 mL, 0.9 mmol, 1.0 M in THF) was added. The reaction was gradually warmed to room temperature and stirred overnight. TLC analysis at this stage suggested completion of reaction. The reaction was quenched by addition of MeOH and all the volatiles were removed under reduced pressure. The desired compound was then purified by flash column chromatography (100% EA, R.sub.f=0.4) and obtained as a colourless liquid (45.0 mg, 0.29 mmol, 97%).
[0762] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.93 (td, J=6.8, 3.5 Hz, 1H), 3.68-3.48 (m, 2H), 2.84-2.77 (m, 1H), 2.73 (dd, J=17.6, 9.1 Hz, 1H), 2.36 (dd, J=17.6, 1.5 Hz, 1H), 2.32-2.21 (m, 1H), 2.22-2.12 (m, 3H), 1.67 (ddd, J=14.1, 8.6, 3.5 Hz, 1H), 1.27-1.14 (m, 1H).
[0763] .sup.13C NMR (126 MHz, CDCl.sub.3) 177.5, 86.2, 65.8, 42.3, 39.4, 35.8, 35.7, 35.7.
##STR00203##
(3aS*,6S*,7aS*)-2-Oxooctahydrobenzofuran-6-carboxylic acid 51b
[0764] Following the general procedure for its synthesis, the compound was purified as the acid by column chromatography (General procedure for gradient elution: begin with 20% EtOAc/hexane+1% AcOH, and increase the composition of EtOAc by 10% for every 8 mL of eluent used to 100% EtOAc+1% AcOH). Isolated yield 60% based on reactive diastereomers* (7.6 mg, 0.042 mmol, off white solid).
[0765] .sup.1H NMR (500 MHz, CDCl.sub.3) 4.57 (dt, J=8.9, 6.0 Hz, 1H), 2.75-2.59 (m, 1H), 2.47 (dd, J=17.2, 7.8 Hz, 1H), 2.44-2.37 (m, 2H), 2.29 (dddd, J=13.9, 5.5, 4.0, 1.4 Hz, 1H), 1.90-1.85 (m, 1H), 1.85-1.78 (m, 2H), 1.75-1.66 (m, 2H).
[0766] .sup.13C NMR (126 MHz, CDCl.sub.3) 179.3, 176.6, 78.0, 38.3, 34.0, 32.8, 30.2, 24.1, 22.9. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.1O.sub.4 [MH].sup.: 183.0657, Found: 183.0660.
[0767] *It was observed that only the syn-diacid of 51 provided the lactone 51b, whereas the anti-diacid of 51 was not reactive.
[0768] The relative configuration of 51b was determined from its benzyl ester analogue 51b, the synthesis of benzyl ester 51b was carried out according to the general procedure as described above.
##STR00204##
[0769] .sup.1H NMR (500 MHz, CDCl.sub.3) 7.40-7.30 (m, 5H), 5.13 (s, 2H), 4.55 (ddd, J=9.3, 6.2, 5.0 Hz, 1H), 2.70-2.62 (m, 1H), 2.46-2.39 (m, 2H), 2.41-2.36 (m, 1H), 2.30 (dt, J=13.8, 5.0 Hz, 1H), 1.91-1.84 (m, 1H), 1.84-1.79 (m, 1H), 1.79-1.74 (m, 1H), 1.74-1.63 (m, 2H).
[0770] .sup.13C NMR (126 MHz, CDCl.sub.3) 176.5, 173.8, 135.9, 128.8, 128.5, 128.4, 78.1, 66.8, 38.8, 34.1, 32.5, 30.6, 24.2, 23.1.
##STR00205##
Benzyl 3--oxo-1,3-dihydroisobenzofuran-1-yl)propanoate 30b
[0771] Following the general procedure for its synthesis and benzyl ester formation, the compound was purified as the benzyl ester by pTLC (20% EA/hexanes, R.sub.f=0.30). Isolated yield 57% over 2 steps, (16.9 mg, 0.057 mmol, off white solid, 30b:30a=10:1 by .sup.1H NMR).
[0772] .sup.1H NMR (500 MHz, CDCl.sub.3) 7.90 (d, J=7.5 Hz, 1H), 7.68 (td, J=7.5, 1.0 Hz, 1H), 7.54 (t, J=7.5 Hz, 1H), 7.46 (dd, J=7.5, 1.0 Hz, 1H), 7.39-7.30 (m, 5H), 5.55 (dd, J=8.7, 2.8 Hz, 1H), 5.12 (s, 2H), 2.70-2.57 (m, 1H), 2.57-2.44 (m, 2H), 2.08-1.91 (m, 1H).
[0773] .sup.13C NMR (126 MHz, CDCl.sub.3) 172.6, 170.3, 149.3, 135.8, 134.3, 129.5, 128.8, 128.5, 128.4, 126.2, 126.0, 122.0, 80.1, 66.7, 30.0, 29.6.
[0774] HRMS (ESI-TOF) Calculated for C.sub.18H.sub.17O.sub.4 [M+H].sup.+: 297.1127, Found: 297.1129.
##STR00206##
3-(7-Oxo-5,7-dihydro-[1,3]dioxolo[4,5-f]isobenzofuran-5-yl)propanoic acid 31b
[0775] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 75% (18.7 mg, 0.075 mmol, off white solid).
[0776] .sup.1H NMR (600 MHz, DMSO-d6) 7.24-7.21 (m, 2H), 6.21 (dd, J=3.5, 1.0 Hz, 2H), 5.49 (dd, J=7.5, 3.9 Hz, 1H), 2.37-2.27 (m, 2H), 2.27-2.18 (m, 1H), 1.89-1.80 (m, 1H).
[0777] .sup.13C NMR (151 MHz, DMSO-d6) 173.6, 169.2, 153.5, 149.1, 146.4, 118.7, 103.3, 102.9, 102.4, 79.4, 29.3, 29.1.
[0778] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.10O.sub.6Na [M+Na].sup.+: 273.0375, Found: 273.0384.
##STR00207##
3-(5,6-Dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)propanoic acid 32b
[0779] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 61% (16.2 mg, 0.061 mmol, off white solid).
[0780] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.29 (s, 1H), 7.14 (d, J=0.8 Hz, 1H), 5.54-5.49 (m, 1H), 3.96 (s, 3H), 3.90 (s, 3H), 2.53-2.35 (m, 3H), 2.03-1.94 (m, 1H).
[0781] .sup.13C NMR (151 MHz, CD.sub.3OD) 174.9, 172.8, 156.9, 152.3, 145.8, 118.6, 106.9, 105.2, 81.5, 56.9, 56.7, 30.8, 30.0.
[0782] HRMS (ESI-TOF) Calculated for C.sub.13H.sub.15O.sub.6 [M+H].sup.+: 267.0869, Found: 267.0865.
##STR00208##
3-(5-Methoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)propanoic acid 33b
[0783] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 70% (16.5 mg, 0.07 mmol, off white solid).
[0784] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.53-7.48 (m, 1H), 7.35-7.30 (m, 2H), 5.57 (dd, J=8.0, 3.3 Hz, 1H), 3.88 (s, 3H), 2.50-2.34 (m, 3H), 2.00-1.90 (m, 1H).
[0785] .sup.13C NMR (151 MHz, CD.sub.3OD) 176.9, 172.4, 162.4, 143.5, 128.4, 124.4, 124.0, 108.5, 82.1, 56.3, 31.3, 30.6.
[0786] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.13O.sub.5 [M+H].sup.+: 237.0763, Found: 237.0762.
##STR00209##
3-(6-(2,5-Dioxopyrrolidin-1-yl)-3-oxo-1,3-dihydroisobenzofuran-1-yl)propanoic acid 34b
[0787] Following the general procedure for its synthesis, the compound was purified by pTLC (70% EA/hexanes, 2% AcOH). Isolated yield 50% (15.1 mg, 0.050 mmol, off white solid, 34b:34a=5:1 by .sup.1H NMR).
[0788] .sup.1H NMR (600 MHz, CD.sub.3OD) 7.83 (dd, J=1.8, 0.7 Hz, 1H), 7.76-7.68 (m, 2H), 5.69 (dd, J=8.4, 3.0 Hz, 1H), 2.89 (s, 4H), 2.56-2.39 (m, 3H), 2.02-1.98 (m, 1H).
[0789] .sup.13C NMR (151 MHz, CD.sub.3OD) 178.6, 176.2, 171.3, 150.7, 135.2, 134.2, 127.9, 124.9, 124.2, 82.2, 30.9, 30.3, 29.5.
[0790] HRMS (ESI-TOF) Calculated for C.sub.15H.sub.14NO.sub.6 [M+H].sup.+: 304.0821, Found: 304.0824.
##STR00210##
3-(4-Methyl-3-oxo-1,3-dihydroisobenzofuran-1-yl)propanoic acid 35b
[0791] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 73% (16.0 mg, 0.073 mmol, off white solid, 35b:35a=8:1 by .sup.1H NMR).
[0792] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.53 (t, J=7.6 Hz, 1H), 7.30-7.24 (m, 2H), 5.48 (dd, J=8.5, 3.2 Hz, 1H), 2.68 (s, 3H), 2.67-2.58 (m, 1H), 2.54-2.41 (m, 2H), 2.00-1.92 (m, 1H).
[0793] .sup.13C NMR (151 MHz, CDCl.sub.3) 178.1, 170.6, 149.7, 140.1, 134.1, 131.2, 123.6, 119.2, 79.0, 29.9, 29.3, 17.5.
[0794] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.13O.sub.4 [M+H].sup.+: 221.0814, Found: 221.0814.
##STR00211##
3-(6-Methyl-3-oxo-1,3-dihydroisobenzofuran-1-yl)propanoic acid 36b
[0795] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 55% (12.1 mg, 0.055 mmol, off white solid, 36b:36a=9:1 by .sup.1H NMR).
[0796] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.77 (d, J=7.8 Hz, 1H), 7.33 (d, J=7.8 Hz, 1H), 7.25 (s, 2H), 5.50 (dd, J=8.6, 3.1 Hz, 1H), 2.64-2.57 (m, 1H), 2.53-2.41 (m, 5H), 2.01-1.92 (m, 1H).
[0797] .sup.13C NMR (151 MHz, CDCl.sub.3) 177.4, 170.5, 149.8, 145.7, 130.7, 125.8, 123.6, 122.3, 79.8, 29.9, 29.4, 22.2.
[0798] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.13O.sub.4 [M+H].sup.+: 221.0814, Found: 221.0813.
##STR00212##
3-(7-Methyl-3-oxo-1,3-dihydroisobenzofuran-1-yl)propanoic acid 37b
[0799] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 60% (13.2 mg, 0.055 mmol, off white solid, 37b:37a=1.6:1 by 1H NMR).
[0800] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.73 (dd, J=6.5, 2.3 Hz, 1H), 7.47-7.41 (m, 2H), 5.59 (dd, J=8.6, 2.5 Hz, 1H), 2.67-2.57 (m, 2H), 2.51-2.44 (m, 1H), 2.43 (s, 3H), 1.96-1.87 (m, 1H).
[0801] .sup.13C NMR (151 MHz, CDCl.sub.3) 177.5, 170.7, 147.5, 135.8, 132.7, 129.8, 126.1, 123.5, 79.9, 29.3, 28.4, 18.2.
[0802] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.13O.sub.4 [M+H].sup.+: 221.0814, Found: 221.0816.
##STR00213##
3-(6-Fluoro-3-oxo-1,3-dihydroisobenzofuran-1-yl)propanoic acid 38b
[0803] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 68% (15.2 mg, 0.068 mmol, off white solid, 38b:38a=10:1 by .sup.1H NMR).
[0804] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.90 (dd, J=8.5, 4.8 Hz, 1H), 7.24 (td, J=8.5, 2.1 Hz, 1H), 7.16 (dd, J=7.6, 2.4 Hz, 1H), 5.54 (dd, J=8.6, 3.5 Hz, 1H), 2.69-2.61 (m, 1H), 2.55-2.50 (m, 1H), 2.50-2.42 (m, 1H), 2.03-1.94 (m, 1H).
[0805] .sup.13C NMR (151 MHz, CDCl.sub.3) 177.5, 169.1, 167.6, 165.9, 152.0 (d, J=10.4 Hz), 128.5 (d, J=10.1 Hz), 117.9 (d, J=23.8 Hz), 109.4 (d, J=24.3 Hz), 79.3 (d, J=2.8 Hz), 29.7, 29.2.
[0806] .sup.19F NMR (471 MHz, CDCl.sub.3) 105.19.
[0807] HRMS (ESI-TOF) Calculated for C.sub.11H.sub.10FO.sub.4 [M+H].sup.+: 225.0563, Found: 225.0559.
##STR00214##
3-(6-Chloro-3-oxo-1,3-dihydroisobenzofuran-1-yl)propanoic acid 39b
[0808] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 42% (10.1 mg, 0.042 mmol, off white solid, 39b:39a=5:1 by .sup.1H NMR).
[0809] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.84 (d, J=8.1 Hz, 1H), 7.53 (dd, J=8.2, 1.7 Hz, 1H), 7.49-7.47 (m, 1H), 5.54 (dd, J=8.8, 3.4 Hz, 1H), 2.70-2.61 (m, 1H), 2.58-2.43 (m, 2H), 2.03-1.94 (m, 1H).
[0810] .sup.13C NMR (151 MHz, CDCl.sub.3) 174.8, 169.2, 150.8, 141.2, 130.4, 127.3, 124.7, 122.5, 79.4, 29.7, 29.2. HRMS (ESI-TOF) Calculated for C.sub.11H.sub.10ClO.sub.4 [M+H].sup.+: 241.0268, Found: 241.0268.
##STR00215##
3--Oxo-6-phenyl-1,3-dihydroisobenzofuran-1-yl)propanoic acid 40b
[0811] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 50% (14.1 mg, 0.05 mmol, off white solid, 40b:40a=16:1 by .sup.1H NMR).
[0812] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.95 (d, J=7.9 Hz, 1H), 7.75 (dd, J=8.0, 1.4 Hz, 1H), 7.65-7.59 (m, 3H), 7.52-7.49 (m, 2H), 7.49-7.41 (m, 2H), 5.60 (dd, J=8.0, 2.1 Hz, 1H), 2.69-2.61 (m, 1H), 2.58-2.50 (m, 2H), 2.09-1.99 (m, 1H).
[0813] .sup.13C NMR (151 MHz, CDCl.sub.3) 177.1, 170.3, 150.1, 147.9, 139.7, 129.3, 128.9, 128.9, 127.69, 126.4, 124.9, 120.5, 80.0, 29.9, 29.3.
[0814] HRMS (ESI-TOF) Calculated for C.sub.71H.sub.15O.sub.4 [M+H].sup.+: 283.0970, Found: 283.0964.
##STR00216##
3--Oxo-1,3-dihydronaphtho[2,3-c]furan-1-yl)propanoic acid 41b
[0815] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 60% (15.4 mg, 0.06 mmol, off white solid, 41b:41a=10:1 by .sup.1H NMR).
[0816] .sup.1H NMR (600 MHz, CD.sub.3OD) 8.43 (s, 1H), 8.08 (dd, J=8.3, 1.2 Hz, 1H), 8.07-8.00 (m, 2H), 7.67 (ddd, J=8.2, 6.8, 1.3 Hz, 1H), 7.60 (ddd, J=8.2, 6.8, 1.2 Hz, 1H), 5.76 (dd, J=8.4, 3.4 Hz, 1H), 2.60-2.48 (m, 2H), 2.48-2.37 (m, 1H), 2.13-1.96 (m, 1H).
[0817] .sup.13C NMR (151 MHz, CD.sub.3OD) 176.6, 172.2, 144.6, 137.9, 134.7, 130.9, 130.2, 129.5, 128.2, 127.7, 124.8, 122.3, 82.2, 31.7, 30.5.
[0818] HRMS (ESI-TOF) Calculated for C.sub.15H.sub.13O.sub.4 [M+H].sup.+: 257.0814, Found: 257.0814.
##STR00217##
3--Oxo-5-(trifluoromethyl)-1,3-dihydroisobenzofuran-1-yl)propanoic acid 42b
[0819] Following the general procedure for its synthesis, the compound was purified by pTLC (50% EA/hexanes, 2% AcOH). Isolated yield 40% (10.1 mg, 0.04 mmol, off white solid).
[0820] .sup.1H NMR (600 MHz, CD.sub.3OD) 8.15 (s, 1H), 8.07 (dd, J=8.4, 1.5 Hz, 1H), 7.89-7.84 (m, 1H), 5.75 (dd, J=8.4, 3.1 Hz, 1H), 2.57-2.48 (m, 2H), 2.48-2.40 (m, 1H), 2.07-1.97 (m, 1H).
[0821] .sup.13C NMR (151 MHz, CD.sub.3OD) 176.4, 170.6, 154.7, 133.1 (q, J=33.0 Hz), 132.3 (q, J=3.3 Hz), 128.2, 125.1 (d, J=271.8 Hz), 123.5 (q, J=4.1 Hz), 125.0, 82.3, 30.8, 30.5.
[0822] .sup.19F NMR (376 MHz, CD.sub.3OD) 66.59.
[0823] HRMS (ESI-TOF) Calculated for C.sub.12H.sub.10F.sub.3O.sub.4 [M+H].sup.+: 275.0531, Found: 275.0531.
2.4 Synthesis and Characterization of Substrates for the -Directed, -CH Lactonization Reaction
##STR00218##
2,2,6,6-Tetramethylheptanedioic acid 48
[0824] This compound is commercially available.
##STR00219##
2,2-Dimethylheptanedioic acid 26
[0825] Please see Section 2.4
##STR00220##
Ethyl 1-methyl-2-oxocyclohexane-1-carboxylate SS20
[0826] This compound was prepared according to the general procedure B for the preparation of -substituted heptanedioic acids with the reaction of MeI and ethyl 2-oxocyclohexane-1-carboxylate. 73% yield, (1.08 g, 5.86 mmol, colorless oil).
[0827] .sup.1H NMR (600 MHz, CDCl.sub.3) 4.22-4.14 (m, 2H), 2.54-2.41 (m, 3H), 2.06-1.97 (m, 1H), 1.78-1.57 (m, 4H), 1.50-1.41 (m, 1H), 1.28 (s, 3H), 1.25 (t, J=7.1 Hz, 3H).
[0828] .sup.13C NMR (151 MHz, CDCl.sub.3) 208.5, 173.2, 61.4, 57.3, 40.8, 38.4, 27.7, 22.8, 21.4, 14.2.
[0829] The data is consistent with those reported in the literature.(33)
##STR00221##
2-Methylheptanedioic acid 44
[0830] This compound was prepared according to the general procedure B for the preparation of -substituted heptanedioic acids. 75% yield, (0.78 g, 4.5 mmol, white solid).
[0831] .sup.1H NMR (500 MHz, DMSO) 2.29 (h, J=6.9 Hz, 1H), 2.19 (t, J=7.3 Hz, 2H), 1.57-1.50 (m, 1H), 1.50-1.41 (m, 2H), 1.33 (dq, J=15.7, 6.8 Hz, 1H), 1.25 (qd, J=7.6, 3.7 Hz, 2H), 1.03 (d, J=6.9 Hz, 3H).
[0832] .sup.13C NMR (126 MHz, DMSO) 177.4, 174.4, 38.6, 33.6, 33.0, 26.3, 24.4, 17.0. HRMS (ESI-TOF) Calculated for C.sub.8H.sub.13O.sub.4, [MH].sup.: 173.0814, found: 173.0811.
##STR00222##
2-Ethylheptanedioic acid 24
[0833] Please see Section 2.4
##STR00223##
2-Isopropyiheptanedioic acid 25
[0834] Please see Section 2.4
##STR00224##
2-(tert-Butyl)heptanedioic acid 46
[0835] This compound was prepared according to the general procedure for the preparation of -substituted heptanedioic acids.
[0836] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA+1% AcOH, gradient elution) Isolated yield: 44% over 2 steps (0.95 g, 4.4 mmol, colourless oil)
[0837] .sup.1H NMR (500 MHz, DMSO) 11.97 (s, 2H), 2.18 (t, J=7.4 Hz, 2H), 1.97 (dd, J=11.8, 2.9 Hz, 1H), 1.55-1.43 (m, 3H), 1.39 (dddd, J=12.8, 9.4, 6.3, 2.8 Hz, 1H), 1.26-1.11 (m, 2H), 0.91 (s, 9H).
[0838] .sup.13C NMR (126 MHz, DMSO) 176.1, 174.4, 55.6, 33.6, 32.1, 27.7, 27.6, 26.9, 24.5. HRMS (ESI-TOF) Calculated for C.sub.11H.sub.19O.sub.4 [MH].sup.: 215.1283, Found: 215.1281.
##STR00225##
Methyl 1-benzyl-2-oxocyclohexane-1-carboxylate SS21
[0839] This compound was prepared according to the general procedure B for the preparation of -substituted heptanedioic acids with the reaction of BnBr and methyl 2-oxocyclohexane-1-carboxylate. 95% yield, (1.87 g, 7.6 mmol, white solid).
[0840] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.27-7.22 (m, 2H), 7.22-7.17 (m, 1H), 7.11-7.07 (m, 2H), 3.64 (s, 3H), 3.32 (d, J=13.8 Hz, 1H), 2.87 (d, J=13.8 Hz, 1H), 2.52-2.35 (m, 3H), 2.05-1.97 (m, 1H), 1.78-1.57 (m, 3H), 1.46 (ddd, J=13.8, 12.1, 4.5 Hz, 1H).
[0841] .sup.13C NMR (151 MHz, CDCl.sub.3) 207.3, 171.6, 136.7, 130.4, 128.2, 126.8, 62.4, 52.3, 41.5, 40.6, 36.0, 27.7, 22.6.
[0842] The data is consistent with those reported in the literature.(37)
##STR00226##
2-Benzylheptanedioic acid 45
[0843] This compound was prepared according to the general procedure B for the preparation of -substituted heptanedioic acids. 85% yield, (1.28 g, 5.1 mmol, white solid).
[0844] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.32-7.27 (m, 2H), 7.24-7.20 (m, 1H), 7.19-7.15 (m, 2H), 3.06-2.98 (m, 1H), 2.74-2.65 (m, 2H), 2.40 (ddd, J=15.2, 8.1, 4.4 Hz, 1H), 2.32 (ddd, J=15.3, 8.6, 4.4 Hz, 1H), 1.72-1.48 (m, 4H), 1.44-1.25 (m, 2H).
[0845] .sup.13C NMR (151 MHz, CDCl.sub.3) 182.5, 180.7, 139.0, 129.0, 128.6, 126.6, 47.6, 38.4, 33.9, 31.5, 26.2, 24.7.
[0846] HRMS (ESI-TOF) Calculated for C.sub.14H.sub.18O.sub.4Na [M+Na].sup.+: 273.1103, Found: 273.1095.
##STR00227##
1-(4-Carboxybutyl)cyclobutane-1-carboxylic acid 47
[0847] This compound was prepared according to the general procedure for the preparation of -substituted heptanedioic acids.
[0848] Elution condition: (20% EA/hexanes+1% AcOH to 50% EA/hexanes+1% AcOH, gradient elution)
[0849] Isolated yield: 30% over 2 steps (0.60 g, 3.0 mmol, off-white solid)
[0850] .sup.1H NMR (500 MHz, DMSO) 12.01 (s, 2H), 2.27 (qd, J=8.0, 4.4 Hz, 2H), 2.19 (t, J=7.3 Hz, 2H), 1.89-1.71 (m, 4H), 1.71-1.63 (m, 2H), 1.47 (p, J=7.5 Hz, 2H), 1.20-1.07 (m, 2H).
[0851] .sup.13C NMR (126 MHz, DMSO) 177.9, 174.4, 46.9, 37.3, 33.6, 33.5, 29.5, 24.8, 24.1, 15.0. HRMS (ESI-TOF) Calculated for C.sub.10H.sub.15O.sub.4 [MH].sup.: 199.0970, Found: 199.0971.
##STR00228##
3-Isopropyiheptanedioic acid 28
[0852] Please see Section 2.4
##STR00229##
3-(tert-Butyl)heptanedioic acid 29
[0853] Please see Section 2.4
##STR00230##
2-Benzylsuccinic acid 49
[0854] This compound is commercially available.
##STR00231##
3-Benzylpentanedioic acid 50
[0855] This compound was prepared exactly according to the procedures published by Bonati and co-workers.(38)
[0856] .sup.1H NMR (500 MHz, DMSO) 12.15 (s, 2H), 7.36-7.26 (m, 2H), 7.24-7.18 (m, 1H), 7.18-7.12 (m, 2H), 2.60 (d, J=6.9 Hz, 2H), 2.38 (p, J=6.7 Hz, 1H), 2.26-2.14 (m, 4H). .sup.13C NMR (126 MHz, DMSO) 173.5, 139.6, 129.1, 128.3, 126.1, 39.0, 37.2, 33.5. HRMS (ESI-TOF) Calculated for C.sub.12H.sub.13O.sub.4 [MH].sup.: 221.0814, Found: 221.0815.
##STR00232##
(1R*,3S*)-3-(Carboxymethyl)cyclopentane-1-carboxylic acid 23
[0857] Please see Section 2.4
##STR00233##
4-(Carboxymethyl)cyclohexane-1-carboxylic acid 51
[0858] This compound was prepared according to the following procedure.(36) 4-(Carboxymethyl)benzoic acid (0.3 g, 1.67 mmol) was dissolved in glacial acetic acid (15.0 mL) and PtO.sub.2 (60.0 mg) was added. The reaction vessel was purged with H.sub.2 and the hydrogenation reaction was carried out at room temperature with a ballon of H.sub.2 and stirred for 3 days. Analysis of an aliquot of the reaction mixture at this point suggested completion of reaction. The reaction mixture was filtered with a plug of Celite and the filtrate was evaporated to dryness to give the titled compound as a white solid in 93% yield (0.29 g, 1.56 mmol).
[0859] NMR for minor diastereomer: .sup.1H NMR (500 MHz, DMSO) 2.09-2.05 (m, 3H), 1.89-1.79 (m, 2H), 1.79-1.69 (m, 2H), 1.59 (ddt, J=11.4, 7.7, 3.9 Hz, 1H), 1.28 (qd, J=13.1, 3.4 Hz, 2H), 0.96 (qd, J=13.0, 3.5 Hz, 2H).
[0860] .sup.13C NMR (126 MHz, DMSO) 176.7, 173.7, 42.3, 41.4, 33.7, 31.4, 28.5.
[0861] NMR for major diastereomer: .sup.1H NMR (500 MHz, DMSO) 2.43 (q, J=4.9 Hz, 1H), 2.10 (d, J=7.3 Hz, 2H), 1.89-1.79 (m, 2H), 1.79-1.69 (m, 1H), 1.55-1.50 (m, 2H), 1.47 (ddd, J=13.9, 8.7, 4.5 Hz, 2H), 1.18 (dtd, J=15.2, 11.0, 4.7 Hz, 2H).
[0862] .sup.13C NMR (126 MHz, DMSO) 176.1, 173.8, 39.9, 39.3, 32.4, 28.9, 25.7. HRMS (ESI-TOF) Calculated for C.sub.9H.sub.13O.sub.4 [MH].sup.: 185.0814,
[0863] Found: 185.0813.
EXPERIMENTAL SECTION REFERENCES
[0864] 1. R. Giri, N. Maugel, J. J. Li, D. H. Wang, S. P. Breazzano, L. B. Saunders, J. Q. Yu, Palladium-catalyzed methylation and arylation of sp.sup.2 and sp.sup.3 CH bonds in simple carboxylic acids. Journal of the American Chemical Society. 129, 3510-3511 (2007). [0865] 2. Z. Zhuang, C. B. Yu, G. Chen, Q. F. Wu, Y. Hsiao, C. L. Joe, J. X. Qiao, M. A. Poss, J. Q. Yu, Ligand-Enabled -C(sp.sup.3)-H Olefination of Free Carboxylic Acids. Journal of the American Chemical Society. 140, 10363-10367 (2018). [0866] 3. Z. Zhuang, A. N. Herron, Z. Fan, J. Q. Yu, Ligand-Enabled Monoselective -C(sp.sup.3)-H Acyloxylation of Free Carboxylic Acids Using a Practical Oxidant. Journal of the American Chemical Society. 142, 6769-6776 (2020). [0867] 4. Z. Zhuang, J. Q. Yu, Lactonization as a general route to -C(sp.sup.3)-H functionalization. Nature. 577, 656-659 (2020). [0868] 5. F. Ghiringhelli, A. Uttry, K. K. Ghosh, M. van Gemmeren, Direct -and -C(sp.sup.3)-H Alkynylation of Free Carboxylic Acids. Angewandte Chemie International Edition. 59, 23127-23131 (2020). [0869] 6. Z. Zhuang, A. N. Herron, J. Q. Yu, Synthesis of Cyclic Anhydrides via Ligand-Enabled CH Carbonylation of Simple Aliphatic Acids. Angewandte ChemieInternational Edition. 60, 16382-16387 (2021). [0870] 7. L.-C. Kao, A. Sen, Platinum(II) Catalysed Selective Remote Oxidation of Unactivated CH Bonds in Aliphatic Carboxylic Acids. J. Chem. Soc., Chem. Commun., 1242-1243 (1991). [0871] 8. B. D. Dangel, J. A. Johnson, D. Sames, Selective functionalization of amino acids in water: A synthetic method via catalytic CH bond activation. Journal of the American Chemical Society. 123, 8149-8150 (2001). [0872] 9. K. K. Ghosh, M. van Gemmeren, Pd-Catalyzed -C(sp.sup.3)-H Arylation of Propionic Acid and Related Aliphatic Acids. ChemistryA European Journal. 23, 17697-17700 (2017). [0873] 10. K. K. Ghosh, A. Uttry, A. Koldemir, M. Ong, M. van Gemmeren, Direct -C(sp.sup.3)-H acetoxylation of aliphatic carboxylic acids. Organic Letters. 21, 7154-7157 (2019). [0874] 11. K. K. Ghosh, A. Uttry, F. Ghiringhelli, A. Mondal, M. van Gemmeren, Ligand-Enabled -C(sp.sup.3)-H Olefination of Free Carboxylic Acids. Angew. Chem. Int. Ed. 59, 12848-12852 (2020). [0875] 12. A. Uttry, S. Mal, M. van Gemmeren, Late-Stage -C(sp.sup.3)-H Deuteration of Carboxylic Acids. Journal of the American Chemical Society. 143, 10895-10901 (2021). [0876] 13. Z. Wang, L. Hu, N. Chekshin, Z. Zhuang, S. Qian, J. X. Qiao, J.-Q. Yu, Ligand-controlled divergent dehydrogenative reactions of carboxylic acids via CH activation. Science. 374, 1281-1285 (2021). [0877] 14. M. Cianfanelli, G. Olivo, M. Milan, R. J. M. Klein Gebbink, X. Ribas, M. Bietti, M. Costas, Enantioselective CH Lactonization of Unactivated Methylenes Directed by Carboxylic Acids. Journal of the American Chemical Society. 142, 1584-1593 (2020). [0878] 15. L. Vicens, M. Bietti, M. Costas, General Access to Modified -Amino Acids by Bioinspired Stereoselective -CH Bond Lactonization. Angewandte ChemieInternational Edition. 60, 4740-4746 (2021). [0879] 16. M. S. Chen, M. C. White, A Predictably Selective Aliphatic CH Oxidation Reaction for Complex Molecule Synthesis. Science. 318, 783-787 (2007). [0880] 17. J. Schwarz, B. Konig, Decarboxylative reactions with and without lighta comparison. Green Chemistry. 20, 323-361 (2018). [0881] 18. S. K. Sartori, M. A. N. Diaz, G. Diaz-Munoz, Lactones: Classification, synthesis, biological activities, and industrial applications. Tetrahedron. 84, 132001-132039 (2021). [0882] 19. M. Seitz, O. Reiser, Synthetic approaches towards structurally diverse -butyrolactone natural-product-like compounds. Current Opinion in Chemical Biology. 9 (2005), pp. 285-292. [0883] 20. H. T. Simonsen, C. Weitzel, S. B. Christensen, in Natural Products: Phytochemistry, Botany and Metabolism of Alkaloids, Phenolics and Terpenes (Springer Berlin Heidelberg, 2013), pp. 3069-3098. [0884] 21. K. Strmgaard, K. Nakanishi, Chemistry and biology of terpene trilactones from Ginkgo biloba. Angewandte ChemieInternational Edition. 43, 1640-1658 (2004). [0885] 22. G. Shabir, A. Saeed, H. R. El-Seedi, Natural isocoumarins: Structural styles and biological activities, the revelations carry on. Phytochemistry. 181, 112568-112787 (2021). [0886] 23. A. D. Kinghorn, H. Falk, S. Gibbons, J. Kobayashi, Eds., Progress in the Chemistry of Organic Natural Products (Springer Nature, 2017), vol. 104. [0887] 24. F. Zaragoza Drwald, Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design (Wiley, 2004). [0888] 25. G. Xia, J. Weng, L. Liu, P. Verma, Z. Li, J. Q. Yu, Reversing conventional site-selectivity in C(sp 3)-H bond activation. Nature Chemistry. 11, 571-577 (2019). [0889] 26. P. Novak, A. Correa, J. Gallardo-Donaire, R. Martin, Synergistic palladium-catalyzed C(sp.sup.3)-H Activation/C(sp.sup.3)-O bond formation: A direct, step-economical route to benzolactones. Angewandte ChemieInternational Edition. 50, 12236-12239 (2011). [0890] 27. J. M. Lee, S. Chang, Pt-Catalyzed sp.sup.3 CH bond activation of o-alkyl substituted aromatic carboxylic acid derivatives for the formation of aryl lactones. Tetrahedron Letters. 47, 1375-1379 (2006). [0891] 28. T. Lin, G. Wang, W. Shan, D. Zeng, R. Ding, X. Jiang, D. Zhu, X. Liu, S. Yang, H. Chen, Myrotheciumones: Bicyclic cytotoxic lactones isolated from an endophytic fungus of Ajuga decumbens. Bioorganic and Medicinal Chemistry Letters. 24, 2504-2507 (2014). [0892] 29. S. N. Khan, M. K. Zaman, R. Li, Z. Sun, A General Method for Photocatalytic Decarboxylative Hydroxylation of Carboxylic Acids. Journal of Organic Chemistry. 85, 5019-5026 (2020). [0893] 30. S. Begum, T. K. Chakraborty, Cp2TiCl-Mediated Reductive Cyclization: Total Synthesis of Pestalotiolactone A, Myrotheciumone A, and Scabrol A. Journal of Organic Chemistry. 86, 11812-11821 (2021). [0894] 31. E. M. Mpondo, J. Garcia, A. J. Chulia, New Phthalides from Gentiana pedicellata. Planta Medica. 53, 297-298 (1987). [0895] 32. Z. Li, Z. Wang, N. Chekshin, S. Qian, J. X. Qiao, P. T. Cheng, K.-S. Yeung, W. R. Ewing, J.-Q. Yu, A tautomeric ligand enables directed CH hydroxylation with molecular oxygen. Science. 372, 1452-1457 (2021). [0896] 33. O. S. Shneider, E. Pisarevsky, P. Fristrup, A. M. Szpilman, Oxidative umpolung -alkylation of ketones. Organic Letters. 17, 282-285 (2015). [0897] 34. M. Azimioara, P. Alper, C. Cow, D. Mutnick, V. Nikulin, G. Lelais, J. Mecom, M. McNeill, P. Y. Michellys, Z. Wang, E. Reding, M. Paliotti, J. Li, D. Bao, J. Zoll, Y. Kim, M. Zimmerman, T. Groessl, T. Tuntland, S. B. Joseph, P. McNamara, H. M. Seidel, R. Epple, Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists. Bioorganic and Medicinal Chemistry Letters. 24, 5478-5483 (2014). [0898] 35. D. D. Bume, C. R. Pitts, R. T. Jokhai, T. Lectka, Direct, visible light-sensitized benzylic CH fluorination of peptides using dibenzosuberenone: selectivity for phenylalanine-like residues. Tetrahedron. 72, 6031-6036 (2016). [0899] 36. J. T. Pinhey, E. Ritchie, W. C. Taylor, The Chemical Constituents Of Himantandra (Galbulimima) Species. Australian Journal of Chemistry. 14, 106-134 (1961). [0900] 37. J. le Ntre, D. van Mele, C. G. Frost, A new method for constructing quaternary carbon centres: Tandem rhodium-catalysed 1,4-addition/intramolecular cyclisation. Advanced Synthesis and Catalysis. 349, 432-440 (2007). [0901] 38. F. Bonati, G. Minghetti, Mercury(II) Derivatives Of Acetylacetone. Journal of Organometallic Chemistry. 22, 5-10 (1970).
[0902] The features disclosed in the foregoing description, or the following claims, or the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be utilized for realizing the invention in diverse forms thereof.
[0903] The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.
[0904] All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.